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Studies described in this thesis deal with the preventive effects of a 
neurogenic/neurotropic peptidergic compound, P021, on neurogenesis and synaptic deficits, 
neurodegeneration, cognitive impairment, and A and tau pathologies in a 3xTg-AD mouse 
model of Alzheimer’s disease (AD). 
Background: AD is a chronic progressive neurodegenerative disease. Its multifactorial nature 
and the heterogeneity make its treatment especially challenging. Although it is a major burden in 
society, at present there is no drug that can stop or slow down the progression of the disease. 
Currently, the only available treatments are symptomatic and for mild to severe stages. The 
development of a drug that can prevent AD at its early stages would be of major importance. The 
use of neurotrophic factors mimetic for the treatment of AD is an exciting therapeutic strategy. It 
focuses mainly on boosting synaptic plasticity and neurogenesis which lead to shifting the 
balance from neurodegeneration to regeneration of the brain as well as preventing A and tau 
pathologies. Herein, I present the preventive effects of P021 treatment in 3xTg-AD mice that is 
initiated very early in the disease during the period of synaptic compensation and is continued 
for the lifespan of the animal.  
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Aims: The specific aims were: 1) to study the presence of the synaptic compensation 
phenomenon in the brain as a self-repairing mechanism in 3xTg-AD mice; 2) to study the 
preventive effects of P021 on cognitive deterioration when administered during the 
compensation period; 3) to study the preventive effects of P021 on amyloid beta (A) and tau 
pathologies; and 4) to study the effect of P021 on synaptic deficit, neuronal degeneration and 
neurogenesis.  
Methods: A battery of behavioral tests was conducted to assess the cognitive performance in 
3xTg-AD mice with and without treatment with P021 at different disease stages. 
Immunohistochemical and biochemical analyses were performed to determine the levels of 
synaptic protein expression as well as A and tau pathologies at different time points that 
correspond to different stages of disease progression. Neurodegeneration was studied 
immunohistochemically with Fluorojade C staining. Neurogenesis was studied 
immunohistochemically with DCX (double cortin) and Ki-67 staining.  
 Results: The 3xTg-AD mice at the age of 12 weeks were found to be cognitively impaired and 
showed a decrease in multiple synaptic and neuronal markers. This decrease was compensated 
by the brain until ~16 weeks of age. Beyond 16 weeks the brain was found to fail to compensate 
for the synaptic deficit. P021 intervention, started at 14 weeks of age, prevented cognitive 
impairment 9 months post-treatment, as tested by the Morris Water maze task. At 15-17 months 
post-treatment P021 was able to rescue short-term spatial reference memory as well as episodic 
memory, as determined by the novel object location and the novel object recognition tasks. The 
treatment with P021 also prevented A and tau pathologies during 9-18 months post-treatment. 
P021 was able to rescue synaptic deficit and neurodegeneration 9-18 months post-treatment and 
boost neurogenesis at 9 months post-treatment. P021 treatment increased survival from 41% in 
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3xTg-AD-vh to 87% in 3xTg-AD-P021 mice. In the entire study I did not find any severe side 
effects of P021 including loss of appetite or body weight.  
Conclusions: Early intervention with P021 during the period of synaptic compensation of the 
brain was successful in preventing cognitive impairment in 3xTg-AD mice. The P021 treatment 
prevented synaptic and neurogenesis deficits, neurodegeneration, and A and tau pathologies. 
These findings provide a proof of principle of the potential therapeutic effect of P021 on several 
major features of AD.  
Key Words: Aβ pathology, Alzheimer’s disease, brain derived neurotrophic factor, cognitive 
impairment, neurodegeneration, neurogenesis, neurotrophic factor, mortality, synaptic plasticity, 
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Alzheimer’s disease (AD) is the sixth leading cause of death in the United States and the 
most common form of dementia; it accounts for 60-80% of dementia cases. Although AD is 
known as a disease of old age, with more than 95% of AD sporadic cases occurring at an age of 
>65 years, the remaining <5% are familial cases and have early onset, usually around the age of 
40 to 50 years. AD is a progressive neurodegenerative disease with a slow memory loss at early 
stages followed by severe cognitive impairment and memory loss at later stages along with 
personality changes and susceptibility to infectious diseases such as pneumonia, which is the 
major cause of death at later stages. It is a non-linear disease in which the first brain changes 
occur more than a decade before the appearance of clinical symptoms.  AD is characterized by 
two histopathological hallmarks, β-amyloidosis and neurofibrillary degeneration, which are the 
biological basis for dementia. The oligomeric forms of tau and amyloid beta (Aβ) are believed to 
be most toxic to neurons because they, respectively, sequester normal tau and bind to cell surface 
receptors and contain β conformation that ends up in  sheets which make them resistant to 
degradation. A accumulation is believed to disrupt the communication between neurons 
through the synapses, which leads to synaptic death and later to neuronal death. The intracellular 
accumulation of tau as neurofibrillary tangles (NFT) is believed to disrupt the axonal transport, 
which leads to synaptic death followed by neuronal death. Indeed, the brain atrophy seen in AD 
is consistent with neurodegeneration seen in patients with severe AD. 
Because of the increase in lifespan in the developed countries, AD has increasingly 
become a major health problem and burden to society. Worldwide, AD currently affects 44 
million people and this number is expected to increase to 135 million by 2050 with the aging of 
the baby boomer generation. The costs for health care in the US alone are estimated to be about 
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$217 billion (Alzheimer's Assocation 2015) in addition to social and emotional costs. Because 
AD has a multifactorial nature and the neuropathological insults that, at present, cannot be 
reliably detected in living individuals start more than a decade before the appearance of the first 
clinical symptoms, it makes it difficult to develop a drug that can stop or at least slow down the 
progression of the disease. Currently there is no treatment for AD. The six approved drugs are 
able only to temporarily improve the clinical symptoms; they do not stop or slow down the 
disease. The majority of the approved drugs for AD are cholinesterase inhibitors such as Tacrine 
(rarely prescribed today), Donepezil for all AD stages, Galantamine for mild to moderate stages, 
and Rivastagmine for mild to moderate stages. Memantine is an NMDA receptor antagonist and 
has beneficial symptomatic effect only during moderate to severe stages of AD. Namzaric is a 
combination of donepezil and memantine. All of these drugs act by increasing neurotransmitter 
release. Tacrine, Galantamine and memantine have also been reported to increase neurogenesis 
(Jin et al., 2006). From 2002-2012, the only new drug approved by the Food and Drug 
Administration (FDA) was memantine. Namzaric was approved in late 2014.  A major problem 
that faces drug development is that it is a lengthy process with a 95% chance of failure, and the 
average time for a development of a drug from the discovery to approval in the market requires 
an average of 10-15 years (Schneider et al., 2014). 
Because of the repeated failures in the development of a drug to treat AD, several 
therapeutic approaches have been developed in recent years in an attempt to design an effective 
drug for AD. There are two major approaches; the first one is to inhibit neurodegeneration and 
disease progression and the second one is to reverse neurodegeneration and prevent cognitive 
impairment by boosting the regenerative capacities of the brain. In most disease modifying 
strategies the first approach used to attempt to inhibit neurodegeneration was to remove toxic 
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protein aggregates such as A aggregates, A plaques, tau aggregates and NFT. However, the 
phase III clinical trials of the drugs targeting Aβ showed that this approach is ineffective at least 
in patients with an advanced stage of the disease. This has led to conducting human clinical trials 
with Aβ passive immunotherapy at mild and prodromal stages of the disease and to tau-based 
therapeutic approaches, especially immunotherapies (Iqbal et al., 2016). The other promising 
approach in developing and designing AD drugs is to reverse synaptic loss and 
neurodegeneration and to boost neurogenesis, focusing mainly on treating the pathophysiological 
features of the disease rather than directly targeting Aβ and tau pathologies. Indeed, previous 
studies showed that synaptic loss is more tightly related to neurodegeneration and the 
progression of the disease than NFT or A plaques (Terry et al., 1991). The use of a small 
neurotrophic peptide mimetic that has neurogenic/neurotrophic effect, is able to cross the blood-
brain barrier (BBB), is bioavailable and biostable, and is safe, with minimal or no side effects, 
represents a promising strategy to reverse neurodegeneration. This strategy has a wide 
therapeutic window compared to toxin clearance approaches and, because of the 
neurogenic/neurotrophic effect, can be used even at a later stage of the disease to stop or slow 
down its progression.  Because of the lack of early diagnosis and the unavailability of efficient 
biomarkers, AD is discovered only after significant pathological changes have happened in the 
brain. Indeed, in individuals with disease-causing autosomal dominant mutations, who are at a 
very high risk to develop AD, A deposition starts 15-20 years before the appearance of any 
clinical symptoms  (Lu et al., 2013; Sperling et al., 2014).  
In our lab we adopted the approach of boosting the regenerative capacity of the brain 
using a neurogenic/neurotrophic peptidergic compound mimetic, named P021 (Ac-DGGLAG-
NH2). P021 is derived from the most active region of the ciliary neurotrophic factor (CNTF) (Li 
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et al., 2010). It has a plasma half life of > 3 h, is 100% stable in the intestinal fluid during 2 h, 
and ~90% stable in gastric juice during 30 min (Kazim et al., 2014). P021 is adamantylated on its 
C-terminal to protect it from degradation by carboxypeptidases and increase its blood brain 
barrier (BBB) permeability. Previously we showed that P021 increases neurogenesis and 
neuronal plasticity (Blanchard et al., 2010b, Bolognin et al., 2012, Kazim et al., 2014). The 
neurogenic and neurotrophic effects of P021 are due to its competitive inhibition with Leukemia 
inhibitory factor (LIF) through the decrease in the phosphorylation of pSTAT3 (Li et al., 2010, 
Kazim et al., 2014). It decreases tau phosphorylation through the increase in BDNF expression 
mainly through enhancing its transcription (Bolognin et al., 2012, Bolognin et al., 2014). The 
increase in BDNF expression leads to an increase in the phosphorylation of GSK3β at serine 9 
which leads to its inactivation. Since GSK 3β is the major serine/threonine kinase that 
phosphorylates tau at many different sites such as Ser199, Ser202, Thr205, Ser396, and Ser404, 
its inactivation results in a decrease in the level of phosphorylation, hence to a global decrease in 
tau pathology. Besides, P021 also has an effect on decreasing A pathology through the decrease 
in the generation of A (Kazim et al., 2014). This P021 effect is thought to occur also through 
the inhibition of GSK3β, which is also implicated in A mediated neuritic damage (DaRocha-
Souto et al., 2012), APP processing and A deposition (Phiel et al., 2003).  
Several reports in the literature emphasize the presence of a compensatory mechanism 
during the early stages of AD to slow down neurodegeneration, synaptic loss and cognitive 
deterioration. The compensatory phenomenon was shown to work by enhancing neurogenesis to 
replace the lost neurons (Li et al, 2008) and increase the production of neurotrophic factors such 
as the brain derived neurotrophic factor (BDNF) (Faria, et., 2014) or synaptic plasticity either by 
an increase in the level of expression of synaptic proteins or in the size of the surviving synapses 
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to compensate for synaptic loss (Scheff et al, 2006). It is  believed that this compensation is 
present in healthy aging, but it is defective in AD and it occurs only during early stages where 
there is minimal brain insult (Bertoni-Freddari et al., 1988, Barnes, 1994, Brown et al., 1998, 
Mukaetova-Ladinska et al., 2000). Probably that is why there is a slow progression of the 
disease. In contrast, once the brain damage reaches a certain threshold, the compensation 
phenomenon fails and the cognitive deterioration and clinical symptoms show a drastic and 
dramatic decline. Therapeutic intervention during the compensation period is believed to boost 
compensation and help prevent cognitive impairment, neurodegeneration and synaptic loss.  
The specific objective of this study was (i) to investigate the presence of the 
compensation phenomenon at a very early stage of the disease akin to AD in 3xTg-AD mice and 
(ii) to start the treatment with P021 when the compensatory phenomenon is still effective to 
investigate the effect of the compound on the prevention of the disease. The specific aims were: 
1) to study the presence of the synaptic compensation phenomenon in the brain as a self-
repairing mechanism in 3xTg-AD mice; 2) to study the preventive effects of P021 when 
administered during the compensation period on cognitive deterioration; 3) to study the 
preventive effects of P021 on amyloid beta (A) and tau pathologies; and 4) to study the effect 
of P021 on synaptic deficit, neuronal degeneration and neurogenesis.  
I present and discuss the data of this study at four different time points: the first one is at 
3 months of age before the treatment with P021; the other time points are 9 months (12 months 
of age), 15 months (18 months of age) and at 18 months after treatment (21 months of age).  
This work is presented as a chapter-based dissertation: Introduction, Background 
(Chapter 1), Material and Methods (Chapter 2), synaptic compensation study in 3xTg-AD mice 
(Chapter 3), the effect of early intervention with P021 on cognitive impairment (Chapter 4), on 
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A and tau pathologies (Chapter 5), and on neuroregeneration and neurodegeneration (Chapter 
6), and a general discussion (Chapter 7). 
With this research I am aiming to answer the following questions: 1) would early 
treatment with P021 be effective on boosting the compensatory mechanism? 2) Would early 
intervention be effective in preventing cognitive impairment? 3) Would it prevent A and tau 
pathologies? And 4) would it prevent neuronal and synaptic loss? Finally, 5) does P021 have the 
potential to be considered for further drug development as a promising novel therapeutic 




Chapter 1. Background 
1.1 Alzheimer’s disease classification, prevalence, and public cost 
1.1.1 AD classification 
AD is classified into two major categories: 1) The sporadic or late onset form, which 
represents the vast majority of AD cases (more than 95%) and tends to develop at the age of > 65 
years with an unknown etiology; and 2) the familial or early onset form, which represents the 
remaining ~5 % of cases. The familial AD is genetically inherited through mutations in one of 
the three genes, the amyloid precursor protein (APP), presenilin 1 or presenilin 2. Generally 
early onset AD or the inherited form tends to progress faster and follows a Mendelian pattern of 
inheritance (Reitz and Mayeux, 2014). Mutations in APP or presenilin 1 are associated with 
complete penetrance, meaning that any individual who has one of the mutations is guaranteed to 
have an early onset of the disease. Presenilin 2 mutation has only 95% penetrance, thus not 
everyone who has the mutation will develop AD. Individuals that have mutation in any of these 
genes tend to have an early onset of AD, sometimes as early as 30 years of age (Alzheimer's 
Assocation 2015) .  
1.1.2 Prevalence and epidemiology 
AD is the major cause of dementia; it represents 60-80 % of all dementia cases with 
about half involving only AD. The incidence of AD increases with age, doubling every 5 years. 
The prevalence also increases with age from 3% at the age of 65 to ~50% at the age of 85 or 
older. Because of the decrease in birth rate and the increase in life expectancy, the percentage of 
elderly people in the US is expected to increase from 12.4% (35 million) in 2000 to 19.6% (71 
million) in 2030. Worldwide the number of people that are 65 years or older is expected to 
increase more than double from 420 million in 2000 to 973 million in 2030 (Castellani et al., 
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2010). In the US alone there are around 5.3 million people that have AD, with 5.1 million aged 
65 years or older and approximately 200,000 with early onset. This number is projected to 
increase up to ~15 million in 2050. Women represent almost two thirds of the AD cases in the 
US. Indeed, out of the 5.1 million affected, 3.2 million are women. Currently in the US every 67 
seconds there is a new case of AD and by 2050 it will be every 33 seconds. With the increase in 
life expectancy and the aging of the baby boomer generation, the number of elderly people may 
even increase. Because aging is a high risk factor for AD, the number of people who develop AD 
would even increase. 
AD is the sixth leading cause of death in the US and the fifth leading cause of death in 
individuals 65 years and older.  Between 2000-2013 deaths ascribed to AD increased by 71% 
while deaths attributed to heart disease (the most frequent cause of death) decreased by 14%.  In 
the US AD rose from the 25th most burdensome disease in 1990 to the 12th most burdensome 
disease in 2010 (Alzheimer's Assocation 2015). In 2005, the highest prevalence of dementia was 
recorded in the US and Western Europe, affecting 6.4 and 5.4% of the population at age 60, 
followed by Latin America and China (Mayeux and Stern, 2012).  
1.1.3 Public cost 
The financial cost of AD is large. Indeed, the lifetime cost per AD person is estimated to 
be $174,000 (Castellani et al., 2010). In 2015, the estimated total health care and hospital 
services for people that are 65 years or older with dementia was $226 billion. The contribution 
from family members and other unpaid caregivers was estimated to be 17.9 billion hours of 
caregiving, which is valued at more than $217 billion. By 2050 the national cost of AD could 
reach $1 trillion. Beyond financial costs AD also causes major social and emotional distress to 




1.2 AD diagnostics and symptoms, risk factors and preventive factors 
1.2.1 Diagnostics and symptoms 
Diagnostic criteria 
Diagnostic criteria for AD were proposed in 1984 by a group of experts put together by  the 
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease 
and Related Disorders Association .These criteria combine both clinical and neuropathological patterns to 
classify AD as possible (for typical clinical syndrome without intervening issues) , probable (for 
diagnosis complicated by other disorders intervening with dementia) and definite (for autopsy confirmed 
disease) AD and they were considered reliable for diagnosing  AD for more than three decades. AD is 
considered as a continuum with a broad spectrum starting with an asymptomatic stage at early adulthood 
to definite AD late in life at the age of 65 years or older. The pathological features of AD include not only 
A and tau pathologies but also synaptic deficit, neuronal loss, unsuccessful neurogenesis and 
microgliosis (Mayeux and Stern, 2012, Reitz and Mayeux, 2014).  
Symptoms 
The early symptoms of AD are mainly difficulty remembering new conversations, names or 
events. It is often accompanied by depression and apathy. This mild cognitive impairment (MCI) is an 
intermediate stage between the expected cognitive decline of normal aging and the more serious decline 
of dementia. It can involve problems with memory, language, thinking and judgment that are greater than 
normal age-related changes but does not interfere notably with the activities of daily life (Gauthier et al., 
2006). In AD this MCI stage leads to symptoms that are mainly related to disorientation, difficulty 
swallowing, walking or carrying a conversation, poor judgment and personality change (Fig. 1). How fast 








Fig. 1: Model of the clinical trajectory of AD (Sperling et al., 2011). 
1.2.2 Risk factors 
Age 
Age is a major risk factor to develop AD. Usually people who are 65 years or older are more 
susceptible to develop AD. However, age alone does not cause AD and AD is not part of  normal aging 
(Alzheimer's Association 2015).  
APOE4 
Inheritance of the APOE4 allele is a major genetic risk factor for developing AD. The 
APOE4 allele is located on the chromosome 19q13. APOE is a lipid-binding protein that is 
expressed in three isoforms in humans: APOE2, APOE3, and APOE4. These isoforms are coded 
by the same gene locus and consist of 299 amino acids; the only structural difference is a single 
amino acid change.  APOE3 has Cys-112 and Arg-158, whereas APOE4 has arginines at both 
sites, and APOE2 has cysteines at both sites. APOE2 has a frequency of ~8.4% in the general 
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population and it is believed to have a protective effect against AD.  APOE3 is the most 
common allele (frequency of ~77.9%) and it is believed to have a neutral effect in developing 
AD. APOE4 is present in ~14% of the population and in ~40% of the late onset of AD cases 
(Wikipedia). People who inherit one copy of the allele APOE4 have a three fold higher risk of 
AD while people who have two copies of the APOE4 have 8-15 fold higher risk of having AD 
and they are more likely to have it than people who carry the APOE2 or the APOE3 alleles. 
Approximately 2% of the US population carry APOE4. Out of all the cases of AD 40-60% of 
people who are diagnosed with AD carry one or two copies of APOE4 (Alzheimer's Assocation 
2015). Each copy of the APOE4 allele lowers the age of onset of AD by 6-7 years. However, 
the presence of the 4 allele is not sufficient or necessary to develop AD (Reitz and Mayeux, 
2014).  
Other factors 
An increasing number of studies link heart diseases to brain diseases, which is why 
cerebrovascular diseases such as hemorrhagic infarcts, small and large ischemic infarcts and 
vasculopathies are considered to be a risk for having AD. Stroke increases the risk of having 
dementia by 4-12 times and the mechanism is unknown. High blood pressure in mid-life has 
been shown to increase the risk of cognitive impairment and dementia in later life. Having type 
II diabetes doubles the risk of having AD for as yet unknown reasons. The increase in cholesterol 
level has been controversial as being a risk factor for AD. However, the increase of cholesterol in 
mid-life is suspected to have a damaging effect in later life (Reitz and Mayeux, 2014). The risk 
of AD is 2.3 times higher in people who experience moderate traumatic brain injury (TBI) and 
4.7 times higher for people who experience severe TBI compared to non injured individuals 
(www.alz.org). People with mild cognitive impairment (MCI) are at higher risk for developing 
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AD, especially if the MCI is accompanied by memory problems, which will more likely lead to 
early AD. 10-20% of people that are more than 65 years old have MCI and among those who had 
serious symptoms 15% develop early AD. However, some MCI cases can reverse to normal 
cognition or the MCI can remain stable and not proceed to AD (Alzheimer's Assocation 2015).  
1.2.3 Preventive factors: 
Exercise 
It has been well documented that physical exercise increases the level of the brain derived 
neurotrophic factor (BDNF) and increases neurogenesis (van Praag et al., 1999) and neuronal 
plasticity. Exercise may also increase brain vascularization (Black et al, 1990), neuronal survival 
and resistance to brain insult (Carro et al., 2001).  
Diet 
Recently it was shown that the Mediterranean diet is associated with a lower risk of 
developing AD and a lower mortality rate in AD patients. The Mediterranean diet is mostly 
composed of vegetables, cereals, fish, a low to moderate intake of dairy products and a low to 
moderate intake of poultry and meat (Castellani et al., 2010). In contrast, the consumption of a 
high fat diet was associated with an increase of cholesterol and an increased risk of vascular 
disease in the brain (Mayeux and Stern, 2012).  
Brain and cognitive reserve 
The fact that some patients have AD neuropathological lesions that are not accompanied 
by cognitive impairment led to the suggestion that these people are resilient and they have high 
cognitive or brain reserve. Brain reserve encompasses both brain size and cognitive reserve. The 
cognitive reserve refers to the ability of the brain to use alternative neuronal networks or 
cognitive strategies to overcome the cognitive impairment and it was associated with a higher 
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level of education (Alzheimer's Association 2015). Thus, a high brain reserve, it is suggested, 
could exert a compensatory and a protective effect against AD. Compensation would be effective 
for a long period of time to protect from cognitive decline. However, once a certain threshold of 
damage was reached, the compensation would fail and the cognitive decline would be more rapid 
and drastic compared to AD non-resilient patients (Sperling et al., 2014). In a large longitudinal 
cohort study consisting of AD, amnestic mild cognitive impairment patients (aMCI) and healthy 
controls, a larger intracranial volume was found to attenuate the effect of atrophy and APOE4 in 
aMCI but it did not correlate with the severity of clinical symptoms or worsening of atrophy. 
However, this protective effect was found to be efficient only during early stages of AD. Once a 
neurodegeneration threshold is reached, brain size is no longer protective (Guo et al., 2013). This 
argues in favor of a role of brain reserve in compensation for neuronal loss instead of 
neuroprotection  
 
1.3 The three common hypotheses of AD 
The exact cause of AD remains to be established. Several hypotheses concerning the 
etiopathogenesis have evolved over the years but to date none of them have been found to 
explain all aspects of the disease. The three major hypotheses are the cholinergic, Aβ cascade, 
and tau hypotheses, as follows. 
1.3.1 Cholinergic Hypothesis 
Previously AD was considered to be a cholinergic disease associated with severe loss of 
central cholinergic neurons and the level of cognitive impairment was correlated with the level of 
cholinergic loss. Indeed, the cholinergic hypothesis states that the cognitive impairment in AD is 
caused by the degeneration of basal forebrain cholinergic neurons due to aberrant signaling of 
the neurotrophin P75 receptor through the increase in proNGF level and decrease in NGF level 
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in AD patients. The increase in proNGF level was shown to stimulate cell death through the P75 
receptor (Podlesniy et al., 2006). This hypothesis led to the development of cholinomimetics like 
Tacrine, Donepezil and Rivastigmine that are being used for the symptomatic treatment of AD. 
1.3.2 A hypothesis 
APP is an integral membrane protein that acts as a signaling receptor. It is produced due 
to alternative splicing of its transcripts as three different isoforms: APP695, APP751, and APP770. 
The three mRNA isoforms are present in almost every tissue in different ratios. It is the mRNA 
and the protein expression of APP695 that is more prominent in neurons.  APP is metabolized 
through two different pathways: amyloidogenic and non amyloidogenic (Fig. 2). In the non 
amyloidogenic pathway APP is first cleaved by -secretase in the A region between Lys16 and 
Leu17 and the resulting carboxy-terminal fragment is further cleaved by γ-secretase enzyme. 
This pathway precludes the production of A. However, in the amyloidogenic pathway APP is 
sequentially cleaved by - and γ-secretases to produce a soluble monomeric A fragment. The 
most commonly produced A isoforms are A1-40 and A1-42. A1-40 is more prone to 
deposit in brain blood vessels, as seen in cerebral amyloid angiopathy, whereas A1-42 is more 
prone to form insoluble aggregates because of its hydrophobic nature. Since A is a normal 
metabolite of APP it is believed that an imbalance between the rate of production and clearance 
of A is what leads to A plaque deposition.  The enzyme BACE1 is responsible for -secretase 
activity, while PS1 and PS2 are part of the γ-secretase complex. The -secretase activity is 
mediated by the ADAM family, especially ADAM10 and ADAM17 (Hicks et al., 2012, 
Tarasoff-Conway et al., 2015). 
Certain APP mutations that are causative of familial Alzheimer’s disease (FAD) also 
result in the increase of A synthesis. Since PS1 and PS2 have γ-secretase activity, certain 
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mutations in either of these proteins can also increase A production. However, it is well 
established that A load does not correlate with cognitive impairment in AD. The A hypothesis 
then places the accumulation of A as the major cause and the earliest key event in the AD 
pathophysiological process, followed later on by NFT and neuronal loss. However, this 
hypothesis remains controversial and challenged mainly because all the clinical trials based on 
anti-A therapies failed to treat AD (Sperling et al., 2014).  
1.3.3 Tau hypothesis 
The tau hypothesis is that abnormally hyperphosphorylated tau is causative of the 
disease. In AD the dementia correlates with the density of tau pathology. For instance, the 
severity of dementia correlates better with the increase in the accumulation of NFT and the level 
of hyperphosphorylated tau in the CSF correlates better with cognitive impairment (Rafii and 
Aisen, 2015). It is hypothesized that due to aberrant signaling of tau protein kinases and/or 
phosphatases, tau becomes hyperphosphorylated and aggregated into NFT, leading to abnormal 
cellular trafficking and disruption of the microtubule-based cytoskeleton, followed by cell death. 
After cell death the oligomeric forms of tau are released to the extracellular environment, which 
stimulates microglial cells, leading to further prion-like spread of tau pathology and 
neurodegeneration. So far the closest approximation to cognitive impairment in AD is the tau 
hypothesis. The strongest support for the tau hypothesis comes from the fact that certain 
mutations in the tau gene cause frontotemporal dementia with Parkinsonism linked to 
chromosome 17 (FTDP-17). Furthermore, several tauopathies are characterized by accumulation 
of abnormally hyperphosphorylated tau in the absence of Aβ pathology. NFT and neuropil 
threads are common pathological features shared between various tauopathies such as 
frontotemporal dementia, Pick’s disease, progressive supranuclear palsy and corticobasal 
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degeneration (Brunden et al., 2009). The fact that all tauopathies share abnormal 
hyperphosphorylated tau inclusions as a common pathological feature that is followed by 
neurodegeneration and clinical phenotype strongly supports the idea that tau by itself can cause 
neurodegeneration without the presence of Aβ.  
 
1.4 Underlying pathologies 
The neuropathological hallmarks of AD are grouped into so-called “negative” and 
“positive lesions”. The negative lesions mainly represent synaptic and neuronal loss and the 
positive lesions mainly represent A plaques and NFT. Plaques are primarily localized in the 
cerebral cortex and NFT are primarily localized in the limbic and cortical association areas 
(Serrano-Pozo et al., 2011a).  
1.4.1 A plaques 
Amyloid beta (A) plaques (Fig. 2) are extracellular, spherical deposits of A (10-200 
µm in diameter) in the cerebral cortex. They are classified as dense core or diffuse plaques. 
Dense-core plaques are thioflavin S and congo-red positive, usually associated with dystrophic 
neurites, reactive astrocytes and synaptic loss, and they are considered to be pathological. They 
are mainly composed of A 42 and their presence is generally associated with cognitive 
impairment. Diffuse plaques are thioflavin S and congo-red negative, with amorphous shape, not 
accompanied with dystrophic neurites or synaptic loss, and they are not considered for a 
pathological diagnosis of AD because they are also found in the brains of healthy individuals. 
The spatio-temporal pattern of the staging of the plaque pathology, unlike NFT, is far less 
predictable but it is generally classified into three stages: first in isocortical areas, then in 
allocortical or limbic areas, and finally in subcortical areas (Serrano-Pozo et al., 2011a).  A 
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deposition does not correlate with the severity of cognitive symptoms. In fact, it was shown 
previously that the A deposition reaches a plateau in the isocortex right after the onset of 
cognitive symptoms even in the preclinical stages of the disease (Ingelsson et al., 2004, Serrano-
Pozo et al., 2011b). 
 
Fig. 2. App processing pathways: amyloidogenic and non-amyloidogenic pathways  
(Hicks et al., 2012). 
1.4.2 NFT 
Tau is a microtubule associated protein that is abundant in neurons; its main function is to bind 
to and stabilize microtubules to facilitate axonal transport. In the normal physiological condition 
tau is seen mainly localized in the axons and it is phosphorylated by several kinases to 
destabilize microtubules and promote plasticity. Normal adult human brain tau contains 2-3 
moles of phosphate, while in the AD brain tau is 3-4 times more hyperphosphorylated (Iqbal et 
al., 2010). Tau hyperphosphorylation happens either because of hyperactive kinases or 
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hypoactive phosphatases. Pathological tau in AD patients is found to be localized in the 
somatodendritic compartment. Hyperphosphorylation of tau leads to destabilization of 
microtubules and sequestration of normal tau by the pathological protein and its self-assembly 
into paired helical filaments (PHF) as neuropil threads and NFT. NFT (Fig. 3) are intraneuronal 
aggregates of hyperphosphorylated tau and misfolded tau and they are seen after neuronal death 
as “ghost” tangles in the extracellular space. NFT have a spatiotemporal spread that correlates 
with the severity of cognitive impairment and they parallel synaptic and neuronal loss. The 
topographic staging of AD is used for the diagnosis of AD. Early NFT formation starts in the 
entorhinal/perirhinal cortex, followed by the hippocampus, the association cortex and finally the 
primary cortex (Braak and Braak, 1991, Serrano-Pozo et al., 2011a, Glass and Arnold, 2012). 
NFT are classified as pre-NFT with diffuse and sometimes punctuate staining in normal-looking 
neurons. Mature or intraneuronal NFT are found in the cytoplasm and they push the location of 
the nucleus to the periphery. The shape of dendrites and the proximal axon looks distorted. 
Extracellular or ghost NFT are found when tangle-bearing neurons are dead and they are 
identified by the absence of a nucleus and stainable cytoplasm (Serrano-Pozo et al., 2011a). NFT 
are localized mainly in the neuron clusters of feed-forward and feed-back connections between 
cortical and subcortical areas, leading to a disconnection between the hippocampus and the 
neocortex and between the neocortical association areas. This disconnection results in the 




Fig. 3: A plaques and NFT in a Bielchowsky silver stained section of AD hippocampus.  
From Iqbal et al., in “An Atlas of Alzheimer’s Disease”; edited by Mony J. DeLeon and Heiko 
Braak, Parthenon Publishers Group, June 15, 1999. 
 
1.4.3 Changes in synaptic plasticity 
Synaptic loss 
The process of neurodegeneration is mainly accompanied by synaptic loss as an early 
event in AD (Masliah and Terry, 1993, Masliah, 2000). In fact synaptic loss is the best correlate 
of cognitive impairment in AD patients and a major contributor to cortical atrophy. The level of 
expression of synaptophysin in the midfrontal and inferior parietal lobes in AD patients and 
cognitive scores prior to death show that synaptophysin loss strongly correlates with cognitive 
impairment as compared to A plaques or NFT (Terry et al., 1991). Synaptic loss is colocalized 
with neuronal loss and sometimes exceeds neuronal loss and this indicates that synaptic loss 
probably precedes neuronal loss. That is why synaptic density is a better correlate of cognitive 
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decline than neuronal loss (Terry et al., 1991, Masliah and Terry, 1993). Furthermore, it was 
shown that synaptic loss in AD does not happen only because of neuronal death but also in living 
neurons (Coleman and Yao, 2003). 
In AD, the hippocampus and the frontal and parietal cortices are among the brain regions 
that are severely affected with synaptic loss while the other brain regions such as the occipital 
cortex are relatively spared (Honer, 2003). A previous study reported that synaptophysin-like 
immunoreactivity dramatically decreased in the hippocampus and the entorhinal cortex in 
autopsies of brains of patients with definite AD compared to controls or multi-infarct dementia 
patients (Heinonen et al., 1995).  
Synaptic loss occurs later than A deposition but represents a better correlate of disease 
progression (Terry et al., 1991, Selkoe, 2002, Shankar and Walsh, 2009).  In autopsied brains of 
patients with moderate to severe AD, evident synaptic loss was found in the hippocampus, 
frontal, inferior parietal and entorhinal cortices 2-4 years after the onset of clinical symptoms.  In 
the CA1 region of the hippocampus, synaptic loss was reported to be 18% in MCI subjects 
compared to 55% in mild AD subjects. Stereological investigation of the number of synapses 
revealed that evident synaptic loss was correlated with impaired episodic memory in MCI 
patients (Lu et al., 2013).  Studies from animal models of AD also corroborated these findings. In 
the 3xTg-AD mouse model, for example, a progressive loss of dendritic spines in the 
somatosensory cortex was reported as early as 4 months of age in layer III neurons and it 
coincided with soluble A and tau hyperphosphorylation at 13 months (Bittner et al., 2010). 
Similar data were reported in Tg2576 mice, which showed that the loss of synapses occurs in a 
region and age-dependent manner (Dong et al., 2007). Furthermore, brain imaging studies using 
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functional MRI (fMRI) showed that in AD patients global disruption of functional connectivity 
was associated with cognitive decline (Supekar et al., 2008).  
Synaptic loss is highly correlated with the number of NFT in the same brain regions, and 
regional differences in the amount of synaptic loss in the cerebral cortex match the pattern of 
neurofibrillary degeneration as shown by BRAAK stages. A detailed study reported a decrease in 
the synaptophysin mRNA level in tangle-bearing neurons compared to healthy ones. However, 
the correlation between plaque numbers and synaptic loss was found to be less consistent and 
failed to establish such a relationship (Arendt, 2009).  
Synaptic compensation 
A transient increase in the level of synaptic markers at the early stages of AD as a 
compensation for synaptic loss is known to occur. It has been shown that the levels of 
synaptophysin and other synaptic proteins increase in the early stages of AD prior to NFT 
formation (BRAAK stage III) and then decrease again when the disease progresses, suggesting a 
phenomenon of synaptic compensation (Mukaetova-Ladinska et al., 2000). An increase in the 
level of PSD-95 in AD patients (Leuba et al., 2008a, Leuba et al., 2008b ) and the presynaptic 
cholinergic bouton density in the midfrontal gyrus of MCI patients was reported (Bell et al., 
2007). Early studies showed that synaptic loss in AD is accompanied by an increase of the 
synaptic size to compensate for synaptic loss. Indeed, in several neocortical areas the increase in 
synaptic size compensates for the significant loss of synapses by maintaining a constant total 
synaptic contact area. However, when the disease progresses and synaptic loss becomes more 
and more dramatic in these areas, the compensation phenomenon is no longer effective. The 
failure in synaptic compensation is more apparent in the neocortical areas that are known to be 
implicated early in synaptic loss such as Brodmann area 9 (Scheff and Price, 2006). These 
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findings were corroborated with results from fMRI studies that suggest there may be a biphasic 
stage in the prodromal stage of the disease in which there is a period of increased brain activation 
which is reduced later during the disease process (Sperling, 2007). In AD, however, although the 
compensatory phenomenon is present early in the disease process it becomes defective at 
advanced pathological stages. This phenomenon may help in slowing the cognitive deterioration 
seen in early AD stages and that may be why we do not see a linear relationship between brain 
pathology and functional measures (Arendt, 2009).  
Altered neurogenesis 
In the brain neurogenesis takes place in the subgranular zone (SGZ) of the DG and the 
subventricular zone (SVZ) (Fig. 4).  Neurogenesis is essential for several aspects of learning and 
memory especially the formation of adult-born neurons is essential for pattern separation (Lacar, 
et al., 2014). Neurogenesis is also essential for the plasticity of the hippocampus and, especially 
in rodents, the olfactory system. Indeed, hippocampal neurogenesis in the CNS contributes to 
information storage and retrieval. Thus an impaired neurogenesis may interfere with synaptic 
and neuronal plasticity as well as normal neuronal function. In AD several studies reported that 
neurogenesis is disrupted very early in the process of the disease, with some reports claiming an 
increase while others claim a decrease in the level of neurogenesis. In autopsied brains an 
increase in neurogenesis was reported. Indeed, the expression of markers of immature neurons 
such as DCX, which signals the birth of new neurons, polysialylated nerve cell adhesion 
molecule , neurogenic differentiation factors and TUC-4  in the SVZ, granular layer of DG (site 
of neurogenesis) and the CA1 region (principal site of hippocampal pathology) were shown (Jin 
et al., 2004b). Similarly, studies employing J20 transgenic mice reported an increase in 
neurogenesis in the SGZ of the DG and the SVZ. Indeed, the number of BrdU positive cells and 
23 
 
immature neuronal marker proteins increased by 2-fold at the age of 3 months, where there was 
no neuronal loss or A deposition in these mice. Studies on neurogenesis in human autopsied 
brains and transgenic mice led to the hypothesis that it is stimulated by the disease itself and not 
by the confounding clinical factors. The increase in neurogenesis may serve to generate new 
neurons to replace the degenerated ones and this may provide a unique approach to AD treatment 
(Jin et al., 2004a).  
Neurogenesis was shown to increase after other pathological conditions such as global 
and focal experimental cerebral ischemia transiently and bilaterally in the SGZ and the SVZ by 
12 fold, followed by normal level in 2-3 weeks. After one month it was shown that the newly 
born neurons migrate into the granular zone of the DG and express the calcium-binding protein 
(Liu et al., 1998, Jin et al., 2001, Yagita et al., 2001, Taupin, 2006). However, the 
aforementioned attempt of the CNS to self-repair after severe pathological insult remains 
unsuccessful. This may be explained in part by the fact that newly born neurons cannot 
differentiate into fully mature cells either because they do not develop into the right type of 
neurons or that they cannot integrate into the surviving circuitry. In support of this hypothesis it 
was previously reported that neurogenesis is unsuccessful because the newly born neurons 
cannot make it to become fully mature in AD brains. Indeed the levels of MAP2 a and b 
(markers of mature neurons) decrease dramatically in the DG of AD brains. However, the total 
expression of MAP2 including MAP2c (a marker of immature neurons) was less affected. These 
findings suggest that although in AD there is an increase in neuronal proliferation, the newborn 
neurons do not fully mature in the DG (Li et al., 2008). The failure of the maturation process in 
AD is suggested to be because of the imbalance in neurotrophic factors, including an increased 
level of FGF2 and decreased levels of BDNF and neurotrophin-4 (Stopa et al., 1990, Hock et al., 
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2000). In fact, it was previously shown that the increase in the level of FGF-2 drives the 
hippocampal progenitor neurons to stay in an undifferentiated actively dividing developmental 
stage. Thus a promotion of the maturation of the newly born-neurons may help improve 
cognition and represents a potential therapeutic strategy.  
Collectively, these studies then suggest that impairment in neurogenesis cannot be only 
the consequence of the disease but can be a cause of cognitive impairment observed in AD 
(Rodriguez and Verkhratsky, 2011).  
The discrepancies seen among the results in the literature could be explained by the fact 
that neurogenesis does not follow a uniform pattern in AD and it varies between stages and 
between brain regions (Perry et al., 2012). The difference in several other parameters could also 
be involved. PS1 mutation for example, is known to have a negative effect on the generation of 
newborn neurons, while a non mutated PS1 would enhance cell proliferation and differentiation 















1.4.4 Imbalance of neurotrophic factors  
Neurotrophic factors are secreted molecules that play a crucial role in synaptic and 
neuronal growth, proliferation, maturation, pruning and survival (Budni et al., 2015). Insufficient 
trophic factors in the crucial regions of the brain like the hippocampus would lead to 
neurodegeneration and also leave them unprotected from pathological insults. The initial 
embryonic expression of neurotrophins approximately coincides with neurogenesis. NT-3 is 
mostly expressed in the immature regions of the CNS and the expression level dramatically 
decreases with their maturation. In contrast the expression level of BDNF is low in immature 
regions of the brain and it increases as these regions mature. The level of expression of NGF 
varies during the development of brain regions in an inconsistent manner. All three 
neurotrophins have a high mRNA expression level in the hippocampus, with the BDNF mRNA 
level 50 times higher than NGF (Hofer et al., 1990, Maisonpierre et al., 1990).  
The process of adult neurogenesis generates too many newborn neurons but only a few of 
them survive to undergo the process of neuronal maturation and become integrated into the 
neuronal circuit. The selection of the neurons that will survive is based on the availability of 
neurotrophic factors in the target neurons. Neurotrophic factors are released by target neurons in 
an activity-dependent manner. A neuron that is not well connected to a target neuron would 
receive an insufficient amount and die, while the best connected would receive a sufficient 
amount and survive to become mature neurons. This ensures that the established connections and 
networks are synaptically active. Synaptic loss and axonal transport dysfunction are among the 
early events that happen in AD. The loss of synapses results in the loss of connection between 
the innervating neuron and the target neuron, and the axonal transport dysfunction leads to a 
defect in the retrograde transport of the neurotrophic factor. Both of these phenomena can lead to 
the death of the innervating neurons because they are not receiving the trophic factor from their 
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target counterpart. This is consistent with what was reported in the literature, that pro-NGF level 
increased in AD patients because of a defect in retrograde transport. So this suggests that 
neurodegeneration may be caused by disconnection between the neuron and its target rather than 
being a consequence of it (Castren and Tanila, 2006).  
During the process of AD there is an imbalance in the level of neurotrophic factors, 
which may explain the failure of maturation of newborn neurons and synaptic loss. In fact, 
employing autopsied brains it has been reported that there is a decrease in the level of expression 
of BDNF in the hippocampus and the parietal cortex accompanied by a decrease in the ratio of 
BDNF/NT-3 in the frontal and the parietal cortices compared to control groups. However, the 
levels of NGF and NGF/NT-3 were significantly increased in the hippocampus and the frontal 
cortex in AD. The levels of NT-4/5 and NT-4/NT-3 were slightly reduced in the hippocampus 
and the cerebellum in the AD group compared to control cases. The level of NT-3, however, was 
unchanged in all the brain regions studied. The decrease of BDNF expression could then explain 
the lack of trophic support, which results in the degeneration of specific neuronal populations 
such as the cholinergic neurons. In NFT bearing neurons BDNF was not expressed, while it was 
expressed in tangle-free neurons, implicating its protective effect against neurodegeneration 
(Lanni et al., 2010). 
BDNF 
BDNF is synthesized in the entorhinal cortex and retrogradely transported to the 
hippocampus, where it regulates LTP and LTD, axonal sprouting, synaptic plasticity, 
proliferation of dendritic arbor and neuronal differentiation (Murer et al., 2001, Tyler et al., 
2002). It is a vital component of synaptic plasticity and memory function. LTP provides the 
cellular mechanism of memory formation and consolidation and it is facilitated by BDNF 
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through binding to its TrkB receptor. TrkB receptors are found mainly in the hippocampus and 
some of them in the basic cholinergic neurons to support cholinergic function. TrKA receptors 
that respond to NGF are found mainly in the basal forebrain cholinergic neurons. Thus, any 
imbalance in the level of BDNF or NGF in the brain would affect memory formation and lead to 
neurodegeneration. Indeed, the level of expression of these two neurotrophins and their receptors 
is affected very early in AD. The level of BDNF expression was reported to be decreased by 23 
% in AD compared to normal controls in the frontal cortex. Pro-BDNF level also was shown to 
slightly progressively decrease from MCI (21%) to AD (30%) in the parietal cortex (Ferrer et al., 
1999, Fahnestock et al., 2002, Michalski and Fahnestock, 2003, Peng et al., 2005, Allen et al., 
2011). However, in other studies an increase in the BDNF level has been reported in the AD 
brain compared to MCI and control brains. TrkB levels also were reported to increase in the CA1 
region of patients at early AD stage (Kao et al., 2012, Faria et al., 2014). The increase in BDNF 
level happened early in the disease stage and it might be as a compensation to slow down the loss 
of memory. However, later in the process of the disease the compensation mechanism becomes 
unsuccessful and the levels of BDNF are decreased dramatically. Thus, possibly for this reason 
the memory loss and cognitive deterioration are marked in the later stages of the disease.  
Alteration in BDNF level might result in insufficient differentiation of neurons, synaptic 
loss and cognitive dysfunction (Song et al., 2015). Indeed, a previous study correlated the 
decrease in BDNF and Pro-BDNF levels to a decline in cognitive abilities very early in the 
disease stage (Peng et al., 2005). A recent study in the oldest old, the 90+ study, reported that the 
level of BDNF and Aβ 42 correlated with dementia in Brodmann areas 7 and 9. BDNF mRNA 
level was decreased in demented vs non-demented subjects regardless of pathology. Soluble Aβ 




NGF is synthesized in the hippocampus and it reaches its neuronal targets in the forebrain 
through a retrograde transport. In AD the level of NGF is reported to be decreased. However, the 
NGF level is unchanged or increased in the hippocampus, which argues in favor of a clear defect 
in the retrograde transport or an inefficient uptake of NGF to NGF-sensitive neurons. 
Neurodegeneration leads to an insufficient amount of NGF to reach the soma of the basal 
forebrain neurons, which leads to further degeneration (Hock et al., 2000, Price et al., 2007). 
Later studies, however, showed that the level of Pro-NGF is actually increased and the level of 
NGF decreased in the postmortem AD brains, and that the increase in Pro-NGF level is 
associated with poorer cognitive performance. The predominant form of NGF in the brain is the 
immature form (Pro-NGF), which is cleaved by plasmin to give the mature form (NGF). In AD 
the level of plasmin decreases and the Pro-NGF cannot mature into NGF. In addition, the 
degradation of mature NGF is increased. This is believed to be most likely a mechanism that 
initiates neurodegeneration of the basic forebrain neurons (Allen et al., 2011).   
FGF-2 
The brain level of FGF-2 or basic FGF is increased in AD compared to control cases and 
this increase is associated with the presence of neuritic plaques and NFT (Stopa et al., 1990) and 
with the increase in tau phosphorylation through the increase in the level of GSK3β and tau itself 
(Schindowski et al., 2008).  The concentration of FGF-2 is 50 times more than NGF (Siegel and 
Chauhan, 2000) and it is well established that FGF-2 has a promitotic role in neurogenesis. 
Studies on FGF receptor 1 conditional knockout mice (a major receptor of FGF-2) suggested its 
involvement in neurogenesis, LTP, memory consolidation but not spatial memory (Zhao et al., 
2007). FGF-2 enhances adult rat hippocampal progenitor cell division and nestin level but 
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inhibits neuronal fate commitment and maturation of these cells in culture. FGF-2 drives the 
cells toward an undifferentiated actively dividing developmental stage (Chohan et al., 2011).  
GDNF 
The level of GDNF expression was reported to be increased in the cerebrospinal fluid and 
decreased in the sera of AD patients compared to controls, while another study showed that the 
level of GDNF increased in the plasma of AD patients as an adaptive compensatory mechanism 
from the brain (Marksteiner et al., 2011, Straten et al., 2011). However, postmortem studies 
showed that there is a dramatic decrease of mature GDNF in the medial temporal gyrus in AD 
patients. These findings were corroborated by another study that showed that the level of GDNF 
decreased in the sera of MCI and AD patients (Airavaara et al., 2011, Forlenza et al., 2015).   
IGF-1 
IGF-1 has been implicated in the development of late onset AD. In this context, IGF-1 
was reported to have an effect on the metabolism and clearance of Aβ as well as the formation of 
NFT. It is even proposed that the IGF-1 receptor (IGF-1R) may promote Aβ production. 
Previous data also showed that the level of IGF-1R inversely correlates with cognitive 
impairment (Lanni et al., 2010). Indeed, a recent study reported that blocking IGF-1R signaling 
in adult APP/PS1 mice results in a significant delay of AD pathology through clearance of toxic 
Aβ (Gontier et al., 2015). In a subsequent study, however, it was reported that the levels of IGF-
1R and insulin receptors were decreased in AD neurons, suggesting that neurons that undergo 





1.5 Current AD therapeutics and therapeutic approaches  
1.5.1 Current AD therapeutics 
Currently there are six FDA-approved drugs for AD. These drugs increase 
neurotransmitter release and temporarily improve AD symptoms without stopping or slowing the 
progression of the disease. Five of these drugs are acetyl cholinesterase inhibitors. The general 
efficacy of cholinesterase inhibitors is considered to be moderate with 2 or 3 points on the 
standard cognitive outcome (Schneider et al., 2014). Based on the cholinergic theory the first 
cholinesterase inhibitor drug, Tacrine, was developed in 1993 but nowadays it is rarely 
prescribed because of possible liver damage and its low bioavailability. In 1996, Donepezil was 
developed and it is used for treatment of all stages of AD.  Rivastigmine was developed in 2000 
to treat mild to moderate stages of AD. Galantamine was approved by the FDA in 2001 to treat 
mild to moderate stages of the disease. In 2003, Memantine, an NMDA mild to moderate 
antagonist, was approved by the FDA for moderate to severe stages of AD to improve memory, 
attention and simple skills. However, Memantine failed to show any significant benefit when 
administered to patients with mild AD.  From 2002-2012, out of 244 drugs tested for AD, only 
Memantine completed clinical trials and was approved. Late in 2014, in a second U.S-controlled 
clinical trial, a combination of Donepezil and Memantine (Namzaric) decreased cognitive 
deterioration and decline in daily activities with minimal new behavioral symptoms in AD 
patients when compared to placebo and was approved as a therapeutic drug for AD (Schneider et 
al., 2014; Alzheimer's Association 2015).  
1.5.2 Anti-Aβ therapeutics 
Based on the amyloid beta hypothesis several clinical trials were conducted using passive 
immunotherapy. Solanezemub, a monoclonal antibody against the mid-domain of Aβ, recognizes 
only soluble monomeric Aβ. A Phase III clinical trial using this antibody showed it to be safe but 
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had no improvement in primary outcome measures; Crenezumab, another antibody directed 
against all forms of Aβ, showed no difference between the placebo and the treatment group in 
the primary cognitive outcome measures; and Gantenerumab, a monoclonal antibody designed 
against a conformational epitope of the fibrillar Aβ, was stopped in phase II/III clinical trials 
because of the lack of a perceived efficacy (Rafii and Aisen, 2015). 
Active immunization using a synthetic fragment of Aβ peptide named AN1792 showed 
exciting data in mice harboring APP mutation. Indeed, it decreased Aβ plaques and improved 
cognition in mice. However, when advanced to clinical trials in patients with mild to moderate 
AD, the active immunization was stopped because of severe side effects such as 
meningoencephalitis with no benefits in AD symptoms. Following AN1792 immunization, 6% 
of the treated patients developed meningoencephalitis. Postmortem analysis determined the 
cause to be an increase in CD4+ infiltration, suggesting a T-cell response to Aβ (Serrano-Pozo et 
al., 2011b).  Based on the results of this clinical trial the National Institute on Aging (NIA) 
proposed that passive immunization might be a safer immunotherapeutic strategy than active 
immunization.  
To date in clinical trials of mild to moderate AD, anti- Aβ therapy was able to clear Aβ 
without slowing down or stopping cognitive impairment. The repeated failures of the thousands 
of trials using anti-Aβ therapies are thought to be because the treatment was probably initiated 
too late to be effective. Indeed, it is believed that therapeutic interventions would be useless once 
dementia is established. Because Aβ deposits precede dementia by an average of 10-15 years, the 
current approach is to start treating patients during the pre-symptomatic stage and during MCI. 
MCI is characterized by a mild cognitive impairment without dementia, while the pre-
symptomatic stage is characterized by an intact cognition that is associated with amyloid 
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deposition. Several large prevention studies such as the A4, DIAN, and API are being conducted 
targeting mainly the prodromal and the pre-symptomatic stages of AD. 
Several BACE inhibitors also were tested for their therapeutic efficacy.  MK-8931 is one 
of them. In a Phase I clinical trial this drug was well tolerated with 92% reduction of Aβ from 
CSF and is now undergoing Phase II/III clinical trials. Some active antibodies to A also were 
used. 
Current research now is focused mainly on developing a drug that can slow or prevent 
disease progression. The anti-amyloid therapeutic strategy focuses on decreasing amyloid 
production, inhibiting β and γ-secretases, α secretase promotors, removal of amyloid, active and 
passive immunization, blocking Aβ signaling and inhibiting Aβ aggregation. The anti-tau 
therapies focus mainly on inhibition of hyperphosphorylation, passive and active immunization 
and inhibition of aggregated tau. Growth factors, insulin sensitization and anti-aging drugs are 
being tried as therapies (Waite, 2015).  
1.5.3 Tau immunotherapies 
Despite the critical role that tau plays in several neurodegenerative diseases most tau-
targeted drug discoveries are still in early stages and are not advanced as much as A therapies. 
This is because the whole AD drug discovery field was focused mainly on anti-A therapies due 
to the presence of the autosomal dominant APP mutations PS1 and PS2 in FAD cases. Several 
active and passive tau immunotherapeutic approaches were tested in different mouse strains and 
showed reduction of tau tangles and improvement in cognition (Ingelsson et al., 2004, Serrano-
Pozo et al., 2011a). Different phosphotau peptides were used for active immunization while anti-
tau antibodies were used for passive immunization (see Iqbal et al., 2016).  
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1.5.4 Prevention strategies 
Based on what is commonly known — that the development of neuropathological lesions 
start in the brain of the presymptomatic AD patient at least a decade before developing the 
clinical symptoms — four large secondary prevention trials were initiated. The main goal of a 
secondary prevention trial is to target people who already have the neuropathological changes 
without the clinical symptoms and treat them to prevent progression to clearly diagnostic AD. 
These trials target especially high risk people such as those who carry the autosomal dominant 
mutations or two copies of the APOE4 allele. The Dominantly Inherited Alzheimer’s Network 
(DIAN) study is testing two anti-A antibodies, Solanezumab and Gantenerumab, in a cohort of 
people that have a mutation in PSEN-1 or PSEN-2 or APP; it is currently in a Phase II biomarker 
trial. The Alzheimer’s Prevention Initiative (API) trial is testing Crenezemab in the large 
Columbian family cohort with an autosomal dominant genetic mutation in PSEN-1. Within the 
next two years the API is also planning to recruit people who are homozygous to APOE4 to test 
active vaccination against A and BACE inhibitors. The TOMORROW trial (a clinical trial 
designed to delay the onset of AD) aims to test Pioglitazone to treat glucose metabolism defects 
in carriers of the TOMM-40 gene. The Anti-amyloid Treatment in Asymptomatic Alzheimer’s 
Disease (A4) study is planning to recruit people who have a high risk of cognitive impairment 
based on the accumulation of A but with or without memory complaints. Older people aged 65-
85 will be recruited in a double blind Phase III clinical trial for Solanezumab vs placebo 
(Sperling et al., 2014, Rafii and Aisen, 2015). However, as stated above, all the prevention trials 
that are initiated are mainly based on anti-A therapies, while there is growing evidence now that 
tau spread starts even from the MCI stage, which makes it more reasonable to use a combination 
therapy for anti-amyloid and anti-tau in the pre-symptomatic AD patients.  
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1.5.5 Use of neurotrophic factors in AD treatment and the limits of their applications in 
clinical trials 
Several neurotrophic factors such as NGF, BDNF, neurotrophin-3 (NT-3), neurotrophin-4 
(NT-4) and CNTF exhibit similar structure and function. Each of these factors plays an important 
role in neural development, maturation, proliferation, differentiation and survival of neurons. 
This makes the use of these factors a promising and exciting therapeutic strategy. However, their 
relatively big size (120Aa), short bioavailability, poor blood brain barrier (BBB) permeability 
and adverse side effects have led to disappointing results and limit their use in clinical trials 
(Saragovi and Gehring, 2000). 
NGF 
In the 1990s a small phase I clinical trial was conducted in Sweden where a mouse NGF 
was administered intracerebroventricularly (ICV) to three AD patients. The first two AD patients 
were infused with a 6.6 mg dose of mouse NGF over three months and the third patient with 
three doses of NGF (<0.25 mg) given separately for a total of  22 weeks. The first two patients 
showed slight improvement in cognitive scores while the third patient showed no improvement. 
However, all patients complained of lumbar pain after 11 days of treatment and two of them 
showed weight loss and loss of appetite. All these symptoms ceased after stopping NGF infusion 
(Olson et al., 1992, Eriksdotter Jonhagen et al., 1998). Another study was conducted on rats by 
ICV administration of a recombinant human NGF over 12 weeks. However, hyperplasia because 
of the proliferation of Schwann cells was a major side effect. The hyperplasia was mainly 
explained by the high dose of NGF infused into the ventricles and the effect was mediated 
through the p75NTR receptor (Winkler et al., 1997). Because of the problems encountered in the 
administration of NGF to the brain other means were developed and another phase I clinical 
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study was conducted using AD patients’ genetically modified fibroblasts with a retroviral vector 
to produce NGF and injection of these cells into the basal forebrain. Two of the patients were 
affected by the severity of the surgical intrusion and the rest showed a slowing in cognitive score 
deterioration by 3 points per year instead of 6 points in the MMSE score (Tuszynski et al., 2005).  
Another method of NGF delivery was developed to overcome the previously mentioned 
problems through CERE-110; CERE-110 is a gene therapy product designed to deliver NGF to 
the brain through an adeno-associated virus (AAV), specifically to the nucleus Basilis of 
Meynert. It is administered surgically in the brain. NGF is a neurotrophic factor that enhances 
the survival and death of cholinergic neurons and increases acetylcholine production (Rafii and 
Aisen, 2015). A Phase I clinical study was successfully completed using CERE-110; it showed 
that CERE-110 was safe and well tolerated for two years with a long-term biologically active 
NGF (Rafii et al., 2014). The Phase II clinical study is currently ongoing (Mandel, 2010, Rafii 
and Aisen, 2015). 
BDNF 
The major limitation of the use of BDNF as a therapeutic agent for AD is that it is not 
biologically stable (serum half-life 10 min) and it cannot cross the blood brain barrier (BBB), 
which restricts its oral, subcutaneous or intravenous delivery. ICV injection of BDNF showed 
beneficial effects on memory and neurodegeneration in animal studies. However, because this 
approach is invasive it is used only for animal model studies and not for human clinical trials. 
Injecting the right dose of BDNF is of major importance because a low dose will not have any 
beneficial effects and a high dose will cause serious side effects (Peng et al., 2005). No human 
clinical trials have been conducted in AD, Parkinson’s disease or Huntington’s disease with 
BDNF. Five clinical trials were conducted (four with ALS and one with diabetic neuropathy) and 
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all of them were discouraging (Lu et al., 2013). In one amyotrophic lateral sclerosis (ALS) 
clinical trial, methionyl human BDNF was infused subcutaneously or intrathetically to patients. 
BDNF was well tolerated but it failed to show any significant effects on patients’ survival 
because of the small number of patients and the contradictory results. The major problem faced 
was that BDNF penetration was limited to the superficial layers and did not go through the 
parenchyma of the brain and spinal cord (Beck et al., 2005, Nagahara and Tuszynski, 2011). The 
most challenging problem in the use of BDNF as a drug is to deliver it directly to its target with 
minimal exposure to undamaged tissues. 
CNTF 
CNTF is a 22.7 KDa protein synthesized by astrocytes and Schwann cells. It is a member 
of the neurokine superfamily. CNTF expression develops during the second postnatal week and 
is almost exclusively limited to the nervous system (Hagg, 2009). In the peripheral nervous 
system, CNTF is synthesized in muscles and released by the motor neuron terminals and then 
retrogradely transported to the cell bodies. It is considered to be an autocrine and paracrine signal 
that is involved in the activation of astrocytes and responsible for hypertrophy in case of injury to 
the intact nervous system. In fact its retrograde transport increases with nerve lesion. After nerve 
lesion, CNTF prevents atrophy of skeletal muscles but has no effect on healthy innervated 
muscles, suggesting its mobilization only in a pathological state. It has been found to be 
decreased in the human sciatic nerve in motor neuron diseases. CNTF acts by binding primarily 
to the GPI-anchored alpha subunit of the CNTF receptor complex alpha (CNTFR). This 
induces the recruitment of two other transmembrane receptor proteins, LIFR and gp130, 
resulting in their dimerization and tyrosine phosphorylation. This leads to the activation of the 
JAN kinase/ STAT signaling pathway (Siegel and Chauhan, 2000). STAT proteins then 
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translocate to the nucleus where they bind specific DNA sequences responsible for the 
transcription of responsive genes (Lanni et al., 2010).  
In a previous study using cultured basal forebrain cholinergic neurons isolated from 2-
week-old rats CNTF was shown to act synergistically with BDNF and promote the survival of 
choline acetyl transferase-positive neurons. BDNF alone induced a three-fold increase of 
neuronal survival. However, when CNTF was added to the culture, the number of survived 
neurons increased to eight fold. When applied alone, CNTF has very little effect on neuronal 
survival. The synergetic effect was localized only to basal forebrain cholinergic neurons and not 
to the hippocampus, basal forebrain or cerebellum. CNTF also enhanced neuronal protection 
synergistically with NT-4 but not NGF. In addition BDNF mediated protection was enhanced by 
the LIF and not IL-6. This suggests the involvement of TrkB and CNTFR  receptors in the 
synergetic effects (Hashimoto et al., 1999). 
When applied after motor neuron injury to animal models of neuromuscular disease, 
CNTF prevented neuronal death and partially restored motor function. Since CNTF is expressed 
mainly by glia cells in the PNS and the CNS, it has been implicated in neural stem cell fate 
determination and survival as well as neuronal and glia differentiation and development (Siegel 
and Chauhan, 2000, Lanni et al., 2010). In a recent study it has been shown that CNTF enhances 
forebrain neurogenesis and it is expressed in the astrocytes in the subventricular zone, the brain 
area where dopaminergic neurons regulate neural precursor cell proliferation. These findings 
suggest a link between CNTF, neurogenesis and dopamine. This link was further supported by 
the findings that CNTF is an endogenous regulatory component of Dopamine D2-receptor-
dependent neurogenesis in the subventricular zone and the dentate gyrus in adult mice (Mori et 
al., 2008, Yang et al., 2008). Indeed, the dopminergic pathway to the striatum regulates CNTF 
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expression and regulates neurogenesis only through CNTF (Yang et al., 2008).  It was shown 
that CNTF supported neuronal survival in vivo and in vitro in models of neurodegeneration (Ip 
and Yancopoulos, 1996). However, attempts to use CNTF as a therapeutic drug were 
unsuccessful. Axokine, a modified version of human CNTF, with a 15 amino acid truncation at 
the C-terminus and substitution of two amino acids, was shown to be 5 times more potent and 
stable than the original CNTF in vivo and vitro (Lanni et al., 2010); when administered 
systematically to patients with ALS it yielded disappointing results. CNTF delivery failed to 
achieve sufficient concentration in the brain, with no significant efficacy; too many adverse side 
effects such as weight loss, muscle pain and anorexia occurred. However, despite these 
disappointing results CNTF clinical trials showed promising effects in Huntington disease and 
retinal degeneration (Lanni et al., 2010). NT-501 is a drug that consists of encapsulated human 
cells that are genetically modified to secrete CNTF; this drug showed significant effects in a 
Phase II clinical trial of retinitis pigmentosa (a photoreceptor degeneration that eventually leads 
to blindness) (Talcott et al., 2011). 
 
1.6 Use of peptide mimetics to overcome the limitations of neurotrophic factor 
therapeutics 
In neurodegenerative diseases such as AD the compensation mechanism, by increasing 
neurogenesis and synaptic plasticity, should at least slow down the progression of the disease at 
the early stages. This makes boosting neurogenesis and synaptic plasticity to treat AD a very 
important and exciting therapeutic approach. The design of small peptide mimetics that are 
biostable, able to cross the BBB and not easily degraded by peptidases can offer the opportunity 
to stimulate the secretion of neurotrophic factors and/or mimic their neurotrophic/neurogenic 
activities.   
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A currently approved drug, Memantine, which inhibits neuronal death, addresses only the 
symptoms of AD and slows down cognitive deterioration without stopping or reversing it. Since 
neuronal loss plays a pivotal role in cognitive impairment, one might expect that a small 
molecule that has a dual function of promoting neurogenesis and neuroprotection could stop the 
sharp and fast cognitive decline and reverse the disease state (Kelleher-Andersson, 2004). 
Several clinical trials were conducted using neurotrophic factors such as NGF, CNTF or BDNF 
as described above in sections 1.5.4 and 1.5.5. However, the major problems have been how to 
deliver them to the brain and how much should be delivered so that it can reach the target 
neurons, the severe side effects, and how the mechanism of neurotrophin signaling is integrated 
in the disease mechanisms (Longo and Massa, 2004).  Because of the multiple effects of the 
neurotrophic factors on neuronal activity major side effects such as pain and gastrointestinal 
symptoms have been reported after BDNF delivery. More severe side effects such as fever, pain 
and anorexia were also reported after using CNTF in clinical trials, which limited the doses 
investigated (Thoenen and Sendtner, 2002). The use of small molecule neurotrophic factor 
mimetics can overcome the blood brain barrier permeability and stability problems encountered 
in the delivery of the full-length proteins.  
In ligand mimetics large polypeptides are reduced to small functional units that contain 
the site of interaction in which the molecule can block or activate specific receptors.  What 
makes mimetics useful is that the protein-protein interaction occurs only in a few key regions or 
“hot-spots” instead of the overall protein surface. Two approaches have been used to develop 
small peptide mimetics. The first one is to mimic antibodies for neurotrophin receptors and the 
second one is to mimic the ligand itself (neurotrophins). Both antibodies and neurotrophin 
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mimetics should bind to the same receptor as the original molecule from which they are derived 
(Saragovi and Gehring, 2000).  
NGF peptide mimetics 
A previous study reported the development of a promising small molecule non-peptide 
ligand of p75NTR that promotes survival-related signaling, inhibits A induced neurodegeneration 
and  reduces neurodegeneration in A treated neuronal cultures. The molecule, named LM11-
A31, is a water soluble amino acid derivative that crosses the BBB and works as an antibody 
analog of NGF. It has a structure similar to the NGF1 loop domain that interacts with p75NTR and 
it prevents neurodegeneration through the activation of the PI3 kinase/AKT signaling pathway 
(Longo et al., 1997). Previous work also showed that when this molecule was administrated early 
in the process of AD pathology right after appearance of A plaques in a mouse model of AD it 
prevented cognitive impairment and atrophy of the basal forebrain cholinergic neurons. 
Administration of the molecule late in the process of AD pathology in two AD mouse models, 
Thy-1 hAPP Lond/Swe (APPL/S) and Tg2576, was able to reverse atrophy in the cholinergic 
neurons of the basal forebrain, reduced cortical atrophy and normalized the increased levels of 
p75NTR in the basal forebrain (Simmons et al., 2014). In another study a small molecule -turn 
analog of an antibody directed against the extracellular domain of the TrkA receptor was 
developed and behaved pharmacologically as a partial agonist (Maliartchouk et al., 2000).  
BDNF mimetics 
The BDNF molecule has a moderate size and charge, which limits its ability to cross the 
BBB and its peripheral administration (Nagahara and Tuszynski, 2011). The use of a small 
molecule mimetic of BDNF that could be applied locally or systematically can overcome the 
limitations to the application of the full length BDNF molecule. It avoids the adverse side effects 
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of the invasive methods of delivery and uncontrolled doses, and  improves BDNF diffusion 
(Zuccato and Cattaneo, 2009). 
 A small molecule that acts as a TrKB receptor agonist or modulator and could imitate the 
biological activity of BDNF by binding with higher affinity to TrkB and p75NTR and have 
neuroprotective effects through its downstream pathways would present a potential therapeutic 
drug for AD. One of the most remarkable BDNF mimetics that has appeared in the literature is 
7,8- dihydroxyflavone (7, 8-DHF), which showed a high affinity to the TrkB receptor, imitated 
BDNF biological activity, reduced A toxicity and synaptic dysfunction, and prevented 
cognitive impairment in animal models. This molecule has a high bioavailability and penetration 
of the BBB.  However, further investigations are required to determine the stability and 
specificity of the drug and the agents that can interfere with its activity (Zhang et al., 2014, Song 
et al., 2015).  
In our lab 5 different tetra peptides corresponding to different active regions of BDNF 
were screened. All five tetra peptides were found to be nontoxic and induce the expression of 
neuronal markers in mouse E18 primary hippocampal cell culture. Two of the five peptides (B3 
and B5) were found to function as partial agonists/antagonists and to compete with BDNF to 
activate the TrkB receptor in a dose dependent manner. The primary results of this screening 
showed that these two peptidomimetics have neurogenic/ neurotrophic effects, can modulate 
BDNF signaling in a partial agonistic/antagonistic manner, and can be promising therapeutic 




P021- a CNTF peptide mimetic 
Employing neutralizing antibodies, our lab showed previously that the 
neurogenic/neurotrophic effect of an anti-dementia drug, Cerebrolysin, in AD patients was due to 
the presence of CNTF, FGF-2, GDNF, IGF-1 and IGF-2. CNTF, however, had the strongest 
neurogenic/neurotrophic characteristics, and could counteract the mitogenic effect of FGF-2 and 
decrease the number of nestin positive cells (Chen et al., 2007).  Based on these findings an 
epitope mapping of the neutralizing antibodies was carried out to help identify the most 
biologically active region of CNTF. An 11-mer peptide, peptide 6 (Aa 146-156, Ac-
VGDGGLFEKKL-NH2), was discovered. Studies on C57BL6 mice showed that this peptide 
boosted neurogenesis by increasing the number of proliferating and differentiated hippocampal 
neurons. It also improved hippocampal spatial memory when administered peripherally via slow 
release bolus. Moreover, the peptide was found to increase synaptic plasticity by increasing in 
the level of expression of synaptophysin and MAP2 (Chohan et al., 2011). Peptide 6 contains a 
putative leukemia inhibitory factor receptor (LIFR)-binding sequence of CNTF and acts by 
competitively inhibiting LIF. It is BBB permeable and it has a plasma half-life of more than 6 h. 
In an attempt to test Peptide 6 as a potential drug in AD another study was conducted in our lab 
in a 3xTg-AD mouse model of AD, which harbors three mutated transgenes (APPSwe, tau P301L 
and PS1 M146V) and shows AD like pathological features. The study was conducted on 6-7 
month old animals in the mild stages of the disease process before development of any overt A 
plaques or NFT. Peripheral administration of peptide 6 by intraperitoneal injection for one month 
induced neurogenesis, reduced ectopic birth in the DG, enhanced synaptic plasticity in the 
hippocampus and cerebral cortex and improved cognition (Blanchard et al., 2010b).  In a 
subsequent study an experimental rat model (AAV1-I2NTF-CTF infected brain) of the sporadic 
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form of AD was treated with peptide 6 for 40 days by daily intraperitoneal injection. Peptide 6 
administration was found to rescue neurodegeneration and cognitive impairment in 2.5 month 
old I2NTF-CTF rats, increasing DG neurogenesis, the mRNA levels of BDNF and synaptic 
plasticity as determined by the increase in synaptic and dendritic marker expression, especially in 
the CA1 and CA3 areas of the hippocampus (Bolognin et al., 2012). Peptide 6 was used in the 
Ts65Dn mouse model of Down’s syndrome. Subcutaneous administration through a slow release 
pellet with a continuous dosing for 30 days enhanced neurogenesis and neuronal plasticity and 
inhibited cognitive impairment in these mice (Blanchard et al., 2011). Furthermore, Peptide 6 
treatment of neuronal cell culture and newborn Wistar rats injected with autism sera reduced 
neuronal death and oxidative stress and restored the balance of neurotrophic factors (Kazim et 
al., 2015).  
The active region of Peptide 6 was further narrowed down and a four amino acid peptide 
(Ac-DGGL-NH2) called Peptide 6c that corresponds to the CNTF amino acids 148-151 was 
generated. Peptide 6c was administered subcutaneously in a continuous dose for 30 days to C57 
BL6 mice. The results showed that Peptide 6c, like its parent molecule, increases neurogenesis, 
synaptic plasticity and cognition without weight loss or any apparent side effects such as 
anorexia or muscle pain. Peptide 6c acts like its parent Peptide 6 by competitively inhibiting the 
LIF through the JAK/STAT pathway.  LIF acts by increasing self-renewal and proliferation of 
neural progenitor cells. By inhibiting this activity Peptide 6c would promote proliferation and 
maturation of neural precursor cells through CNTF signaling and thus boost neurogenesis 
(Blanchard et al., 2010a). Peptide 6c was adamantylated on its c-terminal to increase its 
lipophilicity to cross the BBB and to decrease its degradation by carboxy peptidases to make it 
more druggable. The pentamer Peptide-021 (P021) thus was generated (Fig. 5) with the sequence 
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Ac-DGGLAG-NH2. When administered peripherally to normal WT mice, P021 increased 
neurogenesis and neuronal plasticity, as shown by the increase in the expression of 
synaptophysin and synapsin1, and it significantly improved cognition by enhancing short-term 
memory encoding in the novel object recognition task and spatial memory in the Morris Water 
Maze task. P021 acts the same as peptide 6c by competitively inhibiting LIF through the slight 
inhibition of the LIF-induced STAT3 phosphorylation in a dose-dependent manner (Li et al., 
2010). 
Because aging is a great risk factor for AD, the effect of P021 was studied in a rat model 
of cognitive aging decline. Oral administration of P021 to 22-24 month old Fisher rats 
significantly reduced cognitive decline related to aging, increased neurogenesis and neuronal 
plasticity, increased the level of BDNF expression and significantly decreased the level of 
hippocampus myoinositol, a metabolite that increases with age (Bolognin et al., 2014). Recently 
another study was conducted in which P021 was administered in diet to 9-10 month old 3xTg-
AD mice for 12 months. A significant decrease in tau pathology, probably through the increase 
in BDNF expression level and the inhibition of GSK3, was found in these animals at moderate 
to severe stage of the disease. Furthermore, a decrease in soluble A levels and a trend toward 
decrease in A plaques load were found. P021 also increased neurogenesis and neuroplasticity 














Fig. 5. Steps in the design of Peptide 021 (Li et al., 2010) 
 
 
1.7 The triple transgenic mouse model of AD, 3xTg-AD 
The use of animal models in preclinical studies to test the effect of the drugs and their 
efficacy has been of great importance in advancing the drug discovery field. In AD especially 
several mouse models were used and they helped in better understanding molecular mechanisms 
of the disease and to design more efficient therapeutic approaches in attempts to cure it. The 
3xTg-AD mouse model developed by Oddo et al. (Oddo et al., 2003b) harbors three mutated 
transgenes: APPSwe mutation, tau P301L mutation and PS1 M146V knock-in. It is abiologically 
relevant mouse model to AD because it develops A and tau pathologies in a time and 
topographic manner which closely mimics the human pathological distribution.  Indeed, the Aβ 
pathology starts in the neocortex at ~ 6 months and expands to the hippocampus at ~12 months; 
NFT start at around 12 months in this model (Oddo et al., 2003a, Oddo et al., 2003b). Cognitive 
impairment starts as early as 3 months of age, with synaptic dysfunction preceding the onset of 
A and tau pathologies which also mimic early cognitive impairment in AD patients. This shows 
the relevance of this mouse model to study AD-like pathologies compared to, for instance, the 
46 
 
double transgenic mouse Tg2576xJNPL3 (APPSwe), which fails to develop early behavioral 
impairment (Rodriguez and Verkhratsky, 2011). 
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Chapter 2. Materials and Methods 
2.1 Animals and housing 
The homozygous 3xTg-AD mice express two mutated human transgenes, APPSwe and 
P301L, and human PS1 M146V knock-in. Breeding pairs of these mice were obtained from Dr. 
Frank LaFerla through the Jackson laboratory (New Harbor, ME, USA). Wild type (WT) age-
matched control from the same background strain, hybrid 129/Sv x C57BL/6, were also obtained 
from the Jackson Laboratory. Animals were housed and bred according to approved protocols 
from our Institutional Animal Care and Use Committee (IACUC), according to the PHS Policy 
on Human Care and Use of Laboratory Animals (revised January, 2013). Animals were housed 5 
animals/cage with a 12:12 h light/dark cycle and with free access to food and water. They were 
given a period of acclimatization of 45 min to 1 h before any behavioral test was performed. 
Only young adult female 3xTg-AD mice and age-matched WT control mice were used in this 
study because it has been shown previously that female 3xTg-AD have more aggressive 
pathology than males. They show more A deposition, worse cognitive performance and a 
higher deficit in neurogenesis than males (Clinton et al., 2007, Hirata-Fukae et al., 2008, Carroll 
et al., 2010). To exclude any effect of behavioral studies on neurogenesis, animals other than 
those used for behavioral studies were employed for immunohistochemical/biochemical studies 









Table 1. Total animals used in the study. 
  
Project Animals used 
Synaptic compensation 
Immunohistochemistry  and Western blots 
28 WT; 26 3xTg-AD-vh 
10 weeks (WT, n = 5; Tg-AD, n = 3) 
12 weeks (WT, n = 5; Tg-AD, n = 4) 
13 weeks (WT, n = 4; Tg-AD, n = 4) 
14 weeks (WT, n = 5; Tg-AD, n = 6) 
15 weeks (WT, n = 4; Tg-AD, n = 4) 
16 weeks (WT, n = 5; Tg-AD, n = 5) 
Behavior 
20 WT; 15 3xTg-AD-
vh; 14 3xTg-AD-P021 
P021-prevention study 
Immunohistochemistry and Western blots 
21 WT; 20 3xTg-AD-vh; 22 3xTg-AD-P021 
3 months (WT, n = 6; Tg-AD-vh, n = 6) 
12 months (WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-
P021, n = 5) 
18 months (WT, n = 5; Tg-AD-vh, n = 4; Tg-AD-
P021, n = 5) 
21 months (WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-




2.2 P021 treatment 
After the Morris Water Maze task at ~ 3 months of age, the animals were divided into 
three groups; one group of 3xTg-AD-P021 (n= 36) treated with 60 nmole of P021/g feed in diet; 
another group of 3xTg-AD-vh (n = 35) treated with the same diet but without P021; and a third 
group of WT (n=40) treated with the same diet but without P021.  P021 was formulated by 
Research Diets (New Brunswick, NJ). Food consumption was recorded every two weeks and 
body weight every month. The average mouse food consumption was  2.7 g feed/day. Animals 
were tested behaviorally at four different time points: 0 (before treatment), 9, 15, and 16-17 
months (post-treatment). 15 3xTg-AD-vh, 14 3xTg-AD P021 and 20 WT mice were used for 
behavioral studies. The rest of the animals were used for immunohistochemical and biochemical 
studies at the above time points.  
2.2.1 Design and synthesis of P021  
The chemical structure of P021 is shown in Fig. 6. It is a pentapeptide (Ac-DGGLAG-
NH2; mol. wt. of 578.3) generated by the addition of adamantylated glycine at the C-terminus of 
CNTF tetrapeptide (amino acid residues 148–151). The adamantylated glycine was added to 
P021 to increase its BBB permeability and decrease its degradation by carboxy peptidases 
(Blanchard et al., 2010a, Li et al., 2010, Chohan et al., 2011). P021 was synthesized and purified 
by reverse phase HPLC to > 96% purity as described previously (Li et al., 2010). The sequence 
of the P021 was confirmed by mass spectrometry.  
2.2.2 P021 stability in plasma and gastric and intestinal juices and blood–brain barrier 
permeability 
P021 has >95% stability in artificial gastric juice during 30 minutes, ~100% stability in 
intestinal fluid during 120 minutes, a plasma stability of >3 hours and is BBB permeable (Kazim 










Fig. 6. Chemical Structure of P021. 
 
2.3 Behavioral Procedures 
2.3.1 Elevated Plus Maze 
The elevated plus maze is a test for anxiety/emotionality in mice. The test apparatus was 
composed of four arms (30 x 5 cm) connected together by a 5x5 cm central zone. There were 
two opposite facing closed arms (CA) covered by 20 cm high walls of opaque plexiglass and two 
opposite facing open arms (OA). The entire plus-maze was elevated on a pedestal to a height of 
82 cm above floor level in a separate room from the investigator. The luminosity of the room 
was kept at 60 lx so that light would not exert any anxiogenic effect on the mice. Each animal 
was put in the center zone facing one of the open arms and it was automatically recorded for a 
total of 8 min using the ANY-Maze software tracking system (ANY-Maze software, version 4.5, 
Stoelting Co., Wood Dale, IL, USA). After each session the mouse was removed and returned to 
its cage. The floor was cleaned of feces with 70% alcohol to remove any olfactory cues. For each 
animal the time spent in CA, OA, and the total time spent in the OA + CA were recorded. 
Because mice prefer CA to OA, the percent of time spent in the OA was analyzed to evaluate 
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anxiety-like behavior. The percentage of time in OA was calculated as the percentage of time 
spent in the OA over the total time spent in the OA + CA, i.e., [OA/(OA+CA)] × 100. 
2.3.2 Open-field test 
The open field test was used to assess anxiety-like behavior and locomotor activity in 
mice. An open field apparatus (a PVC square arena, 50 x 50 cm, with walls 40 cm high) was put 
in a separate room from the experimenter and 60 lx of light was used to avoid the anxiogenic 
effects of light on mice. Each animal was allowed to explore the arena for 15 min and 
automatically recorded using the ANY-Maze software tracking system (ANY-Maze software, 
version 4.5, Stoelting Co., Wood Dale, IL, USA). After each session the animal was removed 
and returned to its home cage. The floor was cleaned of feces using 70% alcohol to remove any 
olfactory cues.  Movements of the animal were recorded using a camera that surmounted the 
open field apparatus; the camera was connected to a computer equipped with tracking software 
The time spent in the central zone and the distance traveled were recorded using the ANY-Maze 
software. The anxiety was measured by the analysis of the percentage of time spent in the central 
zone and the locomotor/exploratory behavior by the total distance traveled during the 15 min 
duration of the test. 
2.3.3 Accelerating Rota-rod test 
Rota-rod is a test of locomotor activity in rodents. During a test trial each animal was put 
in one of the four chambers in the apparatus. The motor of the apparatus was set up in an 
accelerating mode (factory setting) at a rate of 0.02 cm/s, from 4 to 40 rpm. Each animal was put 
through two sessions of three trials and the fall latency was measured. 
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2.3.4 Prehensile traction test 
This test was used to measure grip strength. The apparatus consisted of a horizontal wire 
60 cm above the ground. Animals were made to grab the wire with their forepaws and then the 
latency to fall was recorded to a maximum of 60 s.  
2.3.5 Morris Water Maze task  
The Morris Water Maze task is a test of reference memory, which is a measure of hippocampal 
function. The test was a modification of the original procedure by Morris et al. (Morris et al., 1982). 
Animals were divided into three groups: 15 3xTg-AD-vh, 14 3xTg-AD-P021 and 20 age-matched wild 
type (WT) control mice. The procedure was performed in a circular pool tank, 180 cm in diameter. A 13 
cm escape platform was submerged 1 cm below the surface of opaque water in the Northwest quadrant. 
The water was made opaque by the addition of a white non-toxic chalk to make the escape platform 
invisible to mice. Spatial cues were set up in the test room to help the animals find the platform from the 
distant cues. The temperature of the water was kept at 21± 1°C.  In each trial the animal was given 90 s to 
find the escape platform. If the animal did not find the escape platform it was gently guided to it. Each 
animal was left for 20 s on the escape platform and then it was returned to its cage. In each trial the mouse 
was released from a different quadrant with its back toward the center of the tank and the starting point 
was changed each day so that the animal would not learn the place of the platform without using the 
spatial cues. The acquisition trials were conducted for four consecutive days. The retention test or probe 
trial, in which the escape platform was removed and the animal was allowed to swim for 60 s, was 
conducted 24 h after the last acquisition trial. The measure of acquisition was the time and distance swum 
to reach the escape platform. The measures of retention were the percent of time spent in the target 
quadrant and the number of entries into the target zone.  Behavior of the animal in the Morris Water Maze 
was recorded using a Samsung digital camera (SDC 4304) mounted on the ceiling; SMART version 
2.0.14 software (Pan Lab/San Diego Instruments) was used for tracking and timing of each trial. 
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2.3.6 Object location task 
The object location task in the open field is a test for short-term spatial memory, which is 
mainly hippocampal dependent. In this test the 18 month old animals were required to identify 
the location of the object as novel or familiar based on a previous experience. The test consists of 
a habituation phase, a sample phase and a test phase. During the habituation phase animals 
underwent a total of 6 sessions, 2 sessions/day, and each session lasted 10 min within 2 h of 
inter-trial interval. Neophobia measurements, in which an object was put in the center of the 
arena and the amount of exploration time was recorded, were done during the first habituation 
phase. Twenty four hours after the last habituation session the sample phase and the test phase of 
the Novel object location were conducted. During the sample phase two identical objects were 
placed symmetrically in two different places, each 15 cm away from the corner, and animals 
were allowed to explore them for 5 min. One hour later, in the test phase, one of the two objects 
was moved to a new location 15 cm away from the corner, in a symmetrical position to the 
familiar one, and the time spent exploring each object was recorded. To evaluate cognitive 
performance a discrimination index was calculated as follows: [(time exploring the new location 
– time exploring familiar location)/ total time exploring both locations] x 100. Mice were 
considered to be impaired if they spent more time investigating the familiar location than the 
novel one. After each trial the objects were removed and cleaned with 70% alcohol to remove 
any olfactory cues.  
2.3.7 Object recognition task  
The novel object recognition task is a test used to evaluate short-term episodic memory, 
which depends on the entorhinal cortex, hippocampus and frontal cortex. In this task the 19-20 
month old mice were required to identify an object as familiar or novel based on a previous 
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experience with one of the two objects they encountered before in the open field. The general 
procedure of the test consists of three different phases: a familiarization phase, a sample phase 
and a test phase. The familiarization phase consists of four sessions of 10 min each, one session 
per day for four days. During each session each animal was allowed to explore the arena for 10 
min, then was put back into the cage.  On the 5th day animals were subjected to the sample phase 
and each two identical objects were symmetrically placed in the center of the arena 15 cm away 
from each corner. After 15 min delay in which the mouse was returned to its home cage, the 
animal was reintroduced to the arena to perform the test phase. The mouse was then presented to 
a familiar object (previously seen during the sample phase) and a novel object in the same 
location as in the sample phase. The object discrimination index was calculated as (time spent 
close to the new object)/(time close to both old and new objects) during the test phase. Animals 
were considered to be impaired if they had a discrimination index (DI) ≤ 0.5. A discrimination of 
0.5 means that the animal discovered both objects in a similar time and had no preference for 
novelty.  
 
2.4 Tissue processing 
Animals were anesthetized using an overdose of avertin and transcardially perfused using 
0.1 M PBS. The brain was immediately removed from the skull. The right hemisphere was 
immersion fixed with 4% paraformaldehyde in 0.1 M PBS for at least 24 h at 4°C then 
transferred to 30% sucrose; the left hemisphere was dissected into hippocampus, fore, mid, and 
hind brains, and stored at -80C for biochemical studies. After fixation and cryoprotection, the 
right hemisphere was sectioned into 40 um sagittal sections, then saved at -20°C in antifreeze 





For immunohistochemistry 3-5 animals/group were chosen randomly. Every tenth 
section, 5 to 6 sections/mouse, were used for staining intensity-scanning analysis. For 
immunofluorescence, sections recovered from the glycol antifreeze solution were washed three 
times, 1X PBS for 15 min then incubated in 0.5% Triton-X100 in PBS for 15 min. Sections were 
then washed 3 times in 1X PBS for 15 min each and blocked in 5% normal goat serum 
containing 0.05% Tween-20 and 0.05% Triton X-100 for 45 min. Sections were then incubated 
overnight at 4C with the corresponding primary antibodies (see Table 2 for all the antibodies 
that were used in this study). Treatment with the primary antibody was followed by treatment 
with the corresponding secondary fluorescent antibody, either Alexa 488-conjugated goat anti- 
mouse IgG antibody (1:500, Molecular Probes, Carlsbad, CA, USA) or CY3-conjugated goat 
anti-rabbit antibody (1:500, Jackson Laboratory, Bar Harbor, Maine, USA), for 2 h at RT and 
protected from light. Sections were washed 3 times with 1X PBS for 20 min each and then 
mounted on microscope slides with fluorogel mounting medium (Electron microscopy, Hatfield, 
PA). All the slides were then covered with coverslips and stored at 4C until analyzed by 
confocal microscopy under identical conditions. For all the stainings maximum projection 
images were generated using the average of 15 Z-stacks using the 20X objective of a Nikon 90i 
fluorescent microscope equipped with a Nikon C1 three-laser confocal system and a Nikon DS 
U1 digital camera. The entire area of the DG, CA1, CA3, parietal association and frontal cortices 
were analyzed. Mean pixel intensity was measured for each brain region using the Image J 
software package (NIH). 
For A staining an extra step of antigen retrieval was added right after the washes of the 
sections from the glycol anti-freeze solution. Briefly, 5-6 sections per mouse were put in a petri 
dish glass container containing 0.01 M citrate buffer and heated for 2 min until boiling. Sections 
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were then left to cool down at RT and treated with 50% formic acid for 5-7 min. Sections were 
then washed one time in 1X PBS for 15 min and then incubated in 0.5% Triton X-100 and the 
same procedure was followed as stated above.  
To study neurogenesis the DCX and Ki67 double immunostaining were performed 
immunohistochemically. Primary antibodies for DCX (mouse monoclonal IgG) and Ki-67 (goat 
polyclonal IgG) are stated on Table 2. The corresponding secondary antibodies were used: 
Alexa-555 conjugated goat anti-mouse IgG antibody (1:500, Invitrogen, Camarillo, CA, USA) 
and Alexa-488 conjugated donkey anti-goat IgG (1:500, Invitrogen, Camarillo, CA, USA). The 
same procedure as stated above was used for the immunohistochemical staining with the addition 
of the extra step of the antigen retrieval. Sections were then counterstained with the nuclear 
staining TO-PRO-3 iodide (1:1000, Invitrogen, Camarillo, CA, USA) for 30 min and then 
washed two times for 20 min. 5 mice per group and 5 sections (every 10th section) per brain per 
mouse were analyzed. All sections were carefully investigated for the DCX positive staining and 
the Ki67 positive staining. Labeled cells in the granule cell layer and the hilus of the DG of the 
hippocampus were manually quantified using a 40x oil objective of a Nikon 90i fluorescent 
microscope. The number of DCX+ staining cells and Ki-67+ cells was reported as percent of 
control. DCX is a marker of immature adult-born neurons and Ki-67 is a marker of cell 
proliferation. 
 
2.6 Western Blots 
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The brain tissue stored at -80C from each mouse was homogenized using a Teflon-glass 
homogenizer to generate 10% (w/v) homogenate. The pre-chilled homogenization buffer 
contained 50 mM Tris.HCl (pH 7.4), 8.5% sucrose, 2 mM EDTA, 2 mM EGTA, 10 mM β-
mercaptoethanol plus the following protease and phosphatase inhibitors: 0.5 mM AEBSF, 10 
μg/ml aprotinin, 10 μg/ml leupeptin, 4 μg/ml pepstatin, 5 mM benzamidine, 20 mM β-
glycerophosphate, 50 mM sodium fluoride, and 1 mM sodium orthovanadate. Protein 
concentration of each brain homogenate was determined by the Pierce 660 nm protein assay kit 
(Pierce Biotechnology, Rockford, IL USA). The tissue homogenates were boiled in Laemmli’s 
buffer for 5 min and then subjected to 7.5 % or 10% SDS-polyacrylamide gel electrophoresis 
followed by transfer of separated proteins on 0.45 µm Immobilon-P membrane (Millipore, 
Bedford, MA, USA). The blots were developed using the corresponding primary antibodies 
(Table 2). Rabbit monoclonal anti-GAPDH (1:2,000; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) was used for the development of the blots as a loading control. The corresponding 
horseradish peroxidase-conjugated affinity-pure goat anti-mouse IgG (H+L) and anti-rabbit IgG 
(H+L) secondary antibodies were used (1:5,000; Jackson Immuno Research Laboratories, Inc., 
West Grove, PA, USA). The blots were visualized using enhanced chemiluminescence (ECL) 
reagents (Pierce, Rockford, IL, USA). The ECL films of the blots were scanned and then 
analyzed using Image J (NIH) and Multigauge softwares (Fuji Photo Film, Co., Ltd). Each 
protein’s band intensity quantification was the result of the subtraction of the background 
intensity from the original intensity of the band. Finally, the intensity of each band minus the 
background was normalized over the intensity of the GAPDH band minus the background. 
Statistical analysis was conducted using either the GraphPad Prism software package, version 5.0 
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(GraphPad Software Inc., La Jolla, CA, USA), or the Stata 13 statistical package (StataCorp, 




Table 2. Antibodies Used 
 












Covance SMI-52R yes yes 
-III tubulin 
1: 1000 IHC 
1:10000 WB 
Covance PRB-435P yes yes 
PSD95 











 Kind gift from Dr. Peter Davies yes yes 




ABCAM ab17345 yes yes 
GluR 2/3 1:2000 ABCAM 52896 no yes 
4G8 1:200 IHC BioLegend 800701 yes no 
DCX 1:50 IHC Santa Cruz sc-8066 yes no 




Stress Gene VAP-SV060 yes yes 




2.7 Fluorojade C staining 
Fluorojade C staining was performed according to the procedure developed by Schmued 
et al. (Schmued et al., 1997). Briefly, sections were mounted on positively charged slides and 
dried at 30-45C in the oven for 20 min. They were briefly rinsed in distilled water followed by 
incubation in 100% alcohol for 3 min, 70% alcohol for 1 min, 1 min in 30% alcohol and then 
rinsed 1 min in distilled water. To enhance the Fluorojade C staining, sections were first 
incubated in 0.06% potassium permanganate (KMnO4) for 15 min (for 200 ml of distilled water, 
120 mg KMnO4 was added and then stored at 4C) then rinsed with distilled water for 1 min. A 
stock solution of 0.01% of Fluorojade C was prepared (25 mg of Fluorojade C powder was 
added to 250 ml of distilled water), then a working solution of 0.001% from the stock solution 
was used for the staining (20 ml of Fluorojade C stock solution and 180 ml of 0.1% acetic acid). 
After incubation of 30 min the sections were then washed 3 times in distilled water and dried for 
20 min at 30-45C in the oven. The dry sections were incubated 3 times in xylene for 2 min each 
before mounting with DPX Fluka (Milwaukee, WI). Images for the Fluorojade C positive signals 
were captured using a Nikon 90i fluorescent confocal microscope. The percent of area occupied 
was quantified using the Image J. All the pictures were taken using a 20X objective. 
 
2.8 Statistical analysis  
Statistical analyses were conducted using Stata and GraphPad Prism. Tests of scalar 
predictors were done with regression models;  in Stata 13 (StataCorp, College Station, Tx; 
(Liang and Zeger, 1986, Zeger and Liang, 1986)). For multiple group comparisons one-way or 
two-way ANOVAs followed by post-hoc tests were used. T-tests were used for all other inter-
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group comparisons. Data are presented as mean±SD.  For all analyses p < 0.05 was considered to 
be significant.  
 
2.9 Study design.  
In order to study the synaptic compensation phenomenon which represents Specific Aim 
1 of this study, 27 WT and 25 3xTg-AD-vh mice were chosen for immunohistochemical and 
biochemical studies. Six different age groups were used: 10, 12, 13, 14, 15, and 16 weeks. 
Another set of animals, 29 3xTg-AD-vh and 20 WT, went through general behavioral studies and 
the Morris Water Maze task at around the age of 12-14 weeks. Right after completion of the 
Morris Water Maze task, the mice that were used for behavioral studies were divided into three 
groups, 20 WT, 15 3xTg-AD-vh and 14 3xTg-AD-P021, and another set of mice that did not go 
through behavioral studies, 21 WT, 20 3xTg-AD-vh, and 22 3xTg-AD-P021, were employed for 
immunohistochemical and biochemical analyses. For Specific Aim 2 studies, the mice that were 
employed for behavioral analyses were used to study the effect of P021 on cognition. At 9 
months after treatment with P021 the Morris Water Maze task was conducted .Then at 15- 17 
months after treatment the mice were tested by the object location and the object recognition 
tasks. For Specific Aims 3 and 4, brain samples from mice that were not tested behaviorally were 
taken at the age of 3 months just before the start of the treatment as a baseline measure and then 
at 9, 15 and 18 months after treatment with P021 (Fig. 7). P021 was given in food diet at a 
concentration of 60 nmol/g feed; food consumption was   2.7/mouse/day. Food intake and body 





















Fig. 7. Study design. 
IHC, immunohistochemical; 3xTg-AD-P021, P021-treated 3xTg-AD mice; 3xTg-AD-vh, vehicle 







Chapter 3. Synaptic Compensation 
3.1 Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the most 
common form of dementia in elderly people. It is characterized by two histopathological 
hallmarks: β-amyloidosis and neurofibrillary degeneration, maximal densities of which are seen 
at moderate to severe stages of dementia. However, at a very early stage synaptic dysfunction 
and memory loss are observed in AD.  Synaptic loss is the best correlate of dementia, especially 
the loss of the presynaptic marker synaptophysin (Terry et al., 1991). In fact, synaptophysin 
immunoreactivity was reported to decrease by 25% in the cortex of mild AD patients compared 
to normal cases (Masliah et al., 1995, Masliah et al., 2001). Degeneration of the whole synaptic 
element, seen as simultaneous loss of presynaptic proteins synaptophysin and Rab 3A and 
postsynaptic protein synaptopodin, was found in the cortex of AD patients (Davidsson and 
Blennow, 1998). All laminas of the neocortex in AD patients suffer from a synaptic loss of 
approximately 50% (Masliah et al., 1989) and the quantification of the neuronal and synaptic 
density in the temporal and frontal cortices in AD showed a decrease of 48% in the synapse to 
neuron ratio (Bertoni-Freddari et al., 1996). 
 
The use of transgenic animal models of AD made it convenient to understand the 
progression of AD pathology and to develop treatments. Herein, I used the 3xTg-AD mouse 
(Oddo et al., 2003b), a widely used model shown to mimic the neuropathological features of AD 
such as Aβ and tau pathologies. The Aβ pathology starts at around nine months of age, tau 
pathology at around twelve months of age and cognitive impairment as early as three months of 
age in this mouse model (Davis et al., 2013). This model was generated by the co-injection of 
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two mutated human transgenes, APPswe (KM670/671NL) and tau P301L, into the PS1/M146V 
knock-in embryo (Oddo et al., 2003b). The two mutated transgenes are under the control of 
Thymine 1.2 promoter, which is activated during the embryonic days 11 and 15 in mice 
(Campsall et al., 2002).  
In the present study I show that in a manner reminiscent of AD, in 3xTg-AD mice 
cognitive impairment is associated with a transient synaptic compensation, which is followed by 
synaptic deficit.  
 
3.2 Results 
3.2.1 At three months the 3xTg-AD mice are impaired in spatial reference memory 
Since AD is characterized by loss of short-term memory in the early stages of the disease 
as well as loss of long-term memory at later stages, I investigated if young adult 3xTg-AD mice 
are cognitively impaired. Because the hippocampus is the main brain structure implicated in 
memory formation, storage, consolidation and retrieval I employed the Morris Water Maze 
behavioral task, which is hippocampal-dependent, to test 3xTg-AD mice. In this task, mice are 
required to learn the position of a hidden platform using distal spatial reference cues. At the end 
of the learning trials mice have to form a spatial navigation map using the spatial cues to 
determine the position of the platform. 
The analysis of the swim speed revealed no significant difference between the wild type 
and the 3xTg-AD mice (Fig. 8a). For this reason, the learning performance of the animals was 
analyzed as the latency time to reach the escape platform. I found that animals from the two 
different groups learned the task well. This was evident from the decrease in the latency to 
escape across training sessions. However, when I compared the escape latency curve across time, 
I found that the 3xTg-AD learned slower than the WT across the training days (Fig. 8b, p = 
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0.016). These data revealed that at 12-14 weeks 3xTg-AD mice were impaired in spatial 
reference memory. 
To evaluate the memory retention in the 3xTg-AD and WT mice, a probe trial 24 h after 
the last training session was conducted. The 3xTg-AD mice spent significantly less time in the 
target quadrant (Fig. 8c; p<0.001) and visited the target zone less (Fig. 8d; p<0.005) than WT 
animals. These results suggest that memory retention was compromised in 3xTg-AD mice and 




















Fig. 8: At 12-14 weeks the 3xTg-AD (Tg-AD) mice show spatial reference memory 
impairment in Morris Water Maze test when compared with control WT animals. 
a) Swim speed, b) Escape latency, c) Percent of time in target quadrant, d) Number of platform crossings. 
*p < 0.05; **p < 0.01; ***p < 0.001. (WT, n = 20; Tg-AD, n = 29). Data are shown as mean ± SD. 
 
 
3.2.2 3xTg-AD mice have higher locomotivity and motor coordination than WT mice  
The Rota-rod and prehensile traction tests were employed to evaluate locomotivity and 
motor coordination. The 3xTg-AD mice had significantly higher latency time to fall in the Rota-
rod test (Fig. 9a-b; p<0.001) and prehensile traction test (Fig. 9c; p<0.001) than WT. 
Furthermore, the difference increased over trials, showing that the 3xTg-AD mice had enhanced 
motor coordination and motor learning. Similar findings were reported previously (Blanchard et 
al., 2010b, Oore et al., 2013, Stover et al., 2015). 
3.2.3 Anxiety level of 3xTg-AD mice is similar to WT mice 
In the Elevated Plus Maze task the open arm is considered to be more anxiogenic than the 
closed arm. Although I found previously that at 6 to 9 months of age the 3xTg-AD mice show 
more anxiety than WT, in the present study the 12-14 week old 3xTg-AD mice did not show any 
increase in anxiety compared to WT in the Elevated Plus Maze (Fig. 9d). 
I also measured the level of anxiety by open field test in 3xTg-AD and WT mice. 
Animals are considered to be anxious if they spend less time in the center than in the periphery 
of the arena. There was no significant difference between the two groups in the distance covered 





















Fig. 9: At 10-12 weeks of age the Tg mice had markedly higher locomotor activity than WT 
controls. 
a) Rota-rod, b) Prehensile traction test, c) Elevated plus maze, d) Open field. *p < 0.05; **p < 
0.01; ***p < 0.001. (WT, n = 20; Tg-AD, n = 29). Data are shown as mean ± SD. 
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3.2.4 Impairment in spatial reference memory is accompanied by an increase in neuronal 
and synaptic markers to compensate for synaptic loss in 3xTg-AD mice 
Synaptic loss is an established phenomenon and an early event in AD. Synaptophysin 
loss in the frontal cortex strongly correlates with dementia and cognitive impairment (Masliah et 
al., 2001). To examine synaptic loss at very early stages of the disease in different brain regions, 
3xTg-AD mice aged 10, 12, 13, 14, 15, and 16 weeks were studied. Brain sections from these 
animals were immunohistochemically stained using four different antibodies: anti-
synaptophysin, anti-GluR1, anti-MAP2, and anti-beta-III tubulin.  
3.2.5 CA1 region 
Longitudinal changes in mean pixel intensity showed that the synaptophysin expression 
in 3xTg-AD mice from 10-16 weeks of age was best modeled by a cubic regression model. In 
this model synaptophysin expression diminished at 12 weeks of age and was then compensated 
for from 13 to 16 weeks of age (Fig. 10a; Table 3). Similarly, Western blots of synaptophysin 
expression were best fit by a cubic model, with a significant decrease in synaptophysin level in 
the hippocampus at 12 weeks, followed by an increase by 13-14 weeks and then a decrease by 
15-16 weeks in 3xTg-AD mice (Fig. 11a-b, F (3, 18) = 5.47, p = 0.0075). 
The examination of GluR1 expression in the CA1 region showed no significant 
difference across time (Fig. 10b). Similarly, Western blots showed no change of the expression 
level in the hippocampus. 
The level of expression of the dendritic marker MAP2 was best fit by a linear model, 
though the actual level of MAP2 decreased at 12 weeks of age and then increased from 13-16 




The level of expression of β-III tubulin dropped at 12 weeks and then increased from 13-  
16 weeks (Fig. 10d; Table 3), though again the best fit was obtained with a linear model. 
 
Longitudinal Tg-AD F Df p Adj. R2 Model 
Cornis Ammonius 1 (CA1)      
Synaptophysin 4.19 (3, 20) 0.0188 0.385 cubic 
GluR1 - - - - - 
MAP2 1.72 (1, 23) 0.05 0.11 linear 
-III tubulin 3.38 (1, 23) 0.0789 0.12 linear 
Cornis Ammonius 3 (CA3)      
Synaptophysin 5.88 (3, 20) 0.0048 0.39 cubic 
GluR1 - - - - - 
MAP2 - - - - - 
-III tubulin 2.62 (3, 21) 0.0775 0.17 cubic 
Dentate gyrus (DG)      
Synaptophysin 4.71 (3, 16) 0.0154 0.37 cubic 
GluR1 - - - - - 
MAP2 5.44 (2, 22) 0.012 0.27 quadratic 
-III tubulin 4.27 (2, 22) 0.0272 0.2139 quadratic 
Parietal Cortex (PC)      
Synaptophysin 4.46 (3, 20) 0.0149 0.31 cubic 
GluR1 - - - - - 
MAP2 6.13 (2, 21) 0.008 0.3 quadratic 
-III tubulin 5.7 (2, 21) 0.01 0.29 quadratic 
Frontal Cortex (FC)      
Synaptophysin 7.89 (3, 20) 0.0011 0.47 cubic 
GluR1 - - - - - 
MAP2 - - - - - 
-III tubulin 3.15 (1, 22) 0.0896 0.0856 linear 
 
Table 3. Longitudinal best-fitting regression models for immunohistochemistry of Tg-AD 






















Fig. 10: In the CA1 region, Tg mice showed a decrease in synaptophysin, MAP2 and -III 
tubulin  at 12 weeks which was compensated by 13 weeks. 
 a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and 
analyzed by confocal microscopy in a single experiment under identical conditions and settings 
so that they could be directly compared across the six age groups. *p<0.05; **p<0.01; 
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification 














Fig. 11: Expression levels of synaptophysin and GluR1 in the hippocampus in Western 
blots.  
Longitudinal analysis of synaptophysin (10-16 weeks). (a, b) and (c, d) cross-sectional (10-13 weeks, Tg 
and WT mice). a, c are Western blots. *p<0.05; **p<0.01; ***p<0.001. (WT, n = 28; Tg-AD, n = 
26, n = 3 to 5/group).  
 
 
3.2.6 CA3 region 
The level of expression of synaptophysin in the CA3 region was best fit by a cubic model 
(Fig. 12a; Table 3). As in the CA1 region, the expression of synaptophysin dropped at 12 weeks 
and increased from 13 to 16 weeks of age. No significant change was detected in the GluR1 and 
MAP2 levels in the CA3 region (Fig. 12b, c; Table 3). -III tubulin was best modeled by a cubic 
regression with a decrease in the level of expression at 12 weeks and increase from 13-16 weeks 





















Fig. 12: Tg mice showed a decrease in the level synaptophysin and -III tubulin in the CA3 
region at 12 weeks, followed by a compensatory increase by 13 weeks. 
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and 
analyzed by confocal microscopy in a single experiment under identical conditions and settings 
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01; 
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification 




3.2.7 DG region 
In the DG the level of synaptophysin dropped at 12 weeks of age and then increased from 
13 to 16 weeks. The changes followed a cubic model (Fig. 13a; Table 3). No change was found 
in the expression of GluR1 (Fig. 13b). The level of expression of MAP2 followed a quadratic 
model (Fig. 13c, Table 3); -III tubulin expression was best fit by a quadratic model with a drop 





















Fig. 13: Synaptophysin, MAP2 and -III tubulin in the DG region decreased at 12 weeks 
for synaptophysin and 13 weeks for MAP2 and -III tubulin with compensatory increase at 
later ages. 
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and 
analyzed by confocal microscopy in a single experiment under identical conditions and settings 
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01; 
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification 
is shown as mean ± SD. 
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3.2.8 Parietal cortex region 
Expression of synaptophysin, MAP2, and -III tubulin showed a drop in the expression 
level across time at 12 weeks and an increase from 13-16 weeks. A cubic model best fit the 
expression of synaptophysin, while -III tubulin and MAP2 followed a quadratic model (Fig. 
14a, c, d; Table 3). The level of expression of GluR1 did not change significantly (Fig. 14b; 
























Fig. 14: The levels of synaptophysin, -III tubulin and MAP2 in the parietal cortex showed 
a decrease at 12 weeks, followed by a compensatory increase by 13-16 weeks. 
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and 
analyzed by confocal microscopy in a single experiment under identical conditions and settings 
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01; 
***p<0.001. Scale bar: 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification is 




3.2.9 Frontal cortex region 
The level of expression of synaptophysin and MAP2 changed across time. Synaptophysin 
followed a cubic model (Fig. 15a; Table 3) while for -III tubulin a linear model fit best (Fig. 
15d; Table 3). Both markers decreased at 12 weeks of age and increased from 13-16 weeks. No 
significant change was detected in the expression of GluR1 (Fig. 15b; Table 3) or MAP2 (Fig. 


















Fig. 15: In the Frontal cortex, the levels of synaptophysin and -III tubulin significantly 
changed at 12 weeks. No change was detected for the GluR1 level. Compensation happened 
from 13-16 weeks. 
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections were immunostained and 
analyzed by confocal microscopy in a single experiment under identical conditions and settings 
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01; 
***p<0.001. Scale bar: 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification is 
shown as mean ± SD. 
 
3.3 Cross-sectional comparison between 3xTg-AD and control mice confirms 
synaptic compensation in the former 
3.3.1 CA1 region 
Cross-sectional comparison of 3xTg-AD with WT mice revealed a comparative synaptic 
loss at 12 weeks followed by compensation in different brain regions at different ages. In the 
CA1 region there was a non-significant trend toward decrease in synaptophysin expression at 12 
weeks and a relative increase from 13 to 15 weeks (Fig. 16a; Table 4). Western blots showed 
changes in synaptophysin expression best fit by a quadratic model with synaptic loss at 12 weeks 
compensated from 13 weeks (Fig. 11c-d, F (2, 7) = 12.56; p < 0.005).  
GluR1 non-significantly increased in 3xTg-AD mice compared to WT at 13 weeks of 
age, although there was no decrease at 12 weeks (Fig. 16b; Table 4).  
Similarly, MAP2 expression was comparable in 3xTg-AD and WT mice, though the level 
of MAP2 decreased at 13 weeks, increasing at 14 weeks (Fig. 16c; Table 4).  
-III tubulin did not change significantly but the lowest level was at 13 weeks of age with 





Cross-sectional WT vs 
Tg-AD week 10 week 12 week 13 week 14 week 15  week 16 
Cornis Ammmonius 1 
(CA1) p  p p  p  p  p  
    Synaptophysin - - - - - - 
    GluR1 - - 0.08 - - - 
     MAP2 - - - - - - 
    -III tubulin - - - - - - 
Cornis Ammonius 3 
(CA3) 
          Synaptophysin - - - - - - 
    GluR1 - - - - - - 
     MAP2 - 0.07 - - - 0.0066 
    -III tubulin - - - - - - 
Dentate gyrus (DG) 
          Synaptophysin - - - - - - 
    GluR1 
          MAP2 - 0.0009 - - - 0.03 
    -III tubulin - - - - - - 
Parietal Cortex (PC) 
          Synaptophysin - 0.03 - - - - 
    GluR1 - - - - - - 
    MAP2 - - - - - - 
    -III tubulin - - - - - - 
Frontal Cortex (FC) 
          Synaptophysin - 0.03 0.02 0.0033 - - 
    GluR1 - - 0.08 - - - 
    MAP2 - - - - - - 
    -III tubulin - - - 0.06 - - 
       
 


















Fig. 16: Cross-sectional comparison of Tg and WT mice for the relative expression of 
synaptophysin, GluR1, MAP2 and -III tubulin in the CA1 region from 12 to 16 weeks 
showed a decrease at 12-13 weeks, followed by compensation at different ages in different 
brain regions in Tg mice. 
a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections from WT and Tg mice at 
each age were immunostained and analyzed by confocal microscopy under identical conditions 
and settings to enable comparison between the two groups of animals. *p<0.05; **p<0.01; 
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 25, n = 3 to 5/group). Quantification 
is shown as mean ± SD. This experiment was repeated 3 times. 
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3.3.2 CA3 region 
Synaptophysin expression did not differ significantly between 3xTg-AD and WT. The 
lowest level of synaptophysin was detected at 12 weeks in 3xTg-AD mice with an increase at 14 
weeks (Fig. 17a; Table 4).  
GluR1 expression did not change significantly, decreasing at 13 weeks and increasing 
only at 14 weeks (Fig. 17b; Table 4).  
MAP2 decreased at 12 weeks, increased at 15 weeks, then dropped significantly at 16 
weeks (Fig. 17c; Table 4).  
-III tubulin expression in the CA3 did not change significantly. The lowest level was at 
13 weeks of age with a slight increase from 14-15 weeks and a decrease at 16 weeks (Fig. 17d; 



























Fig. 17: Cross-sectional comparison of Tg and WT mice for relative expression of all the 
markers in the CA3 region from 12 to 16 weeks showed a non-significant decrease in the 
MAP2 level at 12 weeks followed by a compensation and then a decrease again at 16 weeks. 
No significant changes were found for the other three markers. a) synaptophysin; b) GluR1; c) 
MAP2; and d) -III tubulin. Sections from WT and Tg mice at each age were immunostained 
and analyzed by confocal microscopy under identical conditions and settings to enable 
comparison between the two groups of animals. *p<0.05; **p<0.01; ***p<0.001. Scale bar = 
100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification is shown as mean ± SD. 





3.3.3 DG region 
Synaptophysin in the DG did not differ significantly between WT and Tg-AD across 
time, though some compensation occurred at 15 weeks (Fig. 18a; Table 4).  
Overall there was no significant difference in the expression of GluR1; it was lowest at 
12 and 13 weeks followed by compensation at 15 weeks (Fig. 18b; Table 4).   
 MAP2 decreased at 12 weeks, increased from 13-15 weeks, and then dropped again at 16 
weeks (Fig. 18c; Table 4). 
Overall -III tubulin did not change significantly. The lowest level was at 13 weeks with 



















Fig. 18: Cross-sectional comparison of Tg and WT mice for relative expression of synaptophysin, 
GluR1, MAP2 and -III tubulin from 12 to 16 weeks in the DG region showed a non-significant 
decrease for the MAP2 level at 12 weeks, a compensation from 13-15 weeks and a decrease again at 
16 weeks. No significant changes for the other three markers occurred. a) synaptophysin; b) 
GluR1; c) MAP2; and d) -III tubulin. . Sections from WT and Tg mice at each age were 
immunostained and analyzed by confocal microscopy under identical conditions and settings to 
enable comparison between the two groups of animals. *p<0.05; **p<0.01; ***p<0.001. Scale 
bar: 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group). Quantification is shown as mean ± SD. 





3.3.4 Parietal cortex region 
Synaptophysin decreased significantly at 12 weeks and increased from 13-16 weeks (Fig.  
19a; Table 4). 
GluR1 did not differ significantly; the lowest level was at 12 weeks with an increase at 14 
weeks (Fig. 19b; Table 4).  
 MAP2 change was not significant; the lowest level was at 13 weeks with an 
increase at 14 weeks (Fig. 19c, Table 4).  
-III tubulin was lowest at 13 weeks and increased at 14 weeks (Fig. 19d. Table 4). The 





















Fig. 19: Cross-sectional comparison of Tg and WT mice for relative expression of 
synaptophysin, GluR1, MAP2, and βIII tubulin from 12 to 16 weeks in the parietal cortex. 
Only synaptophysin showed a decrease at 12 weeks followed by compensation at later time 
points. 
 a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections from WT and Tg mice at 
each age were immunostained and analyzed by confocal microscopy under identical conditions 
and settings to enable comparison between the two groups of animals. *p<0.05; **p<0.01; 
***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 5/group ). Quantification 
is shown as mean ± SD. This experiment was repeated 3 times. 
 
 
3.3.5 Frontal cortex 
Synaptophysin decreased at 12 weeks and increased at 14 weeks. The compensation for 
synaptic loss occurred from 13 to 15 weeks (Fig. 20a; Table 4).  
GluR1 non-significantly decreased at 13 weeks and rose from 14-16 weeks (Fig. 20b; 
Table 4).  
MAP2 did not change significantly. The lowest level was at 13 weeks, rising at 14 weeks 
(Fig. 20c, Table 4).  
-III tubulin in Tg-AD mice was lowest at 12 weeks and increased non-significantly at 14 


















Fig. 20: Cross-sectional comparison of Tg and WT mice for relative expression of 
synaptophysin, GluR1, MAP2, and βIII tubulin from 12 to 16 weeks of age in the frontal 
cortex. 
The levels of synaptophysin, MAP2, and -III tubulin decreased from 12-13 weeks and then 
increased at 14-16 weeks. a) synaptophysin; b) GluR1; c) MAP2; and d) -III tubulin. Sections 
from WT and Tg mice at each age were immunostained and analyzed by confocal microscopy 
under identical conditions and settings to enable comparison between the two groups of animals. 
*p<0.05; **p<0.01; ***p<0.001. Scale bar = 100 µm. (WT, n = 28; Tg-AD, n = 26, n = 3 to 





3.4 Changes in expression levels of neuronal and synaptic proteins in WT mice  
3.4.1 CA1 region 
Synaptophysin and GluR1 did not change significantly in WT mice (Fig. 21a; Table 5). 
MAP2 and -III tubulin significantly changed over time in the CA1 region, best modeled with a 
cubic regression (Fig. 21a; Table 5). MAP2 decreased from 12 to 13 weeks and came back to 
normal level at 14 to 15 weeks. -III tubulin decreased at 12 weeks and then increased at 13 
weeks.  
3.4.2 CA3 region 
No significant changes were detected in synaptophysin, MAP2 or -III tubulin (Fig. 21b; 
Table 5). GluR1 followed a cubic pattern, with the lowest level at 15 weeks and an increase at 16 
weeks (Fig. 21b; Table 5).  
3.4.3 DG region 
No significant changes for any of the markers were detected in the DG area (Fig. 21c; 
Table 5).  
3.4.4 Parietal cortex 
The only change that was seen in this region was in the expression level of GluR1. It 
followed a quadratic fit with a decrease from 12-15 weeks and then an increase by 16 weeks 
(Fig. 21d; Table 5). All the other markers showed no differences.   
3.4.5 Frontal cortex 






Longitudinal WT F df P Adj. R2 Model 
Cornis Ammmonius 1 (CA1) 
        Synaptophysin - - - - - 
   GluR1 - - - - - 
   MAP2 5.35 (3, 20) 0.007 0.36 cubic 
   -III tubulin 4.82 (3, 20) 0.011 0.33 cubic 
Cornis Ammonius 3 (CA3) 
        Synaptophysin - - - - - 
   GluR1 2.47 (3, 22) 0.08 0.15 cubic 
   MAP2 - - - - - 
   -III tubulin - - - - - 
Dentate gyrus (DG) 
         Synaptophysin - - - - - 
   GluR1 - - - - - 
   MAP2 - - - - - 
  -III tubulin - - - - - 
Parietal Cortex (PC) 
        Synaptophysin - - - - - 
   GluR1 5.81 (2, 22) 0.009 0.28 quadratic 
   MAP2 - - - - - 
   -III tubulin - - - - - 
Frontal Cortex (FC) 
        Synaptophysin - - - - - 
   GluR1 - - - - - 
   MAP2 - - - - - 
  -III tubulin - - - - - 
 



















Fig. 21: Longitudinal comparison of relative expression of synaptophysin, GluR1, MAP2 
and βIII tubulin in WT mice showed some changes but no overall decrease from age 10 
weeks to 16 weeks. 
a) CA1; b) CA3; c) DG; d) parietal cortex and frontal cortex. Sections were immunostained and 
analyzed by confocal microscopy in a single experiment under identical conditions and settings 
so that that they could be directly compared across the six age groups. *p<0.05; **p<0.01; 




Cross-sectional comparison between 3xTg-AD and control mice shows that synaptic 
compensation happened at different time points in different brain regions 
 
The comparison of the changes in the expression of the different synaptic and neuronal 
markers mentioned above in the 3xTg-AD mice as % of WT showed that synaptic compensation 
happened in different brain regions at different time points (Fig. 22, table 5). Indeed, for the 
synaptic marker synaptophysin for example synaptic compensation in the CA3 region happened 
at 14 weeks (Fig. 22, table), while in the parietal cortex compensation happened at 13 weeks 
(Fig. 22, table 5). Table 5 shows all the regional changes for all the synaptic and neuronal 


































Fig. 22: Change in Tg mice as % of WT showed that synaptic compensation occurred at 
different time points in different brain regions. A summary of data taken from Figures 16-
20.  Sections from WT and Tg mice at each age were immunostained and analyzed by confocal 
microscopy under identical conditions and settings to enable comparison between the two groups 




3.5 Discussion  
Dementia status in AD is preceded by a relatively long and variable period of MCI. In 
some individuals the MCI stage does not progress to AD. This variable MCI stage is probably 
due to the compensatory neuroregenerative response of the AD brain which, because of an 
insufficient neurotrophic environment, does not succeed completely (Li et al., 2008, Iqbal et al., 
2014a). Histopathological studies have shown that the compensatory phenomenon does occur in 
the AD brain (Mukaetova-Ladinska et al., 2000). 
The present study revealed that the spatial reference memory impairment in the young 
adult 3xTg-AD mice seen at around 12-14 weeks of age is accompanied by a decrease in the 
presynaptic marker synaptophysin, the postsynaptic marker GluR1, the dendritic marker MAP2 
and the neuronal marker β-III tubulin. However, reminiscent of the AD brain, the 3xTg mice 
showed a decrease in synaptic and neuronal markers at 12 weeks followed by a transient increase 
from 13 to 16 weeks of age. I speculate that this increase is a failed attempt of the brain to 
compensate for synaptic loss. Beyond the age of 4 months, the 3xTg-AD mice are known to have 
a decrease in synaptophysin as well as an apparent synaptic dysfunction (Oddo et al., 2003b, 
Blanchard et al., 2010b). Most importantly, when I expressed the data of 3xTg-AD mice as a 
percent of control (WT) for different ages from age 10-16 weeks, different brain regions 
compensated for the synaptic loss at different time points. Although the WT mice also showed 
changes in these markers from 10-16 weeks of age, the changes seen in WT mice were totally 
different from those seen in 3xTg-AD mice.  
The present study showed that there was an upregulation in the level of expression of 
different synaptic, dendritic and neuronal markers, especially the increase in the expression level 
of synaptophysin in cognitively impaired 3xTg-AD mice. Previous studies reported an increase 
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in glutamatergic buttons in the midfrontal gyrus in MCI patients and an increase in 
synaptophysin immunoreactivity and cholinergic buttons in the plaque proximity areas in the 
APP K670N,M671L+ PSlM146L double transgenic mice which, however, decreased with the 
progression of the disease (Hu et al., 2003, Bell and Cuello, 2006, Bell et al., 2007). Similarly, 
spatial reference memory impairment in aged rats was shown to be associated with an increase in 
the levels of expression of PSD95 and GluR1 compared to control animals (Nyffeler et al., 
2007). 
Consistent with the present study, a previous study reported an increase in the level of 
expression of synaptophysin and SNAP-23 in AD brains at Braak stage 3 with minimal to mild 
clinical grades of dementia compared to normal controls and an increase in the expression levels 
of MAP2 and α-synuclein at Braak stage 4 in the neocortex in AD (Mukaetova-Ladinska et al., 
2000). However, a sharp decrease in synaptophysin expression in AD was seen only at Braak 
stages 5 to 6 with the full spectrum of amyloid beta and tau pathologies and moderate to severe 
clinical grades of dementia. Similarly, an increase in the level of PSD-95 expression in the 
entorhinal cortex of AD cases  (Leuba et al., 2008a; Leuba et al., 2008b) and a decrease in the 
level of synaptophysin expression compared to age-matched controls was previously reported 
(Leuba et al., 2008b). The agreement between human and animal studies indicates that the 
upregulation in synaptic, dendritic and neuronal markers found in the present study is most 
probably due to a compensatory phenomenon initiated by the diseased brain to save the 
remaining intact synapses. 
In light of what was found previously in human subjects, findings of the present study in 
3xTg-AD mice could be mimicking what happens in AD patients at early stages of the disease. 
For instance, at the age of 12-14 weeks the 3xTg-AD mice are considered to be in the early 
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stages of AD-like disease. They have only intracellular amyloid beta (A) and cognitive 
impairment; A plaque and tau pathologies are seen only at 9-12 months onwards.  
It is believed that synaptic compensation could happen at different levels: at the activity 
level, at the network level and at the synaptic level. At the activity level compensation occurs 
when a neuron senses its own spiking activity level through calcium-dependent sensors and 
adjusts it accordingly by the phenomenon of synaptic scaling, mainly through adjusting the 
abundance of glutamate receptors postsynaptically. The neuron can also self-adjust by local 
synaptic compensation through a change in the efficacy of neurotransmitter release 
presynaptically. At the level of the neuronal network, when target neurons are denervated they 
inform afferent neurons via signaling about the need for synaptic input. Remaining intact 
neurons compensate by increasing the synaptic area so that the total synaptic contact area per 
unit volume of the cortex remains intact (Scheff, 2003). 
Coupling between astrocytes and neurons can also contribute to global synaptic 
homeostasis because glial cells are well placed to sense the overall activity of neurons 
(Stellwagen and Malenka, 2006). Using random synaptic deletions to simulate global synaptic 
compensation, computational studies showed that all the remaining intact synapses would 
increase their activity (or scaling) in a similar way by multiplying their weight by the same factor 
(Horn et al., 1993).  From a neurobiological perspective, synaptic compensation could happen by 
the upregulation of the expression levels of certain presynaptic and postsynaptic markers, e.g., 
the increase in the expression levels of synaptophysin, PSD95 and GluR1 reported previously 
(Leuba et al., 2008a, Leuba et al., 2008b, Hu et al., 2003, Nyffeler et al., 2007) as well as the 
findings of the present study. The synaptic compensation could result from neuritic outgrowth. 
Indeed, it has been proposed that after their death affected neurons liberate growth factors that 
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could be used by surviving neurons for growing new neurites (Uylings and de Brabander, 2002). 
Another mechanism of synaptic compensation could be activation of silenced synapses following 
the death of inhibitory neurons and an increase in neurogenesis in the dentate gyrus (Jin et al., 
2004b). 
There are three major points of view concerning the mechanism of synaptic 
compensation. One view considers the phenomenon to be beneficial, helping to slow down the 
progression of the disease (Iacono et al., 2008). The second view considers it as detrimental 
because it affects the brain network and drives disease progression (Nyffeler et al., 2007, 
Abuhassan et al., 2014, Berchtold et al., 2014). The third one considers compensation as 
beneficial at the early stage of the disease because it slows down its progression (Mesulam, 
2000, Small, 2008). However, in the long run it is detrimental because it becomes the driving 
force to affecting the whole neuronal network.  
I speculate that in the present study the decrease in synaptophysin, MAP2 and -III 
tubulin at 12 weeks of age in the 3xTg-AD animals compared to WT and the transient increase in 
these three markers from 13 to 16 weeks of age is due to a compensatory mechanism in which 
the diseased brain attempts to repair itself. Because the disease is not fully developed in the 
young 3xTg-AD mice, the brain still has the capacity to compensate for the synaptic loss. This 
compensatory mechanism may be the biological basis of slowing down the development of the 
AD-like pathological features in this mouse model. Indeed, it is known that the 3xTg-AD mouse 
develops Aβ and tau pathologies only at an advanced age: Aβ pathology at ~9 months and tau 
pathology at around 12 months. Thus, it takes several months for these pathological features to 
develop and this is considered a long enough period for the progression of the pathologies. I 
speculate that a similar phenomenon may be occurring in asymptomatic AD or MCI patients’ 
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brains. In fact, the mild cognitive impairment period is relatively long, lasting several years, and 
this may be due to the compensation or the self-repair attempt of the brain. However, as the 
disease progresses the brain is overwhelmed and synaptic loss reaches a certain threshold level 
beyond which the brain cannot compensate any more. Perhaps this is why the acceleration of 
cognitive decline and the appearance of clinical features of AD occur at an advanced stage.  
For this reason, prevention strategies starting at an early stage of the disease could be 
more effective than intervention at a later stage after a drastic synaptic and neuronal loss is 
reached. Once the brain has undergone a severe insult of synaptic and neuronal loss, repair 
would be more difficult than prevention at an early stage of the disease. Acting when synaptic 










The cumulative incidence of AD is estimated to increase from ~5% at the age of 70 to 
~50% at the age of 90  (Jahn, 2013). AD interferes with the process of memory formation from 
the molecular level to the level of the whole brain network. In most cases of AD, slow cognitive 
deterioration occurs several years before the clinical symptoms are brought to attention. During 
the very early stages of AD, short-term memories are severely affected and patients have 
difficulties remembering new information and familiar people’s names. Executive functions such 
as judgment and problem solving and organizational skills are also affected; long-term and 
declarative memories, however, are less deteriorated. Small personality and behavioral changes 
are reported. Agitation, anxiety and psychosis are not reported in the initial stages. In contrast, 
during moderate to severe stages cognitive deterioration becomes more pronounced and newly 
learned material is rapidly lost with patients described as “living in the past”. Difficulties in 
spatial navigation and disorientation in the familiar environment become marked symptoms as 
well as the inability to recognize family members and close relatives. Executive function and 
logical reasoning are severely deteriorated while behavioral symptoms such as hallucinations, 
delusions and illusionary misidentification become more common. Sleep disruption, agitation 
with temper tantrums, physical and verbal aggression and anxiety are also common in this stage. 
Apathy, however, is the most persistent and frequent symptom exhibited by 72% of the patients 
through all stages of AD (Mega et al., 1996). Behavioral disturbances represent the major burden 
and source of distress to the caregiver and lead to elder abuse in the US. This results in the 
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institutionalization of patients to nursing homes, which leads to an increase in the financial cost 
(Binetti et al., 1998). At the most severe stages almost all the cognitive functions are gone, with 
patients becoming totally dependent on caregivers and having difficulties even in chewing and 
swallowing food. Most patients become bedridden at this stage and the major cause of death is 
pneumonia (Lyketsos et al., 2011, Tarawneh and Holtzman, 2012). Women are known to be at a 
higher risk than men to suffer from AD.  This may be because of the decrease in the level of 
estrogen after menopause (Irvine et al., 2012). 
The severity of cognitive impairment directly correlates with the density of NFT. NFT 
formation starts in the memory-associated areas such as the entorhinal cortex and the 
hippocampus, then spreads to parietal, temporal and finally frontal cortices. Indeed, findings 
from the Nun Study and the Adult Changes in Thought (ACT) study reported a strong correlation 
between the BRAAK stages and the status of dementia (SantaCruz et al., 2011). Furthermore, the 
NFT density in the entorhinal cortex and the temporal lobe showed a strong correlation with 
cognitive scores in non-demented people. Another study also suggested that the accumulation of 
NFT may be responsible for memory loss associated with normal aging as well as the memory 
deficit seen in MCI (Guillozet et al., 2003). In contrast, A plaque deposition did not correlate 
either with neuronal loss and NFT or with the severity of the disease (Gomez-Isla et al., 1997). 
The number of senile plaques in the cerebral cortex also tends to stay stable with the severity of 
the disease stages. The fact that A plaque deposition does not correlate with cognitive scores, is 
not specific for memory related lesions and is found in many cognitively normal individuals 
(Tomlinson et al., 1970, Alafuzoff et al., 1987, Arriagada et al., 1992b, Guillozet et al., 2003) 
strongly suggests that A burden does not play a significant role in memory impairment during 
the early stages of the disease (Guillozet et al., 2003). However, the spatial and temporal 
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distribution of the NFT and the numerical density better match the clinical features of dementia 
than the A plaque burden (Tomlinson, 1982, Alafuzoff et al., 1987, Arriagada et al., 1992a, 
Berg et al., 1993, Gomez-Isla et al., 1997, Berg et al., 1998, Giannakopoulos et al., 2003). The 
severity of cognitive symptoms was found to be even more correlated with the severity of 
neuronal loss (Gomez-Isla et al., 1997) and even more with synaptic deficit, especially with 
synaptophysin loss (DeKosky and Scheff, 1990, Terry et al., 1991). 
Medical intervention delaying disease onset by 5 years could reduce the number of AD 
patients by 57% and decrease the projected Medicare financial costs from $627 billion to $344 
billion (Sperling et al., 2011). Once a reliable screening instrument is developed and a treatment 
that slows the progression of the disease by 50% is discovered, the risk of having AD in people 
aged 65 and older would decrease from 10% to 5.7%. Furthermore, even delaying the onset of 
the disease by 6 months would, it is estimated, decrease the number of people developing AD by 
half a million by 2050 (Brookmeyer et al., 1998). Currently approved drugs produce only modest 
improvements of cognitive symptoms, resulting mostly in stabilization rather than alleviation of 
the cognitive symptoms (O'Hara et al., 2001). 
The use of transgenic mouse models greatly helped to understand the molecular 
mechanisms of AD and facilitated preclinical studies that could lead to development of potential 
AD drugs. The 3xTg-AD mouse model has proven to be a biologically relevant model to AD 
pathology. Unlike other transgenic mice, 3xTg-AD mice develop A plaques and 
hyperphosphorylated tau without NFT, resembling rarer cases of AD (Tiraboschi et al., 2004). It 
is even recently reported that these mice develop a deficiency in episodic memory as early as 3 
months of age that deteriorates similarly to the deterioration seen in patients. In the present study 
I found (Chapter 3) that, similar to the visuospatial impairment seen in AD, the 3xTg-AD mice 
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are impaired in spatial memory as examined by the Morris Water Maze task. The aim of this 
study is to investigate the effect of P021 on preventing or delaying the cognitive impairment by 
initiating the treatment at 3 months, which is around the period of synaptic compensation. P021 
and its parent molecule Peptide 6 were previously shown to be effective in reversing cognitive 
impairment in 3xTg-AD mice when the treatment was started at later stages of the disease 
(Blanchard et al., 2010b, Kazim et al., 2014). P021 was also found to rescue cognitive 
impairment in aged Fisher rats (Bolognin et al., 2014) and in a rat model of the sporadic form of 
AD (Bolognin et al., 2012).  
In the present study, I investigated the effect of P021 treatment starting at around the 
period of synaptic compensation and lasting for ~18 months in 3xTg-AD mice. I found that, 
reminiscent of AD, cognitive deterioration in 3xTg-AD mice starts very early in the disease 
process and lasts for the lifetime. Furthermore, P021 treatment right after the onset of cognitive 
impairment and very early in the disease process can completely prevent cognitive impairment in 
3xTg-AD mice. Treatment with P021 decreases the mortality rate without apparent side effects 
such as weight loss or decrease in food consumption in 3xTg-AD mice.  
 
4.2 Results  
4.2.1 Treatment with P021 can rescue reference memory deficit  
As described in Chapter 3, I found that the 3xTg-AD mice were cognitively impaired as 
determined by the Morris Water Maze task very early in the disease process at ~3 months of age. 
Since the Morris Water Maze task measures spatial reference memory that is purely hippocampal 
dependent and spatial reference memory is affected early in AD patients, I sought to study the 
effect of P021 treatment on preventing or reversing this impairment. The Morris water Maze task 
was conducted after 9 months of treatment with P021, when the animals were aged 12 months. 
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During the task animals went through four training trials per day for four days for a total of 16 
trials. There was no difference in the swim speed during the four training days (Fig. 23a). 
Analysis of the latency to escape showed that the learning curve of the 3xTg-AD-vh was slower 
compared to WT (Fig. 23b, p < 0.001) and 3xTg-AD-P021 mice (Fig. 23b, z = 4.78 p = 0.031). 
All three groups of mice learned the task, however. The analysis of distance by day showed also 
that the learning curve of 3xTg-AD-vh mice was slower than WT (Fig. 23c, p <0.0001) and 
3xTg-AD-P021 animals (Fig. 23c, p = 0.039) and they traveled farther to find the escape 
platform. These data showed that the 3xTg-AD-vh mice were impaired and that P021 was able to 
reverse this impairment.   
To evaluate retention memory in the 3xTg-AD mice three probe trials were conducted. 
The first one (PT1) was twenty-four hours after the last training trial. The second probe trial 
(PT2) and the third probe trial (PT3) were separated by twenty days from each other and from 
the first probe trial. The percent of time spent in the target quadrant and the number of crossings 
of the previous place of the platform were determined to evaluate the performance of the 
animals. During PT1, the 3xTg-AD-vh spent significantly less time in the target quadrant 
compared to WT (Fig. 23d, post-hoc Bonferroni-adjusted test, p<0.05) and P021 treatment was 
able to reverse this impairment (Fig. 23d, p<0.01). A similar trend was seen in the number of 
visits to the previous place of the platform but there was no significant difference between the 
three groups (Fig. 23g). During PT2, the analysis of the percent of time in target quadrant 
showed that the 3xTg-AD-vh spent less time compared to the WT (Fig. 23e, p<0.05). 
Furthermore, the analysis of the number of crossings of the previous place of the platform 
showed that the 3xTg-AD-vh had made fewer visits compared to the WT and that P021 reversed 
this impairment (Fig. 23h, p = 0.094). For PT3, the percent of time in target quadrant and the 
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number of platform crossings showed a similar trend to PT1 and PT2 but were not significant 
(Fig. 23f, i). These results suggest that memory retention was compromised in 3xTg-AD-vh mice 













Fig. 23: At 12 months of age after 9 months of treatment the 3xTg-AD-vh mice were 
impaired in the Morris Water Maze task and P021 prevented this impairment. 
a) Swim speed, b) Latency to escape, c) Distance traveled, d) percent of time in target quadrant 
in PT1, e) percent of time in target quadrant in PT2, f) percent of time in target quadrant in PT3, 
g) number of platform crossings PT1, h) number of platform crossings PT2, and  i) number of 
platform crossings PT3. Tq: target quadrant, AL: adjacent left, AR: adjacent right, Oq: opposite 
quadrant. *p<0.05; **p<0.01, ***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data 






4.2.2 Treatment with P021 can rescue short-term reference memory impairment 
The neophobia test is used to measure the rodent’s fear of discovering novelty, in this 
case a novel object. This test was conducted during the first habituation session before the object 
location test. The statistical analysis of the percent of time spent in the center exploring the novel 
object showed that both the WT and 3xTg-AD-vh mice spent similar time exploring the new 
object, while the P021-treated spent significantly more time exploring the novel object compared 
to the two previous groups (Fig. 24a, p = 0.0086). The novel object location in the open field 
was conducted twenty four hours after the last habituation session. The Object location test 
comprised a sample phase and a test phase. The analysis of the data from the sample phase 
showed that, as expected, there was no difference in exploring the two identical locations 
between the three groups of mice (Fig. 24b). However, the data from the test phase showed that 
3xTg-AD-vh mice spent more time investigating the familiar location than the novel one, while 
the WT and 3xTg-AD-P021 groups spent more time exploring the novel location than the 
familiar one (Fig. 24c, p = 0.0072).  
Together these data showed that the 3xTg-AD-vh at the age of 18 months had impairment 















Fig. 24. At 18-19 months of age after 15-16 months of treatment, when compared to WT, the 3xTg-
AD-vh showed impairment in short-term spatial reference memory in the object location task and 
P021 was able to prevent this impairment as well as decrease neophobia in 3xTg-AD mice. a) 
Neophobia test, b) sample phase, and c) test phase. *p<0.05; **p<0.01, ***p<0.001. (WT, n = 20; Tg-
AD-vh, n=15; Tg-AD-P021, n = 14). Data are shown as mean ± SD. 
 
4.2.3 P021 can rescue episodic memory impairment  
The Novel object recognition task is based on a rodent’s preference to explore novelty. It 
is thought to depend solely on the entorhinal cortex, hippocampus and frontal cortex. This test is 
considered to test only some aspects of the episodic memory because the experimenter has no 
access to the temporal dimension of the episode. The only accessible components are the 
memory, the place and the context in which an object is encountered and thus the test is 
considered to be a test of short-term memory (Ennaceur, 2010). The sample phase was conducted 
twenty-four hours after the last habituation phase and the analysis of the data showed, as 
105 
 
expected, no difference between the three groups in exploring the two identical objects (Fig. 
25a). The trial test was conducted 15 min after the sample phase. I found that the 3xTg-AD-vh 
mice were impaired and that the WT mice were also impaired because of the effect of aging. 
They either spent a similar amount of time near the familiar and the novel objects or spent more 
time near the familiar one. However, the 3xTg-AD-P021 spent more time exploring the novel 
object than the familiar one (Fig. 25b, p = 0.0234). These data suggest that at 19-20 months of 
age the 3xTg-AD-vh and WT mice were impaired and that the chronic treatment with P021 








Fig. 25: The object recognition task at 19-20 months of age (after 16-17 months of P021 treatment) 
showed that the WT and 3xTg-AD-vh were impaired in episodic-like memory and that P021 
rescued this impairment in 3xTg-AD mice. a) Sample phase and b) test phase. *p<0.05; **p<0.01, 
***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data are shown as mean ± SD. 
 
4.2.4 Prevention of cognitive impairment across time  
Data from all three cognitive tests were converted to cognitive scores. Cognitive scores 
from each test were calculated as: mean of each mouse - mean of all mice) / SD (all mice). The 
cognitive score represents the number of SD from the mean. Then cognitive scores from all tests 
were compared across time with the two-way ANOVA. The results showed that very clearly 
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across time there was a decrease in cognitive performance in 3xTg-AD mice compared to WT (p 
= 0.017). However, in 3xTg-AD-P021 there was a marked enhancement of cognitive 











Fig. 26. Comparison of cognitive scores over time in all the behavioral tests. *p<0.05; **p<0.01, 
***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data is shown as mean ± SEM. 
 
4.2.5 P021 treatment can decrease mortality and has no effect on body weight or food 
consumption.  
Analysis of survival rates at the end of the study showed that P021 treatment decreased 
the mortality rate in 3xTg-AD-P021 mice. Indeed, the survival rate of 3xTg-AD-vh at week 71 
was significantly less (41%) than the survival rate of 3xTg-AD-P021 (87%) (2[1, df] = 9.437, p = 
0.0021) (Fig. 27a). The body weight analysis showed no difference among the three groups (Fig.  




Together these data suggest that the delay of the onset of cognitive impairment in 3xTg-
AD - P021 may have been able to decrease the mortality rate in the treated animals without 






















Fig. 27: Survival curve analysis showed an increase by 87% in 3xTg-AD-P021 compared to 
only 41% in 3xTg-AD-vh mice survived by 71 weeks with no side effects of P021 on food 
intake or body weight. a) survival curve, b) body weight, and c)  food intake. *p<0.05; 
**p<0.01, ***p<0.001. (WT, n = 20; Tg-AD-vh, n=15; Tg-AD-P021, n = 14). Data are shown as 





The clinical diagnosis of AD relies mainly on the appearance of signs of cognitive 
impairment and memory loss, especially loss of short-term and declarative memories. The severe 
decline in mental abilities, or what is referred to as dementia, is the major burden in AD. Indeed, 
it compromises daily activities for the patient and makes him/her totally dependent on caregivers 
in the severe stages. Delaying the onset of dementia and cognitive deterioration would be of 
major importance in AD.  Furthermore, preventing AD would result in the decrease in the 
mortality rate due to this disease, since it is the sixth leading cause of death in the USA. Thus, a 
drug that could delay or reverse cognitive deterioration would be ideal because it could prevent 
AD and decrease the death rate due to this disease.  
The present study showed that, reminiscent of AD, the 3xTg-AD mice are impaired in 
spatial reference memory as tested by the Morris Water Maze task. I further show that the 
initiation of treatment with the neurogenic/neurotrophic compound P021 right after the start of 
the cognitive impairment, around the period of synaptic compensation, for 9 months is able to 
prevent cognitive impairment completely in the 12 month old 3xTg-AD mice. Our results also 
show that impairment in short-term spatial memory, as tested with the novel object location task, 
is completely prevented after 15 months of treatment with P021 when the 3xTg-AD mice are 18 
months old. Using the novel object recognition task that measures episodic-like memory, I show 
complete prevention of cognitive impairment after treatment of ~3 month old mice with P021 for 
16-17 months. Most importantly, the analysis of survival rates shows that P021 treatment is able 
to increase the survival rate from 41% in 3xTg-AD-vh to 87% in 3xTg-AD-P021. These 
beneficial effects of long-term treatment with P021 on cognition and survival rate in 3xTg-AD 
mice are seen in the absence of any apparent side effects such as decrease in the food 
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consumption or body weight.  
All of these data collectively suggest that initiation of the treatment with P021 very early 
in the disease process can delay the onset of cognitive impairment and decrease the mortality rate 
without apparent side effects in the 3xTg-AD mice. Thus, P021 could potentially delay the onset 
of cognitive impairment in AD patients.   
The present findings that the 3xTg-AD mice are impaired at 3 months of age (Chapter 3) 
was also reported previously in the literature (Davis et al., 2013). The three-month time point 
apparently overlaps with the onset of cognitive impairment in these mice, since it was previously 
reported that at 2 and 2.5 months the 3xTg-AD mice are cognitively normal and that they were 
not born with cognitive impairment (Billings et al., 2005, Gimenez-Llort et al., 2007). Our 
findings are consistent with the previous report that the 3xTg-AD mice are cognitively normal 
until 3 months of age and then cognitive deterioration happens in an age-dependent manner due 
to the transgenic products or their derivative (Billings et al., 2005).  According to the findings of 
this study and previous findings, the 3xTg-AD mice remained impaired throughout their lifespan 
as assessed by the Morris Water Maze and other behavioral tasks (Gimenez-Llort et al., 2007, 
McKee et al., 2008, Filali et al., 2012). It is very difficult in AD patients to detect the onset of 
cognitive impairment because of the lack of a reliable biomarker. In contrast, mice can be 
assessed behaviorally by a battery of tests to detect the early signs of cognitive impairment and 
correlate it with molecular and cellular changes. This then emphasizes the usefulness of this 
study, first because I was able to detect the very early onset of cognitive impairment and follow 
cognitive deterioration across time in 3xTg-AD mice, and second because I was able to study the 




The results of this study show that the oral treatment of 3 month old 3xTg-AD mice for 9 
months with P021 can prevent cognitive deficit, and this is consistent with our previous reports, 
where we started the treatment with P021 or Peptide 6 later during the disease process 
(Blanchard et al., 2010b, Kazim et al., 2014). We previously showed that P021 is a 
neurogenic/neurotrophic compound that increases synaptic plasticity, neurogenesis and BDNF 
expression and  decreases tau and possibly A pathologies (Blanchard et al., 2010a, Blanchard et 
al., 2010b, Li et al., 2010, Bolognin et al., 2012, Bolognin et al., 2014). Since the cognitive 
impairment reported in this study starts very early in the disease process with the onset of 
synaptic loss without apparent A and tau pathologies, I speculate that the preventive effects of 
P021 on cognition at 12 months of age are mainly mediated by its beneficial effects on synaptic 
plasticity and neurogenesis. Similarly, it was reported previously that the neurogenic and 
neurotrophic effects of Amitriptyline (FDA approved tricyclic antidepressant drug) are able to 
reverse cognitive impairment in 3xTg-AD mice at 14 months of age (Chadwick et al., 2011). 
Furthermore, it is well documented that BDNF is an essential effector of spatial learning and that 
its level increases three and six days after training in the hippocampus and the entorhinal cortex 
(Kesslak et al., 1998, Harvey et al., 2008). The fact that P021 acts by increasing BDNF 
expression could also explain the rescue of the cognitive deterioration seen at 12 months of age 
in 3xTg-AD mice in the present study.  
The present study shows that in the novel object location task at 18 months of age the 
3xTg-AD mice are impaired. Furthermore, the 15 month treatment with P021 can rescue this 
impairment. The impairment in the novel object location task in the 3xTg-AD mice found in this 
study is consistent with previous findings in 15-18 month old 3xTg-AD mice (Gulinello et al., 
2009). Since at this stage A and tau pathologies are prominent as well as synaptic loss, I 
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speculate that the beneficial effects of P021 could be also because of its preventive effects on A 
and tau pathologies; the effect of BDNF on prevention of cognitive impairment in 12-14 month 
old 3xTg-AD mice has been reported (Corona et al., 2010). Our previous studies showed that 
P021 acts by decreasing the hyperphosphorylation of tau through the GSK3 pathway (Kazim et 
al., 2014). P021 acts by increasing BDNF expression that acts through the PI3k-Akt pathway to 
increase the phosphorylation of GSK3 on serine 9 and inhibits its activity. Since GSK3 is a 
major tyrosine kinase that phosphorylates tau, that is most likely why we see the decrease in tau 
phosphorylation. The partial decrease in A is also suggested to be through inhibiting GSK3 
activity, since it has been shown previously that GSK3 mediates A neuritic damage 
(DaRocha-Souto et al., 2012) and that its inhibition decreases both A and tau pathologies and 
rescues cognitive impairment in other AD mouse models (Noble et al., 2005, Hu et al., 2009, 
Sereno et al., 2009, Onishi et al., 2011).  
Since episodic memory is severely affected during the AD pathological process, I 
investigated the impairment in episodic-like memory in 3xTg-AD mice and the effect of 16-17 
month treatment with P021 on alleviating it. This study showed that the 19-20 month 3xTg-AD-
vh mice were impaired in episodic memory, but surprisingly I found that the WT mice were also 
impaired because of the effect of aging. The treatment with P021 rescued the episodic-like 
memory deficit seen at this age. Our findings are corroborated by previous findings that showed 
that at 12 months of age both WT and 3xTg-AD mice were impaired in an episodic-like memory 
task, the WWWhich occasion (What-Where-Which occasion) task (Davis et al., 2013). Most 
importantly, episodic memory impairment has been reported previously in cognitive aging 
because it is sensitive to gray and white matter loss as well as to subtle changes in dendritic 
spines that affect synaptic plasticity (Burke and Barnes, 2006, Charlton et al., 2010, He et al., 
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2012). The present finding that the WT mice were spared in short-term spatial memory and 
impaired in episodic like memory was also reported previously in rats (Winters et al., 2004). 
Indeed, depending on the place of the lesions, rats can be impaired in the novel object 
recognition but not the novel object location and vice versa. The hippocampus is believed to be 
essential for object location but not object recognition. However, the entorhinal cortex was 
shown to be important in object recognition but not object location, and this suggests a functional 
dissociation between the two regions (Winters et al., 2004). 
To our knowledge this is the first study showing that P021 treatment for 18 months can 
dramatically increase the survival rate in 3xTg-AD mice by more than 40%. The 3xTg-AD-vh 
mice showed a low level of survival, especially from 12-18 months of age at the peak of A and 
tau pathologies. Our findings are in agreement with previous literature that showed a decrease in 
the long term survival rate in AD patients during a 14 year period from an expected rate of 
16.6% to 2.2%. Furthermore, the decrease in the survival rate becomes more dramatic in AD 
with multi-infarct dementia: 1.7% versus an expected 13.3% (Molsa et al., 1986). The increase in 
disease severity was found to be associated with an increase in the level of mortality similar to 
what I reported here, i.e., that the highest mortality level was registered at the peak of A and tau 
pathologies. The increase in the long-term survival rate seen after P021 treatment further 
emphasizes that a therapeutic drug that would be able to delay the onset of cognitive impairment 
and underlying pathologies in AD could decrease the level of death due to this disease. The lack 
of a therapeutic drug makes AD the sixth major leading cause of death in the USA and the most 
common cause in people aged 65 years or older.  
Since P021 is derived from the CNTF, and CNTF in clinical trials showed serious side 
effects such as muscle pain, anorexia, loss of appetite and weight loss (see Chapter 1), I 
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measured body weight and food consumption throughout the study. The results revealed no 
effect of P021 on food intake or body weight; this further emphasizes that P021 is a potentially 
safe drug that can be developed to treat AD.  
 
4.4 Conclusion  
In conclusion, our data show that early treatment with P021 right after the onset of 
cognitive impairment during the period of synaptic compensation can prevent cognitive 
impairment for the different stages of the disease, mild (12 months) and moderate to severe (18-
20 months), in 3xTg-AD mice. I also found that P021 treatment for the 18 month period can 
dramatically decrease the mortality level by more than 40% in 3xTg-AD mice. The beneficial 
effects of oral treatment with P021 can occur in the absence of severe side effects such as loss of 
appetite or weight loss. These findings show that P021 is a promising therapeutic compound for 







Chapter 5. Effect of P021 on A and tau pathologies 
 
5.1 Introduction 
AD is caused by severe neuronal loss in the limbic and neocortical areas but the real 
cause of neurodegeneration is still unknown. AD accounts for 60-80% of dementia cases; multi-
infarct dementia or vascular dementia comes in second place, accounting for 20-30% of 
dementia cases (www.alz.org; Ott et al., 1995). Multi-infarct dementia is caused when the brain 
tissue loss reaches 100-150 ml. The risk of multi-infarct dementia usually increases with the 
number of infarctions that occur over time. Small infarcts usually occur because of the decrease 
in blood flow to the brain. Decrease in the blood flow to the brain leads to a decrease in the 
brain’s oxygen level, which leads to brain tissue loss due to ischemia. The decrease in the blood 
flow, it is suggested, results from the increase in A deposition in the brain’s blood vessels, 
called cerebral vascular angiopathy. According to the A hypothesis, the excess production of 
A or its soluble forms is the trigger for the neurofibrillary degeneration and dementia associated 
with AD. 
A is a metabolic product of the cleavage of the amyloid precursor protein (APP). The 
APP transcript is alternatively spliced into three different mRNAs: APP770 and APP751, which 
each contain a Kunitz-type serine protease inhibitor domain (APP-KPI), and APP695, which 
lacks this domain. APP 695 is expressed primarily in neurons, whereas APP 770 and 751 are 
expressed in neurons and glia. In AD the mRNA levels of the three APPs have been shown to be 
increased, but in neurons there was a shift from the APP 695 mRNA into APP-KPI mRNAs, 
APP770 and APP751 (Matsui et al., 2007). There are two pathways for APP processing, either 




-secretase  to produce the C99 fragment that is later processed by the γ-secretase to produce A 
peptides, including A 40 and 42, the most abundant fragments in A plaques (Robakis, 2010). 
The non-amyloidogenic pathway involves cleavage with -secretase within the A-sequence on 
the APP, followed by γ-secretase, to produce the APP C-terminal fragment, thus inhibiting -
secretase and the formation of A peptides.  
 
 
Fig. 28. Amyloidogenic and non-amyloidogenic pathways (Zhang, 2012). 
 
Currently the A  hypothesis, which postulates amyloid deposition and soluble A as 
causing disease, represents the basis of several therapeutic strategies, especially several 
prevention studies such as DIAN and API (see Chapter 1). However, this hypothesis remains 
controversial because the A load fails to correlate with the severity of dementia or neuronal and 
synaptic loss (Terry et al., 1981, Braak and Braak, 1991, Neve and Robakis, 1998). Furthermore, 




(Crystal et al., 1988, Arriagada et al., 1992a, Davis et al., 1999). Behavioral abnormalities in Tg 
mice were also shown to be independent of A deposition (Robakis, 2010). Several transgenic 
mice that express high levels of A deposition failed to show significant neurodegeneration.  A 
has been shown to exacerbate tau pathology in Tg mice. However, these Tg mouse models were 
generated overexpressing mutated tau, while to date no tau mutations have been found in AD 
(Iqbal and Grundke-Iqbal, 2010). Furthermore, in the familial cases of FTDP-17 caused by tau 
mutations in chromosome 17 there is only tau pathology and no -amyloidosis. In other 
dementia cases such as hereditary cerebral hemorrhage with amyloidosis of Dutch origin 
(HCHWA-D) and sporadic cerebral amyloid angiopathy (SCAA) -amyloidosis is extensive in 
the absence of any tau pathology (Coria et al., 1987, van Duinen et al., 1987). Moreover, a recent 
study reported that there is no colocalization between A deposition and tau NFT in most AD 
brain regions, suggesting that A is a poor variable to explain the development of tau pathology 
(Lace et al., 2009). The successive failures in anti-A therapeutic approaches in phase II and 
phase III clinical trials makes it unlikely that A is the major trigger of AD dementia and 
neurofibrillary degeneration, especially as the anti-A therapies were successful in clearing A 
from the parenchyma of the brains of AD patients, as shown with postmortem studies, and yet no 
cognitive improvement or halting of the disease progression was observed (Holmes et al., 2008).  
A main support of the A hypothesis is the presence of  presenilin (PS) mutations in the 
FAD cases, which is believed to cause the increase in the generation of the neurotoxic A 
fragment 1-42 and increase the ratio of A 42/40. PS1 is a transmembrane protein involved in 
the γ secretase processing of APP and the production of A peptide. In FAD cases more than 130 
PS1 mutations were reported. To explain the mechanism of neurodegeneration in FAD cases the 




leads to an increase in the generation of the neurotoxic A fragment that promotes cerebral 
amyloidosis and formation of A oligomers (Hardy and Selkoe, 2002, Koo and Kopan, 2004). 
However, a recent study reported that only three out of eight PS1 mutations showed an increase 
in A production. This shows that mutation in the PS is not always accompanied by an increase 
in A 42 generation or even increases the ratio of A 42/40. Some PS mutations even cause a 
loss instead of a gain of function in γ-secretase activity (Shioi et al., 2007). Indeed, it has been 
reported that PS2 mutations are not accompanied by an increase in A42 production or an 
increase in A42/A40 ratios (Walker et al., 2005). The increase in A production also does not 
correlate with the age of the onset of disease in AD cases with PS1 mutations (Citron et al., 
1997, Mehta et al., 1998). Furthermore, even though the APPSwe mutation increases the 
production of A40 and A 42 it does not result in a change in the A42/A40 ratio (Kumar-
Singh et al., 2006). Thus it was suggested that the FAD mechanism of neurodegeneration may be 
independent of the effect of presenilins on A production (Shioi et al., 2007). 
A peptides are expressed by all cells. They are normal components of human serum and 
CSF, there is little evidence of disease associated abnormalities of A and no toxic oligomers are 
specific to AD.  It is unclear under what conditions these peptides become toxic. Several studies 
currently suggest that A deposition could be secondary to neuronal dysfunction of AD but not a 
primary agent that causes the disease (Robakis, 2010). The FAD mutations in PS1, PS2, and 
APP may not cause neurodegeneration because of their effect on increasing the generation of Aβ 
but by altering the signal transduction pathways, especially those involving protein phosphatase-
2A (PP2A) and glycogen synthase kinase-3β (GSK-3β) (Iqbal et al., 2014b). In a recent study 




APP was shown to interact with the cell death receptor 6 to promote neurodegeneration in mice 
(Nikolaev et al., 2009). 
Hyperphosphorylation of tau, on the other hand, is a major cause of neurodegeneration in 
tauopathies (Table 6) (Lee et al., 2001, Brandt et al., 2005, Goedert and Jakes, 2005, Brunden et 
al., 2010). NFT are one of the earliest pathological substrates of aging and a neuropathological 
continuum from aging to MCI and AD (Arriagada et al., 1992b, Guillozet et al., 2003). In the 
rare form of AD with plaques only and hyperphosphorylated tau without tangles (POAD) 
cognitive deterioration is slower and the onset of the disease tends to start later than typical AD 
patients with NFT and amyloid plaques (PTAD). Patients in the POAD group tend to die at older 
ages and there is a trend toward shorter duration of the disease (Tiraboschi et al., 2004). 
Furthermore, the severity of cognitive impairment is directly correlated with the number of NFT 
(Arriagada et al., 1992a). In contrast, A plaque deposition does not correlate either with 
neuronal loss and NFT or with the severity of the disease (Gomez-Isla et al., 1997). 
Tau is a major microtubule-associated protein in the brain. Tau’s normal function is to 
interact with microtubule binding domains to stabilize and maintain their structure. In the normal 
brain tau contains 2-3 moles of phosphate per mole of the protein; in the AD brain it is 3-4-fold 
hyperphosphorylated. The hyperphosphorylation of tau leads to its binding and sequestration of 
normal tau and the other two microtubule associated proteins (MAP1 and MAP2), which causes 
disruption of microtubules (Kopke et al., 1993, Alonso et al., 1994, Alonso et al., 1996, Alonso 
et al., 1997). Hyperphosphorylation of tau is suggested to happen because of an imbalance 
between tau protein kinase and phosphatase activities. In AD two main features are observed in 
tau pathology: either there is microtubule destabilization, which is considered to be a loss of 




Tau is synthesized in the human brain as six isoforms generated by alternative splicing of 
its pre-mRNA at exons 2, 3, and 10, generating the protein with 352 to 441 amino acids in 
length. Variation in the splicing of exons 2/3 inclusion/exclusion are called 0N (no inclusion of 
exons 2 and 3), 1N (inclusion of exon 3), and 2N (inclusion of exons 2 and 3). The alternative 
splicing of exon 10 generates tau isoforms either with three (3-R) or four (4-R) carboxyl-terminal 
MT-binding repeat motifs. The six isoforms are 4R2N, 4R1N, 4R0N, 3R2N, 3R1N, and  3R0N 
(Iqbal et al., 2005, Brunden et al., 2010, Wolfe, 2012). In human tau expression is under 
developmental control: in the fetus tau is exclusively 3R0N but in adults all six isoforms are 
expressed.  
Neither A nor NFT are specific to AD. They are also found in normal individuals in 
small numbers. Previous reports emphasized that a better correlate of cognitive impairment in 
AD is synaptic and neuronal loss (DeKosky and Scheff, 1990, Terry et al., 1991, Gomez-Isla et 
al., 1997). Thus, a combination of a drug that could inhibit A and tau pathologies and 
neurodegeneration and increase the regenerative capacities of the brain would be ideal to treat 
AD and related neurodegenerative diseases.  
We previously reported that P021 has a neurogenic/neurotrophic effect and it can 
decrease A and tau pathologies in 3xTg-AD mice in the severe stages of the disease. In the 
present study I investigated the effect of P021 on preventing tau phosphorylation and A plaque 
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5.2.1 Prevention of A and tau pathologies by P021 in 3xTg-AD mice 
Since A and tau pathologies are the two hallmarks of AD I investigated the effect of 
P021 on the prevention of these two pathologies. The effect of P021 was studied by the treatment 
of 3 month old 3xTg-AD mice for 9 months. A and tau pathologies in the 3xTg-AD mouse are 
localized in the CA1 and the subiculum regions as reported previously (Oddo et al., 2003a). The 
immunohistochemical staining with 4G8 antibody was used to detect A pathology but it also 
recognizes APP. Immunohistochemical staining with AT8 antibody was used to detect tau 
hyperphosphorylation in the Ser202/Thr 205 site.  
I found that at 12 months of age in the CA1 region only APP immunostaining could be 
seen and the analysis of the mean pixel intensity showed that P021 had no significant effect (Fig.  
29a). In the subiculum region the staining, however, was both for APP and A plaques. During 
the analysis the gain was lowered for each picture so that only the A plaque load appeared. 
Then A load was quantified and analyzed as percent of area occupied. I found that at 9 months 
after treatment the P021 was able to completely prevent A pathology in the subiculum region 
(Fig. 29a, t-test, p = 0.0037). 
The AT8 staining in the CA1 region was quantified as percent of area occupied. The 
results showed a trend toward a significant effect of P021 on preventing tau pathology in this 
region (Fig. 29b, t-test, p = 0.05). In the subiculum, however, the data were analyzed as mean 
pixel intensity and there was no apparent effect of P021 treatment at this time point (Fig. 29b).  
The PHF1 staining in the CA1 region and the subiculum was quantified as percent of area 
occupied. The results showed a significant effect of P021 on preventing tau 




























Fig. 29. Effect of P021 on the prevention of A and tau pathologies at 12 months. 
a) 4G8 staining CA1 (upper panel) and subiculum (lower panel). b) AT8 staining in the CA1 
(upper panel), and subiculum (lower panel). c) PHF1 staining in the CA1 (upper panel) and the 
subiculum (lower panel). *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (Tg- AD-vh, n = 









5.2.2 Preventive effects of P021 on A and tau pathologies after 15 months of treatment 
(at 18 months of age) 
The analysis of the percent of area occupied by the A load in the CA1 region (Fig. 30a) 
showed no difference between the 3xTg-AD-vh and Tg-AD-P021. However, there was a strong 
preventive effect of P021 in the subiculum region seen as a decrease in the percent of area 
occupied by the A load (Fig. 30a, t-test, p = 0.0028). 
The analysis of the effect of P021 treatment after 15 months on tau hyperphosphorylation 
using the AT8 staining showed that there was a strong significant effect both in CA1 (Fig. 30b, t-
test, p = 0.0015) and subiculum (Fig. 30b, t-test, p = 0.0024) regions. Similarly the analysis of 
the percent of area occupied by PHF1 positive immunohistochemical staining showed that P021 
was able to prevent tau pathology in the CA1 region (Fig. 30c, t-test, p = 0.0018) and the 


































Fig. 30: Effect of P021 on the prevention of A and tau pathologies at 15 months post-
treatment. 
a) 4G8 staining CA1 (upper panel) and subiculum (lower panel). b) AT8 staining in the CA1 
(upper panel), and subiculum (lower panel). c) PHF1 staining in the CA1 (upper panel), and 
subiculum (lower panel). *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (Tg-AD-vh, n = 




5.2.3 Prevention of A and tau pathologies after 18 months of treatment with P021 (21 
months of age)  
At 18 months after treatment, P021 was able to prevent A pathology in the CA1 (Fig. 
31a, t-test, p = 0.0018) and in subiculum (Fig. 31a, t-test, p< 0.0001) in the 3xTg-AD.  
When analyzing the percent of area occupied for tau hyperphosphorylation using AT8 
staining I found that P021 was able to prevent tau pathology in the CA1 (Fig. 31b, t-test, p = 
0.0002) and the subiculum (Fig. 31b, t-test, p = 0.0002). The analysis of the PHF1 positive 
staining as percent of area occupied showed a significant effect of P021 on preventing tau 
pathology in the CA1 (Fig. 31c, t-test, p < 0.0001) and the subiculum (Fig. 31c, t-test, p < 






















Fig. 31: Effect of P021 on the prevention of A and tau pathologies at 18 months post-
treatment. 
a) 4G8 staining CA1 (upper panel) and subiculum (lower panel). b) AT8 staining in the CA1 
(upper panel), and subiculum (lower panel). c) PHF1 staining in the CA1 (upper panel) and 
subiculum (lower panel) and d) Western blots of the hippocampus developed with PHF1 and 
134d and quantification. *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (WT, n = 5; Tg-




5.2.4 Effect of P021 treatment across time on A and tau pathologies 
Regression analysis of the A pathology across time in the subiculum showed that the A 
load increased with age in the 3xTg-AD-vh (Fig. 32a; t = 4.61, p < 0.0001, AdjR2 = 0.42) and 
that P021 treatment was able to decrease it across time starting from 12 months until 21 months 
(Fig. 32a; t = -4.32, p <0.0001, AdjR2 = 0.38).  
The analysis of AT8 as a percent of area occupied across time in the CA1 area with the 
regression analysis showed that the AT8 load increased over time from 12-21 months of age in 
the 3xTg-AD-vh (Fig. 32b; t=5.48, p <0.0001, AdjR2 = 0.42). However, P021 treatment was able 
to lower the AT8 load across time (Fig. 32b, t= -3.24, p = 0.003, AdjR2 = 0.26). Furthermore, I 
found that the AT8 load increased at a slower rate in the 3xTg-AD-P021 compared to the 3xTg-
AD-vh (Fig. 32b, t = -2.37, p = 0.027, AdjR2 = 0.86).  
The analysis of the PHF1 load across time as percent of area occupied in the CA1 area 
showed that  it increased over time in the 3xTg-AD-vh (Fig. 32c, t = 6.64, p < 0.0001, AdjR2 
=0.61) and that P021 treatment was able to inhibit it (Fig. 32c, t = -2.51, p < 0.02, AdjR2 = 0.16). 
Furthermore, P021 treatment was able to slow down the rise of the PHF1 curve across time (Fig. 
32c, t = -4.23, p < 0.0001, AdjR2 = 0.92). In the subiculum area the PHF1 load was higher in the 
3xTg-AD-vh versus 3xTg-AD-P021 across time (Fig. 32d, t = -12.59, p < 0.0001, AdjR2 = 0.85). 
Furthermore, P021 treatment was able slow down the rise of the PHF1 curve across time (Fig. 



























Fig. 32: Analysis of the preventive effects of P021 across time.a) 4G8 staining in the subiculum in 
3xTg-AD-vh (upper panel) and in Tg-AD-P021 (lower panel).  b, c, d) AT8 (b) and PHF1 (c, d) 
staining in CA1 (b, c) and subiculum (d) in 3xTg-AD-vh (upper panel) and in Tg-AD-P021 
(lower panel) *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar = 100m. (Tg-AD-vh, n = 5; Tg-AD-





Several drug driven therapeutics in AD have aimed to clear either A plaques or NFT 
from the brain in a hope to stop the progression of AD pathologies. Since all the attempts to 
develop therapeutics based solely on removing A from the brain have failed, and since AD is 
known to be a multifactorial disease, finding a drug that could affect both pathologies as well as 
increasing neurogenesis and neuronal plasticity could be promising. We showed previously that 
P021 increased neurogenesis and neuronal plasticity and rescued cognitive impairment in several 
AD models (Blanchard et al., 2010b, Bolognin et al., 2012, Kazim et al., 2014), a Down 
Syndrome mouse model (Blanchard et al., 2011) and a cognitive aging animal model (Bolognin 
et al., 2014). Here I show that P021, when administered early during the period of synaptic 
compensation before any overt A or tau pathologies, can prevent them at 9, 15, and 18 months 
post-treatment and also limit the progression of the pathologies across time in 3xTg-AD mice. 
To our knowledge this is the first report of a neurotrophic/neurogenic compound that is able to 
prevent both A and tau pathologies and slows their progression with time. 
The appearance of senile plaques in the brain along with NFT is one of the diagnostic 
features of AD. I investigated the progression of A pathology at three different time points — 
12, 18, and 21 months — and the preventive effect of P021 on it in 3xTg-AD mice. At 12 
months of age I showed a prevention of A pathology in the subiculum but not in the CA1. The 
pathology in the CA1 region was not robust; I saw only APP staining. This may explain the 
effect of P021 on the subiculum and not on CA1.  At 18 months and 21 months, however, the 
pathology was more robust and almost the whole CA1 and subiculum areas were involved. I 
found that P021 has a strong effect in preventing A pathology. This finding is not in agreement 




3xTg-AD mice after the disease onset (6-7 months of age) for 6 weeks, we found no effect of 
P021 on A (Blanchard et al., 2010b). Treatment of 3xTg-AD mice starting at 9-10 months of 
age for 12 months showed that P021 was able to reduce A generation (Kazim et al., 2014). The 
findings of the present study emphasize the importance of early treatment for prevention of A 
pathology. The curve of the progression of A pathology across time showed that the A load 
increased across time in 3xTg-AD-vh. However, in P021 treated animals the progression of the 
disease was slowed down, especially from 18-21 months of age in the subiculum region. 
Since tau hyperphosphorylation correlates with synaptic loss in animal models (Kimura 
et al., 2010) and the density of NFT correlates with the severity of dementia in AD patients 
(Arriagada et al., 1992a, Bierer et al., 1995, Dickson et al., 1995, Giannakopoulos et al., 2003, 
Guillozet et al., 2003) I studied the effect of chronic P021 treatment on tau phosphorylation with 
the phospho-specific tau antibodies AT8 and PHF1. P021’s potential preventive effects were also 
studied across three different time points: 9, 15, and 18 months post-treatment.  
I found that at 12 months of age in the 3xTg-AD the NFT formation starts in the 
subiculum and only a very small area of the CA1 region is occupied. When I analyzed the 
immunohistochemical staining with AT8, I found a high variation from animal to animal but 
after 9 months of treatment 3xTg-AD-P021 showed a trend toward an effect in the CA1 but none 
in the subiculum; however, using the PHF1 immunohistochemical staining, I found that P021 
was able to prevent tau pathology in the CA1 and the subiculum.  
At 18 months of age in 3xTg-AD mice the pathology is already prominent in the 
subiculum and covers a large area in the CA1 region. I found that 15 months of continuous 




a previous study in which we showed that at 15-16 months of age P021 treatment for six months 
was able to reverse tau pathology in 3xTg-AD mice (Kazim et al., 2014). 
At 21 months of age treatment with P021 for 18 months prevented tau pathology both in 
the CA1 region and the subiculum. At this stage AT8 load was evident in the two regions in 
3xTg-AD-vh mice. These results are consistent with our previous findings (Kazim et al., 2014). 
The most important finding of the present study, though, is that P021 was able to slow the 
progression of the disease across time. This finding is of major importance because this shows 
that P021 could be a potential drug for AD that could stop or halt the progression of the disease.  
I speculate that the preventive effects of P021 on A and tau pathologies are through the 
inhibition of GSK3, as we reported previously (Kazim et al., 2014). P021 acts by increasing the 
expression of BDNF, which leads to the increase in the phosphorylation of GSK3 on serine 9, 
which results on its inhibition. Since GsK3 is a major tau protein kinase for phosphorylation of 
the proline-directed sites, its inhibition results in a decrease in tau phosphorylation (Munoz-
Montano et al., 1997). GSK3β also is implicated in A mediated neuritic damage (DaRocha-
Souto et al., 2012), APP processing and A deposition (Phiel et al., 2003). Its inhibition is shown 
to reduce both A and tau pathologies, neuronal survival and cognitive impairment (Sereno et 
al., 2009). 
5.3 Conclusion 
Collectively our data show that chronic early oral treatment with P021 results in 
prevention of A and tau pathologies. I also show, by the analysis of its effect across time, that 
P021 is able to slow down the progression of the disease in the 3xTg-AD mouse model. This 




Chapter 6.  Effect of early treatment with P021 on 
neuroregeneration and neurodegeneration 
 
6.1 Introduction 
Increasing evidence suggests that the beginning of the pathological cascade of AD starts 
many years before the appearance of the clinical symptoms of cognitive impairment. The very 
early stages of AD are thought to start with synaptic dysfunction, followed by neuronal loss, A 
and tau pathologies and cognitive impairment (Selkoe, 2002). Although the severity of dementia 
has been shown to correlate with the density of NFT or NFT plus senile plaques, neither of the 
two pathologies is specific to AD. They are also reported in normal aged individuals. For 
instance, in the oldest old people dementia is associated with very little pathology, while the 
absence of dementia was reported in the presence of high levels of Aβ and tau pathologies 
(Green et al., 2000, Silver et al., 2002). Furthermore, it has been shown that there is a significant 
overlap in the BRAAK stages between demented and non-demented patients (Gold et al., 2000, 
Riley et al., 2002). Synaptic loss, on the other hand, has been shown to be a consistent feature 
that differentiates demented and non-demented people and significantly correlates with the 
severity of dementia (DeKosky and Scheff, 1990, Terry et al., 1991, Scheff and Price, 2003). 
Synaptic loss correlates well with other types of dementia and age-associated decrease in 
cognitive performance, called normal cognitive aging (Coleman et al., 2004). 
Postmortem analysis has revealed a drastic decrease in presynaptic and postsynaptic 
markers in very early AD stages, suggesting the degeneration of the whole synaptic element 
(Davidsson and Blennow, 1998). A decrease in the number of synapses of ~ 25-30%  was 
reported in temporal and frontal cortical biopsies and around 15-35% loss in the number of 




even more pronounced in the hippocampus, reaching 44% to 55% (Scheff et al., 2007). Synaptic 
degeneration is thought to start in the entorhinal cortex, with the dendrites as the first to undergo 
degeneration, since they make up to 90% of synaptic contact. Dendritic loss is found to occur in 
parallel with synaptic loss, and major synaptic loss occurs very early in AD (Davies et al., 1987, 
Masliah et al., 2001). It has been previously shown that the ratio of synapses to neurons 
decreases by 48%, suggesting that synaptic loss is not happening only in the degenerated neurons 
but also in the remaining neurons (Coleman and Yao, 2003). Thus, in AD neurons may survive 
for a long period of time with a progressive deterioration of structure and function (Coleman et 
al., 2004). Surviving neurons account for as much as 38% of synaptic loss in AD. Cognitive 
deficit is thus suggested to occur not only because of synaptic loss but because of the impaired 
capacity of the still surviving synapses.  
In spite of the reduced capacity of synaptic plasticity there is still a residual plastic 
capacity, as shown by the synaptic compensation phenomenon that happens in the early AD 
stages and in transgenic mice (see Chapter 3). In a previous study, although synaptophysin was 
reported to decrease in the frontal cortex of demented people, an increase was found in 
cognitively impaired non-demented 90+ year old individuals. This suggests that synaptic 
compensation counteracts synaptic loss and accounts for preserved cognition in these individuals 
in the presence of extensive pathology (Head et al., 2009). In the Rush Religious Orders Study 
an increase in the level of synaptophysin in the superior frontal cortex of MCI patients was 
reported compared to normal individuals (Counts et al., 2006). Furthermore, an increase in the 
level of synaptophysin in elderly people with extensive pathology and normal cognition was 
found compared to patients diagnosed with clinical and pathological AD (Lue et al., 1996, Lue et 




increase in the number of synapses, since an increase in the synaptic size to keep an intact total 
synaptic contact area in the very early stages of the disease has been found (Scheff and Price, 
2003).  
Brain mass loss/year is estimated to be ~ 0.5% in normal aged individuals and ~5-fold 
higher in AD (Fox et al., 1996). During the period of 7-10 years of disease progression, brain 
loss is estimated to be 200–400 g (Chan et al., 2001). The hippocampus is the major brain region 
that undergoes neuronal loss in AD and the atrophy is as drastic as 10% per year.  More than 
50% of the neurons in the brain are lost and the loss increases with the severity of the disease. 
Neuronal loss in the cortical association areas is thus directly correlated with memory loss 
(Gomez-Isla et al., 1997). It was shown previously that neuronal loss is prominent in layer II of 
the entorhinal cortex in mild AD, which distinguishes it from that layer in non-demented aged 
individuals. Furthermore, the number of neurons is inversely correlated with the number of NFT 
but not with senile plaques (Gomez-Isla et al., 1996). Neuronal loss has been linked to the 
abnormal hyperphosphorylation of tau. As stated previously (chapter 5), hyperphosphorylated 
tau sequesters normal tau, which causes the breakdown of microtubules. This would compromise 
axonal transport and lead to retrograde degeneration and synaptic loss (Iqbal and Grundke-Iqbal, 
2002). These events are believed to lead to brain volume loss and dementia. 
A key mechanism of deficient neurogenesis, neuronal loss and synaptic plasticity could 
be the imbalance of neurotrophic factors (Li et al., 2008). It has been shown that neurons 
maintain two pools of NGF: a constitutive pool in the soma that may maintain neuronal survival 
and a regulatable pool in the dendrites to maintain plasticity. A small change in the NGF level in 
transgenic mice is linked to impaired synaptic plasticity and cognitive performance. 




frequency and it has been shown to inhibit the cleavage of Pro-BDNF to BDNF (Coleman et al., 
2004). An imbalance of neurotrophic factor is suggested to be the cause of the deficit in 
neurogenesis (Li et al., 2008).   
I postulated that providing the diseased brain with neurotrophic activity could boost the 
process of neuroregeneration to counteract synaptic and neuronal loss and enhance neurogenesis. 
Since synaptic and neuronal loss and the compensation phenomenon happen very early during 
the disease process, I attempted to intervene at this early age in the 3xTg-AD mice (~3 months) 
with the neurogenic/neurotrophic peptide P021 to learn if I could prevent the disease progression 
to advanced stages.  
The purpose of this study is thus to investigate the effect of P021 on prevention of 
synaptic and neuronal loss, neurogenesis deficit and neurodegeneration in 3xTg-AD mice by 
starting the treatment at 3 months of age and maintaining it for several months. Synaptic loss was 
studied immunohistochemically and biochemically using different synaptic markers such as 
synaptophysin, synapsin 1, GluR1, PSD-95, NR1 and MAP2 at 3 months of age just before 
treatment with P021, at 12 months (9 months after treatment), at 18 months (15 months after 
treatment), and at 21 months (18 months after P021 treatment). Neurodegeneration at the above 
time points was also studied using Fluorojade C staining. Neurogenesis was studied at 12 months 
of age using DCX and Ki-67 staining. 
 
6.2 Results 
6.2.1 Preventive effect of P021 on synaptic plasticity 
Synaptic loss in 3xTg-AD at 3 months of age before the start of the treatment 
Since my aim was to start the treatment with P021 very early in the disease process at 




treatment. Based on my findings described in chapter 3, the onset of synaptic loss and its 
compensation starts at around three months in 3xTg-AD mice. I analyzed the level of expression 
of MAP2 immunohistochemically and I found a trend toward a decrease in the CA1 (Fig. 33a, e, 
p = 0.05) and a significant decrease in the DG (Fig. 33a, e, p = 0.0429). Similarly, Western blot 
analysis of the hippocampus showed a significant decrease in the protein expression level of 
MAP2 (Fib. 34b, c, t-test, p = 0.01). I found that the synaptophysin expression level decreased 
both in CA3 (Fig. 33b, e, p = 0.0209) and DG (Fig. 33b, e, p = 0.0044). The PSD-95 expression 
showed a significant difference between the WT and 3xTg-AD mice in the parietal cortex (Fig. 
33c, e, p = 0.0395). In the cortex the level of synaptophysin (Fig. 34a, c, p = 0.0014) was 
reduced significantly while that of GluR1 showed a trend toward decrease in 3xTg-AD mice 
(Fig. 34a, c, p = 0.06) as shown by Western blots. The level and the expression of synapsin 1 
were also investigated immunohistochemically and biochemically but there was no significant 
difference between the 3xTg-AD and the WT. Furthermore, the level and the expression of NR1 
in the parietal cortex decreased significantly in the 3xTg-AD mice compared to WT, as shown by 
immunohistochemical analysis (Fig. 33d, e, p = 0.0014) and by Western blots of the cortex (Fig. 
34a, c, p = 0.004). The analysis of the level of the ratio of pCreb and Creb in the cortex by 
Western blots showed a significant decrease in the 3xTg-AD mice compared to WT (Fig. 34a, c, 
p = 0.002). No significant difference was found in the level of PSD95 between the two groups by 
Western blots in the cortex and the hippocampus (Fig. 34a, c). Human-specific monoclonal 
antibody 43D to tau was used to check the 3xTg-AD mice genotype compared to WT by 






























Fig. 33: Synaptic deficit at 3 months of age in 3xTg-AD mice. 
a) Immunohistochemical analysis of the MAP2 level in the CA1 region (upper panel) and the 
DG (lower panel). b) Level of expression of synaptophysin in the CA3 region (upper panel) and 
the DG (lower panel). c) Level of expression of PSD-95 in the parietal cortex. d) Expression of 
NR1 in the parietal cortex and e) quantification of immunohistochemical staining. t-test. 
*p<0.05; **p<0.01; ***p<0.001. Scale bar = 100m. (WT, n = 5; Tg-AD vh, n= 5). 
























Fig. 34: Analysis of the protein level in 3 months old 3xTg-AD mice by Western blots. 
a) Cortex, Western blots b) Western blots analysis of the protein level in the hippocampus and c) 
quantification, t-test, *p <0.05; **p <0.01; ***p <0.001. (WT, n = 6; Tg-AD vh, n= 6). 






Effect of P021 on synaptic plasticity after 9 months of treatment in 3xTg-AD  
I investigated the effect of 9 months of treatment with P021 on synaptic plasticity 
immunohistochemically and biochemically. The immunohistochemical analysis of the 
expression of PSD-95 showed that there was a significant increase in 3xTg-AD-P021 compared 
to WT and 3xTg-AD-vh in the CA1 (Fig. 35a, e, p = 0.0038) and CA3 regions (Fig. 35a, e, p = 
0.0010). In the DG (Fig. 35a, e, p = 0.0314) and parietal cortex (Fig. 35a, e, p = 0.0169) a 
significant difference was found between 3xTg-AD-vh and 3xTg-AD-P021. Similarly, Western 
blot analysis of the hippocampus showed a trend toward a decrease in the level of PDS-95 
expression in the 3xTg-AD-vh mice compared to WT (Fig. 36b, c, p = 0.07) and a trend toward 
an increase in 3xTg-AD-P021 compared to 3xTg-AD-vh (Fig. 36b, c, p = 0.07). I found also that 
the NR1 expression in the CA3 region increased in 3xTg-AD-P021 compared to WT and 3xTg-
AD-vh (Fig. 35c, e, p = 0.0091). 
A trend toward a decrease was found in the MAP2 expression in the CA3 region (Fig. 
35b, e, p = 0.09), DG (Fig. 35b, e, p = 0.0416) and the parietal cortex (Fig. 35c, e, p = 0.0392) in 
the 3xTg-AD-vh compared to WT. However, no apparent effect of P021 to prevent this deficit 
was detected. The analysis of the expression of synapsin 1 immunohistochemically showed a 
trend toward a decrease in the DG in the 3xTg-AD-vh compared to WT (Fig. 35d, e, p = 0.07). 
Similarly, no difference was detected by Western blots (Fig. 36a, c) and no apparent effect of 
P021 was detected either immunohistochemically or by Western blots. I analyzed the level and 
the expression of synaptophysin both immunohistochemically and biochemically and I found a 
significant decrease in 3xTg-AD-vh compared to WT by Western blots (Fig. 36a, c, p = 0.0339). 
However, I did not detect any effect of P021 on synaptophysin expression. I confirmed the 
genotype of 3xTg-AD-vh and 3xTg-AD-P021 mice with Western blots using the human-specific 
















Fig. 35: Effect of P021 on synaptic deficit, 9 months post-treatment in 3xTg-AD mice. 
a) Immunohistochemical analysis of the level of expression of a) PSD-95 in the CA1, CA3, DG, 
and parietal cortex b) MAP2 in the DG (upper panel), CA3 (middle panel), and parietal cortex 
(lower panel) c) NR1 in the CA3 region. d) Analysis of the synapsin 1 level of expression in the 
DG. e) quantification of immunohistochemical staining. One Way ANOVA post hoc test. 
*p<0.05; **p<0.01; ***p<0.001. Scale bar = 100m. (WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-


















Fig. 36: Effect of P021 at 12 months of age in 3xTg-AD mice. 
 a) Analysis of the protein expression level in the cortex by Western blots. b) Analysis of the 
expression level of protein in the hippocampus and c) quantification of the blots. One Way 
ANOVA post hoc test. *p<0.05; **p<0.01; ***p<0.001. (WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-
P021, n = 5). Quantification is shown as mean ± SD. 
 
Effect of P021 on prevention of synaptic loss after 15 months of treatment  
The analysis of the expression of MAP2 immunohistochemically showed that there was a 
trend toward a decrease in the CA1 between WT and 3xTg-AD-vh mice (Fig. 37a, f, p = 0.06). A 




region (Fig. 37a, f, p = 0.0065). In the CA3 region a trend toward a significant decrease was 
detected in 3xTg-AD-vh as compared with WT mice (Fig. 37a, f, p = 0.09). P021 was found to 
rescue this deficit (Fig. 37a, f, p = 0.0226). In the DG (Fig. 37a, f, p = 0.0239) and the parietal 
cortex (Fig. 37a, f, p = 0.0491) a significant preventive effect of P021 was found in 3xTg-AD-
P021 compared with 3xTg-AD-vh mice. 
The analysis of the synapsin 1 expression immunohistochemically showed a decrease of 
the expression in 3xTg-AD-vh and no apparent effect of P021 treatment. Immunohistochemical 
analysis showed a significant decrease in the CA1 region (Fig. 37b, f, p = 0.0395), a trend toward 
a decrease in the CA3 region (Fig. 37b, f, p = 0.07) and trend toward a decrease in the parietal 
cortex (Fig. 37b, f, p = 0.06) in the 3xTg-AD-vh compared to WT.  
Immunohistochemical analysis of the expression of GluR1 showed a significant increase 
in the 3xTg-AD-P021 mice in the CA1 region compared to the 3xTg-AD-vh (Fig. 37c, f, p = 
0.0365). 
Immunohistochemical investigation of the expression of synaptophysin in the CA1 region 
showed a significant increase in the 3xTg-AD-P021 compared to WT (Fig. 37d, f, p = 0.0450) 
and a trend toward an increase in the level of synaptophysin in the parietal cortex in 3xTg-AD-
P021 compared to WT (Fig. 37d, f, p = 0.0623). The analysis of the expression of NR1 showed 
that it increased in the DG (Fig. 37e, f, p = 0.0306) and the parietal cortex (Fig. 37e, f, p = 
0.0476) of the 3xTg-AD-P021 compared to WT.  
Western blot analyses of synapsin1 level in the cortex showed a significant preventive 
effect of P021 (Fig. 38a, c, p = 0.0003) in 3xTg-AD-P021 mice. Similarly, I found an increase in 
the level of synaptophysin in the cortex of the 3xTg-AD-P021 mice compared to 3xTg-AD-vh 




38a, c). In the hippocampus Western blot analysis showed a trend toward an effect of P021 in 
increasing the level of MAP2 and synapsin1 (Fig. 38b, c, p = 0.05 and p = 0.06, respectively). 
The 3xTg-AD-vh and 3xTg-AD-P021 genotypes were determined biochemically using the 43D 















Fig. 37: Preventive effects of P021 on synaptic deficits at 15 months post-treatment by 
immunohistochemistry in 3xTg-AD mice. 
a) Investigation of the level of expression of MAP2 in the CA1, CA3, DG, and parietal cortex. b) 
Synapsin 1 level of expression in the CA1, CA3, and parietal cortex. c) Level of expression of 
GluR1 in the CA1 region. d) Level of expression of synaptophysin in the CA1 and the parietal 
cortex. e) Level of expression of NR1 in the DG and the parietal cortex and f) quantification of 
immunohistochemical staining. One Way ANOVA post hoc test. *p<0.05; **p<0.01; 
***p<0.001. Scale bar = 100m. (WT, n = 5; Tg-AD-vh, n = 3; Tg-AD-P021, n = 5). 



















Fig. 38: Preventive effect of P021 after 15 months post-treatment by Western blots in 3xTd-
AD mice. 
a) Analysis of protein expression in the cortex. b) Analysis of protein expression in the 
hippocampus and c) quantification of the blots. One Way ANOVA post hoc test. *p<0.05; 
**p<0.01; ***p<0.001. (WT, n = 5; Tg-AD-vh, n = 3; Tg-AD-P021, n = 5). Quantification is 
shown as mean ± SD. 
 
Effect of P021 on synaptic loss after 18 months of treatment  
A significant increase of the synapsin 1 expression immunohistochemically in the CA1 
region was found in the 3xTg-AD-P021 compared to WT (Fig. 39a, c, p = 0.0384) and a trend 




NR1 in the parietal cortex decreased in the 3xTg-AD-vh compared to WT (Fig. 39b, c, p = 
0.0305) and a trend toward an increase in 3xTg-AD-P021 compared to 3xTg-AD-vh (Fig. 39b, c, 
p = 0.05) was found. 
Western blot analysis showed a significant increase in the level of synaptophysin in the 
cortex (Fig. 39d, f, p = 0.03). In the hippocampus, synaptophysin showed a trend toward a 
decrease in the 3xTg-AD-vh compared to WT (Fig. 39e, f, p = 0.07). In the cortex, a trend 
toward a decrease in the ratio of pCreb and Creb was detected in the 3xTg-AD-vh compared to 
WT and 3xTg-AD-P021 (Fig. 39d, f). The MAP2 level showed a significant increase in the 
P021-treated group compared to 3xTg-AD-vh in the cortex (Fig. 39d, f). The level of PSD-95 in 
the hippocampus showed a trend toward an increase for the 3xTg-AD-P021 compared to the 
3xTg-AD-vh (Fig. 39e, f, p = 0.09). The GluR1 expression showed a significant decrease in the 
3xTg-AD-vh (Fig. 39e, f, p = 0.02) and a trend toward an effect of P021 (Fig. 39e, f, p= 0.06) in 
the hippocampus, no changes were detected in the cortex (Fig. 39d, f). The level of the ratio of 
pCreb and Creb showed a significant increase in the 3xTg-AD-P021 compared to the other two 
groups (Fig. 39e, f, p = 0.0007). The GluR2/3 level showed a significant increase in the WT 


















Fig. 39: Preventive effect of P021 on synaptic deficit at 18 months post-treatment in 3xTg-
AD mice. 
a) Immunohistochemical analysis of synapsin 1 level in the CA1 region and b) NR1 level of 
expression in the parietal cortex. c) Immunohistochemical quantification. d) Western blot 
analysis of level of expression of synaptic proteins in the cortex and e) in the hippocampus and f) 
quantification of the blots. One way ANOVA post hoc test. *p<0.05; **p<0.01; ***p<0.001. 
Scale bar = 100 m. (WT, n = 5; Tg-AD-vh, n = 5; Tg-AD-P021, n = 5). Quantification is shown 





6.2.2 Preventive effects of P021 on neurodegeneration 
Effect of P021 on prevention of neurodegeneration after 9 months of treatment in 3xTg-
AD mice 
Neurodegeneration was analyzed using Fluorojade C staining and the data were analyzed 
as percent of area occupied by the degenerated neurons. The degenerated neurons were stained 
as bright green on a dark green background. The quantification of the percent of area occupied 
revealed that the area occupied by degenerated neurons was significantly higher in the 3xTg-AD-
vh compared to WT and 3xTg-AD-P021 in the CA3 (Fig. 40a, d, p = 0.0066), DG (Fig. 40a, d, p 
< 0.0001), parietal (Fig. 40a, d, p = 0.0351), and frontal (Fig. 40a, d, p = 0.0121) cortices. P021 
treatment for 9 months showed a complete rescue of the neurodegeneration. 
Preventive effect of P021 on neurodegeneration at 15 months post-treatment in 3xTg-AD 
mice 
Neurodegeneration was found to increase in the 3xTg-AD-vh compared to WT, and the 
P021 treatment for 15 months was able to prevent this impairment. These changes were seen in 
the CA1 (Fig. 40b, d, p = 0.0039), CA3 (Fig. 40b, d, p = 0.0431), DG (Fig. 40b, d, p = 0.0021), 
and parietal cortex (Fig. 40b, d, p = 0.0001). 
Preventive effect of P021 on neurodegeneration at 18 months post-treatment in 3xTg-AD 
mice  
At 21 months of age the percent of area occupied by the degenerated neurons was higher 
in 3xTg-AD-vh compared to WT, and P021 treatment was able to completely prevent this deficit 
in CA1 (Fig. 40c, d, p = 0.0011), CA3 (Fig. 40c, d, p = 0.0133), DG (Fig. 40c, d, p = 0.0013), 
























Fig. 40: Preventive effect of P021 on neurodegeneration in 3xTg-AD mice. 
a) At 9 months post-treatment in the CA3, DG, parietal and frontal cortices (WT, n = 5, Tg-AD-
vh, n = 5; Tg-AD-P021, n = 5). b) At 15 months post-treatment in the CA1, CA3, DG, and 
parietal cortex (WT, n = 5, Tg-AD-vh, n = 3; Tg-AD-P021, n = 5). c) At 18 months post-
treatment in the CA1, CA3, DG, and parietal cortex and (WT, n = 5, Tg-AD-vh, n = 5; Tg-AD-
P021, n = 5). d) quantification of immunohistochemical staining. One way ANOVA post hoc 
test. *p<0.05; **p<0.01; ***p<0.001. Scale bar = 100 m. Quantification is shown as mean ± SD. 
 
 
6.2.3    Effect of P021 on boosting neurogenesis 
 The effect of P021 on boosting neurogenesis was investigated at 9 months post-treatment 
(12 month old 3xTg-AD) by immunohistochemical staining for Ki-67, a cell proliferation marker 
that measures early stages of the neurogenesis and DCX a marker for immature adult-born 




DCX+ cells was significantly reduced in the 3xTg-AD-vh compared to WT (Fig. 41a, c, p = 
0.0009) and that P021 rescued this deficit (Fig. 41a, c, p < 0.0001). Remarkably, the level of 
neurogenesis was rescued to more than WT level (Fig. 41a, c, p < 0.001). Similarly, a decrease in 
the number of Ki-67+ cells was observed in the 3xTg-AD-vh mice compared to WT (Fig. 41b, c, 























Fig. 41: Preventive effects of P021 on neurogenesis in DG at 9 months post-treatment in 
3xTg-AD mice. 
a) DCX and TOPRO staining in WT (left panel), 3xTg-AD-vh (middle panel), and Tg-AD-P021 
(right panel). b) Ki-67 and TOPRO staining in WT (left panel), 3xTg-AD-vh (middle panel), and 
Tg-AD-P021 (right panel). c) Densiometric quantification of the number of DCX+ and Ki-67+ 
cells. Arrow heads indicate positive cells. One way ANOVA post hoc test. *p<0.05; **p<0.01; 





Since synaptic and neuronal losses occur very early in the disease process and are the 
best correlates of cognitive impairment and dementia in AD, I postulated that an efficient 
treatment for AD would be one that starts early in the disease process and is able to achieve 
synaptoprotection and neuroprotection and thus halt the disease progression. I further postulated 
that a treatment that is initiated during the period of synaptic compensation would make this 
phenomenon successful and help slow down synaptic and neuronal loss as well as boosts 
neurogenesis and consequently cognitive deterioration. Herein, I applied such a strategy: I 
administered the P021 in diet during the synaptic compensation period and I followed its effect 
at 9, 15, and 18 months post-treatment.  
In the present study I found that at 3 months of age, before the start of the P021 
treatment, there was a synaptic loss, as seen by the decrease in the level of MAP2, 
synaptophysin, PSD-95, NR1, and the ratio of pCreb and Creb. At 9 months post-treatment I 
found a synaptic deficit in the 3xTg-AD-vh mice compared to the WT, as shown by a decrease in 
the level of MAP2 and synapsin 1. While I found a rescue of synaptic deficit post-9 month 
treatment as seen immunohistochemically with PSD-95 and NR1, the strongest effect of P021 on 
rescuing synaptic deficit was at 15 months post-treatment on the MAP2, synaptophysin, synapsin 
1, GluR1 and NR1 expression levels as shown immunohistochemically and biochemically. At 18 
months post-treatment P021 was able to prevent synaptic deficit, as shown by 
immunohistochemistry and Western blots.  
Our data showed that at exactly 3 months of age, before I started the treatment with P021, 
there was synaptic loss, as shown by a decrease in the synaptophysin, MAP2, PSD-95 and NR1 
expression levels, the ratio of pCreb and Creb, as well as a trend toward a decrease in the GluR1 




described in Chapter 3. An early drop in the synaptophysin level of expression is also known in 
early AD patients and this decrease is correlated with early cognitive impairment and the severity 
of dementia (Heffernan et al., 1998, Masliah et al., 2001, Callahan et al., 2002). Similarly, I 
found here and in Chapter 3 an early reduction in the synaptophysin level as well as cognitive 
impairment in the 3xTg-AD mice. 
At 9 months post-treatment the analysis of the expression level of PSD-95 
immunohistochemically showed that P021 treatment was able to rescue the decrease in the 
expression in 3xTg-AD mice in the CA1, CA3, DG and parietal cortex. Similarly, with Western 
blots I found a trend toward a decrease in the level of PSD-95 in the 3xTg-AD-vh and a trend 
toward an effect of P021 in the hippocampus. The expression of NR1 decreased also in the 
3xTg-AD-vh in the parietal cortex and a trend toward an effect of P021 was seen. I found a 
synaptic deficit, as seen in the drop of MAP2 expression in the DG, CA3, and parietal cortex and 
the synapsin 1 expression in the DG in 3xTg-AD mice. These data showed that P021 at 12 
months of age was effective in restoring synaptic loss, as seen in a restored expression level of 
PSD-95 and NR1. Our immunohistochemical findings were further corroborated with the 
Western blot analysis of the cortex. 
At 15 months post-treatment P021 showed the strongest effect on preventing synaptic 
loss. This may be because at 18 months of age the 3xTg-AD-vh mouse brain has already 
undergone extensive synaptic loss so the effect of P021 becomes quite apparent. Indeed, P021 
rescued the decrease in MAP2 expression in all the brain regions analyzed 
immunohistochemically (CA1, CA3, DG and parietal cortex). Synaptophysin loss was also 
prevented in the CA1 and the parietal cortex. A decrease in the GluR1 expression was also 




synaptophysin further corroborated our data. Similar data was reported in other P021 studies 
(Blanchard et al., 2010a, Blanchard et al., 2010b, Li et al., 2010, Blanchard et al., 2011, Chohan 
et al., 2011, Bolognin et al., 2012, Kazim et al., 2014). The preventive effect of P021 on rescuing 
synapsin 1 expression was seen by Western blot analysis. This strong effect of P021 should be 
interpreted in light of our previous data on Aβ and tau pathologies and cognition. I showed 
previously (Chapter 4) that there was a strong effect of P021 on preventing cognitive impairment 
and A and tau pathologies (Chapter 5), thus P021 would be expected to prevent synaptic 
pathology as well.  
At 18 months post-treatment an effect of P021 on rescuing the synapsin1 expression was 
seen immunohistochemically in the CA1 region of the hippocampus. A trend toward a rescuing 
effect of P021 on the expression of NR1 in the parietal cortex was found. Western blot analysis 
of the cortex and the hippocampus revealed a preventive effect of P021 on rescuing the level of 
synaptophysin and MAP2 in the cortex and the ratio of pCreb and Creb in the hippocampus. A 
trend toward an effect of P021 on rescuing PSD-95 and GluR1 expression was also found in the 
hippocampus. Thus, collectively, our data show that early chronic treatment with P021 can be 
effective even until later age in rescuing neuronal plasticity deficits in 3xTg-AD mice. 
In the present study I found that the different brain regions of the 3xTg-AD-vh mice had 
undergone massive degeneration compared to WT mice, and P021 treatment was able to rescue 
this impairment at 12, 18 and 21 months of age.  
The level of neurogenesis in the present study was investigated by the quantification of 
the number of DCX+ cells and Ki-67+ cells in the DG area at 9 month post-treatment with P021. 
My results show that neurogenesis was defective in 3xTg-AD-vh mice and that the treatment 




inhibition of the LIF signaling pathway or the increase in the BDNF expression. My results are 
in agreement with what was shown previously when P021 was injected subcutaneously to 
normal adult C57Bl6/J mice (Li, et., 2010) or by oral gavage to a rat model of cognitive aging 
(Bolognin et al., 2014). 
 
6.4 Conclusion 
My data showed that there was a synaptic loss in 3 month old 3xTg-AD mice. After 9, 
15, and 18 months of treatment, P021 was able to prevent synaptic loss. Furthermore, 
neurodegeneration analysis using Fluorojade C staining showed that P021 completely prevented 
neurodegeneration at the three different time points. At 12 month of age (9 month post-
treatment) P021 was also able to rescue the deficit in neurogenesis. These data showed that P021 







Chapter 7. Discussion 
 
Taken together, the results of the present project demonstrate for the first time that the 
administration of the neurogenic/neurotrophic peptidergic compound P021 at a very early stage 
of the disease can prevent synaptic and neurogenesis deficit, cognitive impairment and A and 
tau pathologies in 3xTg-AD mice. Behavioral analysis of 3xTg-AD mice with the Morris Water 
Maze task showed that the 3xTg-AD mice were already cognitively impaired prior to the 
initiation of the treatment with P021. Impairment in cognition was accompanied by a decrease in 
the level of several synaptic markers such as synaptophysin and compensation at later time 
points. The P021 provided during this compensation period showed that it can prevent synaptic 
loss, neurogenesis deficit, cognitive impairment and A and tau pathologies. Most importantly, 
the analysis across time of the effect of P021 on A and tau pathologies demonstrated a strong 
effect on slowing down the progress of A and tau pathologies, as shown by a decrease in the 
4G8 and AT8 load at 9 months, 15 months and 18 months post-treatment. Furthermore, I 
unexpectedly found that P021 was able to increase the survival rate in the 3xTg-AD to 87% 
compared to only 41% for 3xTg-AD-vh. Analysis of body weight and the food intake showed 
that P021 had no apparent side effects.  
 
7.1 Synaptic compensation 
I found that at 12-14 weeks of age the 3xTg-AD mice were impaired. The 
immunohistochemical and biochemical analysis of the brain tissues of 3xTg-AD mice from 10, 
12, 13, 14, 15, and 16 weeks of age demonstrated the level and the expression of several synaptic 
markers, most importantly synaptophysin, dropped sharply at 12 weeks, then came back almost 




phenomenon. The synaptic compensation phenomenon was reported previously in AD patients at 
very early stages of the disease (Counts et al., 2006) and in cognitive aging (Bertoni-Freddari et 
al., 1988, Barnes, 1994, Brown et al., 1998). My data further showed that when I compared the 
expression levels of synaptic markers in the 3xTg-AD to those of WT the compensation 
appeared to be region specific and time specific. Similarly, synaptic compensation in cognitive 
aging was shown to be region specific and it was suggested to account for the spared cognition in 
elderly people (Bertoni-Freddari et al., 1988, Barnes, 1994). In AD, however, synaptic 
compensation seems to be unsuccessful, which is why cognitive deterioration occurs. This is in 
agreement with our finding that the 3xTg-AD mice were impaired in the presence of the 
compensation phenomenon. It could be suggested, however, that synaptic compensation in 
humans is what accounts for a relatively long period of MCI in which cognitive deterioration and 
neuronal and synaptic loss happen very slowly for up to 10 years. Likewise, in the 3xTg-AD 
mice mutations are carried in their genes from embryonic day 11 but the appearance of the A 
and tau pathologies starts only at around 9 months of age for A and 12 months for tau. Several 
reports in the literature emphasize the importance of the compensation phenomenon at the level 
of the synapse and at the level of the new born neurons to boost the efficiency of the therapeutic 
intervention. Thus a drug that could be provided during this period would help the brain to 
counteract the disease progression.  
 
7.2. Effect of P021 on cognitive impairment and survival rate 
Previously, many attempts were made to use neurotrophic factors as therapeutic agents 
for AD. However, most of them failed because of their short half-life, poor BBB permeability 
and several side effects such as loss of appetite, weight loss, muscle pain, anorexia and 




neurotrophic factors in Alzheimer’s therapy. To overcome these problems, several studies shift 
to peptide mimetics, which are derived from the most active region of the neurotrophic factors. 
Since they are very small peptides they have a better ability to cross the BBB, better half-life and 
lesser side effects. The same approach was used in this study. I used P021, which is derived from 
the most active region of the CNTF. We then added the adamantane group to increase its 
lipophilicity and make it BBB permeable and decreased its degradation with peptidases (Li et al., 
2010).  We showed previously that P021 has no apparent side effects (Blanchard et al., 2010b, 
Kazim et al., 2014).  
The present study is solely  preventive; My aim was to provide P021 in the mouse diet 
very early at 3 months of age, during the period of synaptic compensation and before the onset of 
A and tau pathologies, and most importantly before severe synaptic or neuronal loss. The 
chronic administration of P021 in this study from 3 months to 21 months of age showed that 
P021 was able to prevent cognitive impairment completely in the mild and severe stages of the 
AD-like pathological progress in 3xTg-AD mice. I showed that at 12 months of age, after 
treatment with P021 for 9 months, spatial reference memory impairment was prevented in the 
3xTg-AD-P021. Furthermore, at 18-19 months of age, after 15-16 months of P021 treatment, I 
showed that short-term spatial memory impairment was prevented in the 3xTg-AD-P021, as seen 
in a better performance in the object location task compared to 3xTg-AD-vh. Impairment in 
episodic memory was prevented in the object recognition task in the 3xTg-AD-P021 while both 
the 3xTg-AD-vh and WT were impaired. The WT mice were impaired because of the effect of 
aging and this was further corroborated from the literature (Davis et al., 2013). Since spatial 
navigation and episodic memories are severely affected in AD at early stages and I showed in 




effects in AD. Cognitive impairment followed by dementia is one of the major clinical symptoms 
that render AD patients totally dependent on others and bedridden at later stages of their life, so 
if I can prevent cognitive deterioration I will be able to halt or slow down the disease process. 
Not only was early treatment with P021 able to prevent the onset of cognitive impairment, but 
also I unexpectedly found that it increased the survival rate of the 3xTg-AD-P021 compared to 
3xTg-AD-vh. It is well documented in the literature that AD decreases the survival rate of 
patients. For instance, over 14 years the survival rate of AD patient is only 2.4% versus an 
expected rate of 16.6% (Molsa et al., 1995). In our study, the 3xTg-AD-P021 survival rate was 
87% compared to only 41% in 3xTg-AD-vh. This shows that delaying the onset of cognitive 
impairment and the other pathologies in AD patients would help to increase their survival rate. 
 
7.3 Effect of P021 on A and tau pathologies  
A and tau pathologies are the two major hallmarks of AD. Cognitive impairment is 
known to correlate with NFT counts but not with A plaques (Arriagada et al., 1992a, Gomez-
Isla et al., 1997). The spatial distribution of tau pathology follows a stereotypic pattern that starts 
in the limbic system and then spreads to the neocortical regions. Since the limbic regions are the 
primary targets of NFT pathology and they are known for their important role in memory it is 
reasonable to expect a correlation between tau pathology and cognitive impairment. Since tau 
pathology correlates with cognitive impairment its prevention could help to stop cognitive 
deterioration. Indeed, in my study I found that early treatment with P021 in 3xTg-AD mice was 
able to slow down the progression of A and tau pathologies across time from the time of their 
onset until the progression to severe stages. Slowing down the pathologies could be the 
biological correlate to slowing down cognitive deterioration and the rescue of cognitive 




the literature that the use of plasma rich growth factors is able to decrease A deposition, tau 
phosphorylation and cognitive impairment in APP/PS1 mice (Anitua et al., 2014). 
 
7.4 Effect of P021 on neurodegeneration and neuroregeneration 
Synaptic deficit is widely reported to correlate with cognitive impairment (DeKosky and 
Scheff, 1990, Terry et al., 1991). Furthermore, it has been shown that synaptic loss correlates 
with the increase in NFT counts. Synaptic loss was found to follow a similar pattern to NFT 
pathology, in which neurons in the entorhinal cortex are first affected and then the hippocampus 
(Coleman et al., 2004). The hippocampus in AD has been shown to have the greatest synaptic 
loss, from 44% to 55% (Scheff et al., 2007). Early intervention within the onset of synaptic loss 
or before was suggested to be effective on preventing and slowing down the progression of the 
neuropathological features of AD. In this study P021 was provided in food diet just at the onset 
of synaptic loss for nearly the whole mouse lifespan. I found that P021 was able to prevent 
synaptic loss, especially at 18 and 21 months of age. Our data are in agreement with our previous 
studies using P021 in AD mouse models (Blanchard et al., 2011, Bolognin et al., 2012, Kazim et 
al., 2014) as well as other animal models of neurodegenerative diseases (Blanchard et al., 2011) 
and cognitive aging (Bolognin et al., 2014). Similarly, P021 treatment was able to prevent 
neurodegeneration at the three time points.  
7.5 Effect of P021 on neurogenesis  
 Since it is well established that neurogenesis contributes to information storage and 
retrieval as well as the plasticity of the hippocampus, its disruption most likely will affect 
memory and cognitive abilities. Indeed, in AD neurogenesis is disrupted very early in the disease 
process. The impaired neurogenesis in AD was shown to be due to an imbalance of neurotrophic 




and an increase in the expression level of FGF-2. We previously reported an increase in 
neurogenesis in AD postmortem brains in the DG (Li et al., 2008). However, the self-repair 
attempt of the brain remains unsuccessful as the newly born neurons cannot make it to become 
fully mature and integrate into the surviving circuitry in AD brains. I thought that providing the 
brain with the trophic support would help the brain to compensate for the deficit in neurogenesis. 
In this study the effect of P021 to boost neurogenesis was studied at 9 month-post-treatment in 
the DG area. I found that neurogenesis was defective in the 3xTg-AD-vh compared to WT and 
that P021 was able to prevent this deficit and boost neurogenesis to a level more than WT. This 
was seen by the increase in the number of the DCX+ and Ki-67+ cells in the P021 treated group 
in the DG. The fact that neurogenesis decreased in the 3xTg-AD-vh mice was in agreement with 
what was found previously using this mouse model (Hamilton et al., 2010). 
 
7.6 Possible mechanism of prevention of cognitive impairment and pathological 
features with P021 
Previous investigation of the possible mechanisms of P021 showed that P021 acts by 
competitively inhibiting leukemia inhibitory factor (LIF) signaling. In neuronal cell culture P021 
was shown to weakly inhibit LIF signaling through a slight inhibition of the phosphorylation of 
STAT3 in a dose dependent manner (Li et al., 2010). Furthermore, we showed previously that 
P021 acts by increasing the expression level of BDNF. Together the inhibition of LIF signaling 
and the increase in BDNF expression would inhibit stem cell proliferation and promote their 
maturation (Fig. 42a). Furthermore, BDNF has been shown to increase synaptic plasticity, 
neurogenesis and cell survival. The effect of P021 on preventing synaptic plasticity and cognitive 
impairment that I found here is probably due in part to the increase in BDNF expression. It is 




phosphorylation of GSK3β on its Serine 9 site, which is inhibitory. The prevention of A and tau 
pathologies with P021 in this study may be through the inhibition of GSK3 signaling (Fig. 
42b). Indeed, it has been shown that GSK-3 is a major tau kinase (Kosik, 1992) and its 
overexpression leads to hyperphosphorylation of tau and microtubule disruption in mice (Lucas 
et al., 2001). In AD, GSK3β is known to mediate A induced neuritic damage (DaRocha-Souto 
et al., 2012). Moreover, the GSK 3 isoform is known to increase APP processing (Phiel et al., 
2003) and A production. So inactivation of GSK3 would result in a reduction of the A load 
and tau hyperphosphorylation, as seen in the present study. In the neurogenic niches 
hyperactivation of GSK3 leads to impaired neurogenesis in mice. Thus, by decreasing GSK3β 
activity, neurogenesis can be rescued. Since it has been shown that GSK3 promotes apoptosis, 
























Fig. 42: Mechanism of action of P021. a) Neurogenic/ neurotrophic effect of P021. b) Mechanism of 




7.7 Future directions 
My findings (chapter 3) suggest that in 3xTg-AD mice the brain attempts to self-repair by 
the synaptic compensation phenomenon as a reaction to the early synaptic loss. However, even in 
the presence of synaptic compensation this attempt is unsuccessful and does not prevent 
cognitive impairment, as seen in human cognitive aging. Future work should then focus on 
answering the question of what is lacking in this compensation.  Is it insufficient or is it 
abnormal so that it cannot reverse cognitive impairment? An approach to answer this question 
would be to investigate the morphology of the spines with the lipophilic staining DiI to 
determine if they have a normal shape or large and stubby spines that are pathological. Since it is 
reported that in AD patients the compensation in the surviving synapses happens by increasing 
the synapse size so that the total contact surface area is preserved, a measure of the size of the 
synapses could be another approach to investigate in future studies. Future work could also focus 
on determining whether the number of synapses really increased, causing the observed increase 
in synaptic markers, or if it was simply a result of an increase in synaptic size. Furthermore, I 
could investigate the electrophysiological component of this compensation. For example, I could 
record from a single cell with a patch clamp method to detect an increase in the level of the 
excitatory post-synaptic potential. Then I could study it at the level of the neuronal network. If 
there is an increase in the amplitude of neuronal firing would this result in an increase in the 
whole neuronal firing? Would an increase in neuronal firing result in a compensation for the 
whole neuronal network or disrupt it? If the latter was the case, instead of compensating for the 
synaptic loss compensation would become the driving force for synaptic loss and 
neurodegeneration.  
Since our study is of secondary prevention because it was initiated after the onset of 




in utero by providing the drug in the food to the mothers from conception until weaning and then 
later on to pups after weaning. Since the expression of the mutated transgenes in 3xTg-AD mice 
starts from embryonic day 11 and since an early treatment before the onset of synaptic loss and 
cognitive impairment would be more effective, I can consider the data from our study as 
encouraging the start of treatment in utero. Considering all ages together, P021 was able to 
decrease the A and tau loads and it was able to prevent cognitive impairment as well as 
synaptic loss. I expect that in utero treatment would be stronger in preventing the A and tau 
pathologies as well as synaptic loss. This study would be of great importance to human 
preclinical trials, especially those of the familial form of the disease. If toxicological testing 
shows that P021 is safe to use for humans from the embryonic stage then I could prevent AD in 
people who carry the mutated genes in their genome and are destined to develop it later on in 
their life.  
 
7.8 Conclusion 
Together the results of this study showed for the first time that secondary prevention 
using P021 in 3xTg-AD mice is able to prevent cognitive impairment, A and tau pathologies 
and synaptic and neuronal loss and can boost neurogenesis. Taking advantage of the synaptic 
compensation phenomenon and the ability of the brain to self-repair very early in the disease 
process I was able to show that P021 treatment was able to prevent cognitive impairment at three 
different time points at 9, 15-16, and 16-17 months post-treatment. Most importantly I showed 
that P021 treatment increases the survival rate of 3xTg-AD mice and can prevent A and tau 
pathologies. Lastly I found that P021 was able to prevent synaptic loss by increasing the level 
and the expression of different synaptic markers as I showed biochemically as well as 




suggest P021 as a potential drug for AD treatment in future prevention trials, since prevention 






Abuhassan K, Coyle D, Belatreche A, Maguire L (2014) Compensating for synaptic loss in 
Alzheimer's disease. J Comput Neurosci 36:19-37. 
Aimone JB, Li Y, Lee SW, Clemenson GD, Deng W, Gage FH (2014) Regulation and function 
of adult neurogenesis: from genes to cognition. Physiol Rev 94:991-1026. 
Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR (2011) Identification of 
novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human 
middle temporal gyrus of Alzheimer disease. J Biol Chem 286:45093-45102. 
Alafuzoff I, Iqbal K, Friden H, Adolfsson R, Winblad B (1987) Histopathological criteria for 
progressive dementia disorders: clinical-pathological correlation and classification by 
multivariate data analysis. Acta Neuropathol (Berl) 74:209-225. 
Allen SJ, Watson JJ, Dawbarn D (2011) The neurotrophins and their role in Alzheimer's disease. 
Curr Neuropharmacol 9:559-573. 
Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylated tau 
sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 
2:783-787. 
Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in 
the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci USA 91:5562-
5566. 
Alonso AD, Grundke-Iqbal I, Barra HS, Iqbal K (1997) Abnormal phosphorylation of tau and 
the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-
associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. 
Proc Natl Acad Sci USA 94:298-303. 
Alzheimer's A (2015) 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11:332-
384. 
Anitua E, Pascual C, Antequera D, Bolos M, Padilla S, Orive G, Carro E (2014) Plasma rich in 
growth factors (PRGF-Endoret) reduces neuropathologic hallmarks and improves 
cognitive functions in an Alzheimer's disease mouse model. Neurobiol Aging 35:1582-
1595. 
Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118:167-179. 
Armstrong RA (1993) Is the clustering of neurofibrillary tangles in Alzheimer's patients related 
to the cells of origin of specific cortico-cortical projections? Neuroscience letters 160:57-
60. 
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992a) Neurofibrillary tangles but 
not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 
42:631-639. 
Arriagada PV, Marzloff K, Hyman BT (1992b) Distribution of Alzheimer-type pathologic 
changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. 
Neurology 42:1681-1688. 
Association As (2015) 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11:332-
384. 
Avila J (2000) Tau aggregation into fibrillar polymers: taupathies. FEBS letters 476:89-92. 
Barnes CA (1994) Normal aging: regionally specific changes in hippocampal synaptic 




Beck M, Flachenecker P, Magnus T, Giess R, Reiners K, Toyka KV, Naumann M (2005) 
Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. 
Amyotroph Lateral Scler Other Motor Neuron Disord 6:100-103. 
Bell KF, Bennett DA, Cuello AC (2007) Paradoxical upregulation of glutamatergic presynaptic 
boutons during mild cognitive impairment. J Neurosci 27:10810-10817. 
Bell KF, Cuello CA (2006) Altered synaptic function in Alzheimer's disease. Eur J Pharmacol 
545:11-21. 
Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW (2014) Brain gene 
expression patterns differentiate mild cognitive impairment from normal aged and 
Alzheimer's disease. Neurobiol Aging 35:1961-1972. 
Berg L, McKeel DW, Jr., Miller JP, Baty J, Morris JC (1993) Neuropathological indexes of 
Alzheimer's disease in demented and nondemented persons aged 80 years and older. Arch 
Neurol 50:349-358. 
Berg L, McKeel DW, Jr., Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton 
J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM (1998) Clinicopathologic 
studies in cognitively healthy aging and Alzheimer's disease: relation of histologic 
markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 
55:326-335. 
Bertoni-Freddari C, Fattoretti P, Casoli T, Caselli U, Meier-Ruge W (1996) Deterioration 
threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Anal 
Quant Cytol Histol 18:209-213. 
Bertoni-Freddari C, Meier-Ruge W, Ulrich J (1988) Quantitative morphology of synaptic 
plasticity in the aging brain. Scanning Microsc 2:1027-1034. 
Beurel E, Michalek SM, Jope RS (2010) Innate and adaptive immune responses regulated by 
glycogen synthase kinase-3 (GSK3). Trends Immunol 31:24-31. 
Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP (1995) Neocortical 
neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch 
Neurol 52:81-88. 
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes 
the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. 
Neuron 45:675-688. 
Binetti G, Mega MS, Magni E, Padovani A, Rozzini L, Bianchetti A, Trabucchi M, Cummings 
JL (1998) Behavioral disorders in Alzheimer disease: a transcultural perspective. Arch 
Neurol 55:539-544. 
Bittner T, Fuhrmann M, Burgold S, Ochs SM, Hoffmann N, Mitteregger G, Kretzschmar H, 
LaFerla FM, Herms J (2010) Multiple events lead to dendritic spine loss in triple 
transgenic Alzheimer's disease mice. PloS one 5:e15477. 
Black J E, Isaacs KR, Anderson BJ, Alacantra AA, Greenough WT. 1990. Learning causes 
synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. 
Proc Natl Acad Sci 87: 5568–5572. 
 
Blanchard J, Bolognin S, Chohan MO, Rabe A, Iqbal K, Grundke-Iqbal I (2011) Rescue of 
synaptic failure and alleviation of learning and memory impairments in a trisomic mouse 




Blanchard J, Chohan MO, Li B, Liu F, Iqbal K, Grundke-Iqbal I (2010a) Beneficial Effect of a 
CNTF Tetrapeptide on Adult Hippocampal Neurogenesis, Neuronal Plasticity, and 
Spatial Memory in Mice. J Alzheimers Dis 21:1185-1195. 
Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-
Iqbal I (2010b) Pharmacologic reversal of neurogenic and neuroplastic abnormalities and 
cognitive impairments without affecting Abeta and tau pathologies in 3xTg-AD mice. 
Acta Neuropathol 120:605-621. 
Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, 
Iqbal K (2012) An experimental rat model of sporadic Alzheimer's disease and rescue of 
cognitive impairment with a neurotrophic peptide. Acta Neuropathol 123:133-151. 
Bolognin S, Buffelli M, Puolivali J, Iqbal K (2014) Rescue of cognitive-aging by administration 
of a neurogenic and/or neurotrophic compound. Neurobiol Aging 35:2134-2146. 
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol (Berl) 82:239-259. 
Brandt R, Hundelt M, Shahani N (2005) Tau alteration and neuronal degeneration in tauopathies: 
mechanisms and models. Biochim Biophys Acta 1739:331-354. 
Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States 
and the public health impact of delaying disease onset. Am J Public Health 88:1337-
1342. 
Brown DF, Risser RC, Bigio EH, Tripp P, Stiegler A, Welch E, Eagan KP, Hladik CL, White 
CL, 3rd (1998) Neocortical synapse density and Braak stage in the Lewy body variant of 
Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J 
Neuropathol Exp Neurol 57:955-960. 
Brunden KR, Ballatore C, Crowe A, Smith AB, 3rd, Lee VM, Trojanowski JQ (2010) Tau-
directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau 
assembly inhibitors. Exp Neurol 223:304-310. 
Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for 
Alzheimer's disease and related tauopathies. Nature reviews Drug discovery 8:783-793. 
Budni J, Bellettini-Santos T, Mina F, Garcez ML, Zugno AI (2015) The involvement of BDNF, 
NGF and GDNF in aging and Alzheimer's disease. Aging Dis 6:331-341. 
Burke SN, Barnes CA (2006) Neural plasticity in the ageing brain. Nat Rev Neuorsci 7:30-40. 
Callahan LM, Vaules WA, Coleman PD (2002) Progressive reduction of synaptophysin message 
in single neurons in Alzheimer disease. J Neuropathol Exp Neurol 61:384-395. 
Campsall KD, Mazerolle CJ, De Repentingy Y, Kothary R, Wallace VA (2002) Characterization 
of transgene expression and Cre recombinase activity in a panel of Thy-1 promoter-Cre 
transgenic mice. Dev Dyn 224:135-143. 
Cardenas-Aguayo M. del C, Kazim SF, Grundke-Iqbal I, Iqbal K (2013) Neurogenic and 
neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell 
cultures. PloS one 8:e53596. 
Carro E, Trejo JL, Busiguina S, Torres-Aleman I (2001) Circulating insulin-like growth factor I 
mediates the protective effects of physical exercise against brain insults of different 
etiology and anatomy. J Neurosci 21:5678-5684. 
Carroll JC, Rosario ER, Kreimer S, Villamagna A, Gentzschein E, Stanczyk FZ, Pike CJ (2010) 
Sex differences in beta-amyloid accumulation in 3xTg-AD mice: role of neonatal sex 
steroid hormone exposure. Brain Res 1366:233-245. 




Castren E, Tanila H (2006) Neurotrophins and dementia--keeping in touch. Neuron 51:1-3. 
Chadwick W, Mitchell N, Caroll J, Zhou Y, Park SS, Wang L, Becker KG, Zhang Y, Lehrmann 
E, Wood WH, 3rd, Martin B, Maudsley S (2011) Amitriptyline-mediated cognitive 
enhancement in aged 3xTg Alzheimer's disease mice is associated with neurogenesis and 
neurotrophic activity. PloS one 6:e21660. 
Chan D, Fox NC, Jenkins R, Scahill RI, Crum WR, Rossor MN (2001) Rates of global and 
regional cerebral atrophy in AD and frontotemporal dementia. Neurology 57:1756-1763. 
Charlton RA, Barrick TR, Markus HS, Morris RG (2010) The relationship between episodic 
long-term memory and white matter integrity in normal aging. Neuropsychologia 48:114-
122. 
Chen H, Tung YC, Li B, Iqbal K, Grundke-Iqbal I (2007) Trophic factors counteract elevated 
FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 28:1148-1162. 
Chohan MO, Li B, Blanchard J, Tung YC, Heaney AT, Rabe A, Iqbal K, Grundke-Iqbal I (2011) 
Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and 
memory by a neurotrophic peptide. Neurobiol Aging 32:1420-1434. 
Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, 
Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, 
Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ 
(1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue 
amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3:67-72. 
Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM 
(2007) Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-
AD mice. Neurobiol Dis 28:76-82. 
Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in 
Alzheimer disease and other dementias. Neurology 63:1155-1162. 
Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 
24:1023-1027. 
Coria F, Castano EM, Frangione B (1987) Brain amyloid in normal aging and cerebral amyloid 
angiopathy is antigenically related to Alzheimer's disease beta-protein. Am J Pathol 
129:422-428. 
Corona C, Masciopinto F, Silvestri E, Viscovo  a Del, Lattanzio R, Sorda R. La, … Sensi, SL. 
(2010). Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and 
prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death & Disease, 
1(10), e91. 
Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ (2006) Differential expression of synaptic 
proteins in the frontal and temporal cortex of elderly subjects with mild cognitive 
impairment. J Neuropathol Exp Neurol 65:592-601. 
Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, 
Wolfson L (1988) Clinico-pathologic studies in dementia: nondemented subjects with 
pathologically confirmed Alzheimer's disease. Neurology 38:1682-1687. 
DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, 
Hashimoto T, Fan Z, Hudry E, Barroeta I, Sereno L, Rodriguez M, Sanchez MB, Hyman 
BT, Gomez-Isla T (2012) Activation of glycogen synthase kinase-3 beta mediates beta-
amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 45:425-437. 
Davidsson P, Blennow K (1998) Neurochemical dissection of synaptic pathology in Alzheimer's 




Davies CA, Mann DM, Sumpter PQ, Yates PO (1987) A quantitative morphometric analysis of 
the neuronal and synaptic content of the frontal and temporal cortex in patients with 
Alzheimer's disease. Journal 78:151-164. 
Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic 
alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 58:376-388. 
Davis KE, Eacott MJ, Easton A, Gigg J (2013) Episodic-like memory is sensitive to both 
Alzheimer's-like pathological accumulation and normal ageing processes in mice. Behav 
Brain Res. 
DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: 
correlation with cognitive severity. Ann Neurol 27:457-464. 
Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P (1995) Correlations of 
synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16:285-
298; discussion 298-304. 
Dong H, Martin MV, Chambers S, Csernansky JG (2007) Spatial relationship between synapse 
loss and beta-amyloid deposition in Tg2576 mice. J Comp Neurol 500:311-321. 
Ennaceur A (2010) One-trial objets recognition in rats and mice: methodological and theoretical 
issues. Behav Brain Res. 
Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson 
L, Seiger, Shigeta M, Theodorsson E, Viitanen M, Winblad B, Wahlund LO (1998) 
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's 
disease. Dement Geriatr Cogn Disord 9:246-257. 
Fahnestock M, Garzon D, Holsinger RM, Michalski B (2002) Neurotrophic factors and 
Alzheimer's disease: are we focusing on the wrong molecule? J Neural Transm 
Supplementum 241-252. 
Faria MC, Goncalves GS, Rocha NP, Moraes EN, Bicalho MA, Gualberto Cintra MT, Jardim de 
Paula J, Jose Ravic de Miranda LF, Clayton de Souza Ferreira A, Teixeira AL, Gomes 
KB, Carvalho M, Sousa LP (2014) Increased plasma levels of BDNF and inflammatory 
markers in Alzheimer's disease. J Psychiatr Res 53:166-172. 
Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, Tolosa E, Marti E (1999) BDNF and 
full-length and truncated TrkB expression in Alzheimer disease. Implications in 
therapeutic strategies. J Neuropathol Exp Neurol 58:729-739. 
Filali M, Lalonde R, Theriault P, Julien C, Calon F, Planel E (2012) Cognitive and non-cognitive 
behaviors in the triple transgenic mouse model of Alzheimer's disease expressing mutated 
APP, PS1, and Mapt (3xTg-AD). Behav Brain Res 234:334-342. 
Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, Teixeira AL (2015) 
Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented 
Subjects. J Alzheimers Dis 46:423-429. 
Fox NC, Freeborough PA, Rossor MN (1996) Visualisation and quantification of rates of 
atrophy in Alzheimer's disease. Lancet 348:94-97. 
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, 
Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, 
Scheltens P, Tierney MC, Whitehouse P, Winblad B, International Psychogeriatric 





Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold 
G, Hof PR (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive 
status in Alzheimer's disease. Neurology 60:1495-1500. 
Gimenez-Llort L, Blazquez G, Canete T, Johansson B, Oddo S, Tobena A, LaFerla FM, 
Fernandez-Teruel A (2007) Modeling behavioral and neuronal symptoms of Alzheimer's 
disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 31:125-147. 
Glass DJ, Arnold SE (2012) Some evolutionary perspectives on Alzheimer's disease 
pathogenesis and pathology. Alzheimers Dement 8:343-351. 
Goedert M, Jakes R (2005) Mutations causing neurodegenerative tauopathies. Biochim Biophys 
Acta 1739:240-250. 
Gold G, Bouras C, Kovari E, Canuto A, Glaria BG, Malky A, Hof PR, Michel JP, 
Giannakopoulos P (2000) Clinical validity of Braak neuropathological staging in the 
oldest-old. Acta Neuropathol 99:579-582; discussion 583-574. 
Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT 
(1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's 
disease. Ann Neurol 41:17-24. 
Gomez-Isla T, Price JL, McKeel DW, Jr., Morris JC, Growdon JH, Hyman BT (1996) Profound 
loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J 
Neurosci 16:4491-4500. 
Gontier G, George C, Chaker Z, Holzenberger M, Aid S (2015) Blocking IGF Signaling in Adult 
Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-beta Clearance. J 
Neurosci 35:11500-11513. 
Green MS, Kaye JA, Ball MJ (2000) The Oregon brain aging study: neuropathology 
accompanying healthy aging in the oldest old. Neurology 54:105-113. 
Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, 
and memory in aging and mild cognitive impairment. Archives of neurology 60:729-736. 
Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, Choi CH, McBride 
SM, Faber DS (2009) Validation of a 2-day water maze protocol in mice. Behav Brain 
Res 
Guo LH, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R, Alzheimer's Disease 
Neuroimaging I (2013) Brain size and the compensation of Alzheimer's disease 
symptoms: a longitudinal cohort study. Alzheimers Dement 9:580-586. 
Hagg T (2009) From neurotransmitters to neurotrophic factors to neurogenesis. Neuroscientist 
15:20-27. 
Hamilton L-K, Aumont A, Julien C, Vadnais A, Calon F, Fernandes K-J-L (2010) Widespread deficits in 
adult neurogenesis precede plaque and tangle formation in the 3xTg mouse model of 
 Alzheimer’s disease. Europ J of Neurosc 32 : 905-920. 
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and 
problems on the road to therapeutics. Science 297:353-356. 
Harvey DR, McGauran AM, Murphy J, Burns L, McMonagle E, Commins S (2008) Emergence 
of an egocentric cue guiding and allocentric inferring strategy that mirrors hippocampal 
brain-derived neurotrophic factor (BDNF) expression in the Morris water maze. 
Neurobiol Learn Mem 89:462-479. 
Hashimoto Y, Abiru Y, Nishio C, Hatanaka H (1999) Synergistic effects of brain-derived 
neurotrophic factor and ciliary neurotrophic factor on cultured basal forebrain cholinergic 




He J, Carmichael O, Fletcher E, Singh B, Iosif AM, Martinez O, Reed B, Yonelinas A, Decarli C 
(2012) Influence of functional connectivity and structural MRI measures on episodic 
memory. Neurobiol Aging 33:2612-2620. 
Head E, Corrada MM, Kahle-Wrobleski K, Kim RC, Sarsoza F, Goodus M, Kawas CH (2009) 
Synaptic proteins, neuropathology and cognitive status in the oldest-old. Neurobiol Aging 
30:1125-1134. 
Heffernan JM, Eastwood SL, Nagy Z, Sanders MW, McDonald B, Harrison PJ (1998) Temporal 
cortex synaptophysin mRNA is reduced in Alzheimer's disease and is negatively 
correlated with the severity of dementia. Exp Neurol 150:235-239. 
Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljarvi L, Koivisto E, Riekkinen PJ, Sr. (1995) 
Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early 
phenomenon in Alzheimer's disease. Neuroscience 64:375-384. 
Hicks DA, Nalivaeva NN, Turner AJ (2012) Lipid rafts and Alzheimer's disease: protein-lipid 
interactions and perturbation of signaling. Front Physiol 3:189. 
Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, 
Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, 
Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y (2008) 
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer 
transgenic model. Brain Res 1216:92-103. 
Hock C, Heese K, Hulette C, Rosenberg C, Otten U (2000) Region-specific neurotrophin 
imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor 
and increased levels of nerve growth factor in hippocampus and cortical areas. Arch 
Neurol 57:846-851. 
Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde YA (1990) Regional distribution of brain-
derived neurotrophic factor mRNA in the adult mouse brain. EMBO J 9:2459-2464. 
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, 
Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 
immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled 
phase I trial. Lancet 372:216-223. 
Honer WG (2003) Pathology of presynaptic proteins in Alzheimer's disease: more than simple 
loss of terminals. Neurobiol Aging 24:1047-1062. 
Horn D, Ruppin E, Usher M, Herrmann M (1993) Nerual network modeling of memory 
deterioration in Alzheimer's disease. Neural Computation 5:736-749. 
Hu L, Wong TP, Cote SL, Bell KF, Cuello AC (2003) The impact of Abeta-plaques on cortical 
cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like 
transgenic mice. Neuroscience 121:421-432. 
Hu S, Begum AN, Jones MR, Oh MS, Beech WK, Beech BH, Yang F, Chen P, Ubeda OJ, Kim 
PC, Davies P, Ma Q, Cole GM, Frautschy SA (2009) GSK3 inhibitors show benefits in 
an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control 
animals. Neurobiol Dis 33:193-206. 
Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, 
Crain B, Troncoso JC (2008) Neuronal hypertrophy in asymptomatic Alzheimer disease. 
J Neuropathol Exp Neurol 67:578-589. 
Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, Frosch MP, Albert MS, 
Hyman BT, Irizarry MC (2004) Early Abeta accumulation and progressive synaptic loss, 




Ip NY, Yancopoulos GD (1996) The neurotrophins and CNTF: two families of collaborative 
neurotrophic factors. Ann Rev Neurosci 19:491-515. 
Iqbal K, Alonso A, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, 
Rahman A, Tanimukai H, Grundke-Iqbal I (2005) Tau pathology in Alzheimer disease 
and other tauopathies. Biochim Biophys Acta 1739:198-210. 
Iqbal K, Grundke-Iqbal I (2002) Neurofibrillary pathology leads to synaptic loss and not the 
other way around in Alzheimer disease. J Alzheimers Dis 4:235-238. 
Iqbal K, Grundke-Iqbal I (2010) Alzheimer's disease, a multifactorial disorder seeking 
multitherapies. Alzheimers & Dementia 6:420-424. 
Iqbal K, Kazim SF, Bolognin S, Blanchard J (2014a) Shifting balance from neurodegeneration to 
regeneration of the brain: A novel therapeutic approach to Alzheimer's disease and 
related neurodegenerative conditions. Neural Regen Res 9:1518-1519. 
Iqbal K, Liu F, Gong CX (2014b) Alzheimer disease therapeutics: Focus on the disease and not 
just plaques and tangles. Biochem Pharma. 
Iqbal K, Liu F, Gong CX (2016) Tau and neurodegenerative disease: the story so far. Nat Rev 
Neurol 12:15-27. 
Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer Disease and related 
Tauopathies. Curr Alzheimer Res 7:656-664. 
Irvine K, Laws KR, Gale TM, Kondel TK (2012) Greater cognitive deterioration in women than 
men with Alzheimer's disease: a meta analysis. J Clin Exp Neuropsychol 34:989-998. 
Jahn H (2013) Memory loss in Alzheimer's disease. Dialogues Clin Neurosci 15:445-454. 
Jin K, Galvan V, Xie L, Mao XO, Gorostiza OF, Bredesen DE, Greenberg DA (2004a) 
Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. 
Proc Natl Acad Sci USA 101:13363-13367. 
Jin K, Minami M, Lan JQ, Mao XO, Batteur S, Simon RP, Greenberg DA (2001) Neurogenesis 
in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia 
in the rat. Proc Natl Acad Sci USA 98:4710-4715. 
Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, Greenberg DA (2004b) Increased 
hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci USA 101:343-347. 
Jin K, Xie L, Mao XO, Greenberg DA (2006) Alzheimer's disease drugs promote neurogenesis. 
Brain research 1085:183-188. 
Kao PF, Banigan MG, Vanderburg CR, McKee AC, Polgar PR, Seshadri S, Delalle I (2012) 
Increased expression of TrkB and Capzb2 accompanies preserved cognitive status in 
early Alzheimer disease pathology. J Neuropathol Exp Neurol 71:654-664. 
Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K (2014) Disease 
modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a 
triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis 71:110-130. 
Kazim SF, Cardenas-Aguayo Mdel C, Arif M, Blanchard J, Fayyaz F, Grundke-Iqbal I, Iqbal K 
(2015) Sera from children with autism induce autistic features which can be rescued with 
a CNTF small peptide mimetic in rats. PloS one 10:e0118627. 
Kelleher-Andersson J (2004) Neurogenesis as a potential therapeutic strategy for 
neurodegenerative disorders. J Alzheimers Dis 6:S19-25. 
Kesslak JP, So V, Choi J, Cotman CW, Gomez-Pinilla F (1998) Learning upregulates brain-
derived neurotrophic factor messenger ribonucleic acid: a mechanism to facilitate 




Kimura T, Fukuda T, Sahara N, Yamashita S, Murayama M, Mizoroki T, Yoshiike Y, Lee B, 
Sotiropoulos I, Maeda S, Takashima A (2010) Aggregation of detergent-insoluble tau is 
involved in neuronal loss but not in synaptic loss. J Biol Chem 285:38692-38699. 
Koo EH, Kopan R (2004) Potential role of presenilin-regulated signaling pathways in sporadic 
neurodegeneration. Nat Med 10 Suppl:S26-33. 
Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-
associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in 
Alzheimer disease. J Biol Chem 268:24374-24384. 
Kosik KS (1992) Alzheimer's disease: a cell biological perspective. Science 256:780-783. 
Kumar-Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens K, Corsmit E, Cruts M, Dermaut 
B, Wang R, Van Broeckhoven C (2006) Mean age-of-onset of familial alzheimer disease 
caused by presenilin mutations correlates with both increased Abeta42 and decreased 
Abeta40. Hum Mutat 27:686-695. 
Lacar B, Parylak SL, Vadodaria KC, Sarkar A, Gage FH (2014) Increasing the resolution of the 
adult neurogenesis picture. F1000Prime Rep. 2014; 6: 8. 
Lace G, Savva GM, Forster G, de Silva R, Brayne C, Matthews FE, Barclay JJ, Dakin L, Ince 
PG, Wharton SB, Mrc C (2009) Hippocampal tau pathology is related to neuroanatomical 
connections: an ageing population-based study. Brain 132:1324-1334. 
Lanni C, Stanga S, Racchi M, Govoni S (2010) The expanding universe of neurotrophic factors: 
therapeutic potential in aging and age-associated disorders. Curr Pharm Des 16:698-717. 
Lazarov O, Marr RA (2010) Neurogenesis and Alzheimer's disease: at the crossroads. Exp 
Neurolo 223:267-281. 
Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Ann Rev Neurosci 
24:1121-1159. 
Leuba G, Savioz A, Vernay A, Carnal B, Kraftsik R, Tardif E, Riederer I, Riederer BM (2008a) 
Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked 
increase in PSD-95 postsynaptic protein. J Alzheimers Dis 15:139-151. 
Leuba G, Walzer C, Vernay A, Carnal B, Kraftsik R, Piotton F, Marin P, Bouras C, Savioz A 
(2008b) Postsynaptic density protein PSD-95 expression in Alzheimer's disease and 
okadaic acid induced neuritic retraction. Neurobiol Dis 30:408-419. 
Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I (2010) Neurotrophic 
peptides incorporating adamantane improve learning and memory, promote neurogenesis 
and synaptic plasticity in mice. FEBS Lett 584:3359-3365. 
Li B, Yamamori H, Tatebayashi Y, Shafit-Zagardo B, Tanimukai H, Chen S, Iqbal K, Grundke-
Iqbal I (2008) Failure of neuronal maturation in Alzheimer disease dentate gyrus. J 
Neuropathol Exp Neurol 67:78-84. 
Liang K-Y, Zeger S (1986) Longitudinal data analysis using generalized linear models. 
Biometrika 73:13-22. 
Liu J, Solway K, Messing RO, Sharp FR (1998) Increased neurogenesis in the dentate gyrus after 
transient global ischemia in gerbils. J Neurosci 18:7768-7778. 
Longo FM, Manthorpe M, Xie YM, Varon S (1997) Synthetic NGF peptide derivatives prevent 
neuronal death via a p75 receptor-dependent mechanism. J Neurosci Res 48:1-17. 
Longo FM, Massa SM (2004) Neurotrophin-based strategies for neuroprotection. J Alzheimers 
Dis 6:S13-17. 
Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a 




Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear 
beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional 
transgenic mice. Embo J 20:27-39. 
Lue LF, Brachova L, Civin WH, Rogers J (1996) Inflammation, A beta deposition, and 
neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J 
Neuropathol Exp Neurol 55:1083-1088. 
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers 
J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in 
Alzheimer's disease. Am J Pathol 155:853-862. 
Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, 
Brashear R, Miller DS (2011) Neuropsychiatric symptoms in Alzheimer's disease. 
Alzheimers Dement 7:532-539. 
Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, Lindsay RM, 
Yancopoulos GD (1990) NT-3, BDNF, and NGF in the developing rat nervous system: 
parallel as well as reciprocal patterns of expression. Neuron 5:501-509. 
Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello AC, Burgess K, Saragovi HU (2000) A 
designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol 
Pharmacol 57:385-391. 
Mandel RJ (2010) CERE-110, an adeno-associated virus-based gene delivery vector expressing 
human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 
12:240-247. 
Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, 
Auffinger S, Hinterholzl J, Hinterhuber H, Humpel C (2011) Five out of 16 plasma 
signaling proteins are enhanced in plasma of patients with mild cognitive impairment and 
Alzheimer's disease. Neurobiol Aging 32:539-540. 
Masliah E (2000) The role of synaptic proteins in Alzheimer's disease. Ann N Y Acad Sci 
924:68-75. 
Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Jr., Morris JC (2001) 
Altered expression of synaptic proteins occurs early during progression of Alzheimer's 
disease. Neurology 56:127-129. 
Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD (1995) Neurodegeneration in the 
central nervous system of apoE-deficient mice. Exp Neurol 136:107-122. 
Masliah E, Terry R (1993) The role of synaptic proteins in the pathogenesis of disorders of the 
central nervous system. Brain Pathol 3:77-85. 
Masliah E, Terry RD, DeTeresa RM, Hansen LA (1989) Immunohistochemical quantification of 
the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 103:234-
239. 
Matsui T, Ingelsson M, Fukumoto H, Ramasamy K, Kowa H, Frosch MP, Irizarry MC, Hyman 
BT (2007) Expression of APP pathway mRNAs and proteins in Alzheimer's disease. 
Brain Res 1161:116-123. 
Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med 
2. 
McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall 
NW, Dedeoglu A (2008) Ibuprofen reduces Abeta, hyperphosphorylated tau and memory 




Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in 
Alzheimer's disease. Neurology 46:130-135. 
Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, Younkin S, Duff K, Hardy 
J, Hutton M (1998) Increased Abeta42(43) from cell lines expressing presenilin 1 
mutations. Ann Neurol 43:256-258. 
Mesulam MM (2000) A plasticity-based theory of the pathogenesis of Alzheimer's disease. Ann 
N Y Acad Sci 924:42-52. 
Michalski B, Corrada MM, Kawas CH, Fahnestock M (2015) Brain-derived neurotrophic factor 
and TrkB expression in the "oldest-old," the 90+ Study: correlation with cognitive status 
and levels of soluble amyloid-beta. Neurobiol Aging 36:3130-3139. 
Michalski B, Fahnestock M (2003) Pro-brain-derived neurotrophic factor is decreased in parietal 
cortex in Alzheimer's disease. Brain Res Mol Brain Res 111:148-154. 
Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 
receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance 
to IGF-1 and insulin signalling. Neurobiol Aging 31:224-243. 
Molsa PK, Marttila RJ, Rinne UK (1986) Survival and cause of death in Alzheimer's disease and 
multi-infarct dementia. Acta Neurol Scand 74:103-107. 
Molsa PK, Marttila RJ, Rinne UK (1995) Long-term survival and predictors of mortality in 
Alzheimer's disease and multi-infarct dementia. Acta Neurol Scand 91:159-164. 
Mori M, Jefferson JJ, Hummel M, Garbe DS (2008) CNTF: a putative link between dopamine 
D2 receptors and neurogenesis. J Neurosci 28:5867-5869. 
Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with 
hippocampal lesions. Nature 297:681-683. 
Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, 
Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM 
(2000) Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals 
biphasic synaptic protein response during progression of Alzheimer's disease. Am J 
Pathol 157:623-636. 
Munoz-Montano JR, Moreno FJ, Avila J, Diaz-Nido J (1997) Lithium inhibits Alzheimer's 
disease-like tau protein phosphorylation in neurons. FEBS Lett 411:183-188. 
Murer MG, Yan Q, Raisman-Vozari R (2001) Brain-derived neurotrophic factor in the control 
human brain, and in Alzheimer's disease and Parkinson's disease. Prog Neurobiol 63:71-
124. 
Nagahara AH, Tuszynski MH (2011) Potential therapeutic uses of BDNF in neurological and 
psychiatric disorders. Nat Rev Drug Discov 10:209-219. 
Neve RL, Robakis NK (1998) Alzheimer's disease: a re-examination of the amyloid hypothesis. 
Trends Neurosci 21:15-19. 
Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger 
axon pruning and neuron death via distinct caspases. Nature 457:981-989. 
Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, LaFrancois J, 
Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K 
(2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced 
tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102:6990-6995. 
Nyffeler M, Zhang WN, Feldon J, Knuesel I (2007) Differential expression of PSD proteins in 




O'Hara R, Derouesne C, Fountoulakis KN, Yesavage JA (2001) Therapeutic approaches to age-
associated neurocognitive disorders. Dialogues Clin Neurosci 3:191-213. 
Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003a) Amyloid deposition precedes 
tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 
24:1063-1070. 
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, 
Akbari Y, LaFerla FM (2003b) Triple-transgenic model of Alzheimer's disease with 
plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409-421. 
Olson L, Nordberg A, von Holst H, Backman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig P, 
Herlitz A, Lilja A, et al. (1992) Nerve growth factor affects 11C-nicotine binding, blood 
flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural 
Transm Park Dis Dement Sect 4:79-95. 
Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, Fujita H, Uchiyama N, Kori M, 
Takizawa M (2011) A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-
methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau 
phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's 
disease. J Neurochem 119:1330-1340. 
Oore JJ, Fraser LM, Brown RE (2013) Age-related changes in motor ability and motor learning 
in a triple transgenic (3xTg-AD) and control (B6129SF1/J)  mice on accelerating 
Rotarod. Proc Nova Scotian Inst Sci 47:281-296. 
Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A 
(1995) Prevalence of Alzheimer's disease and vascular dementia: association with 
education. The Rotterdam study. Bmj 310:970-973. 
Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic 
factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical 
stages of Alzheimer's disease. J Neurochem 93:1412-1421. 
Perry EK, Johnson M, Ekonomou A, Perry RH, Ballard C, Attems J (2012) Neurogenic 
abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly 
related to cholinergic pathology. Neurobiol Dis 47:155-162. 
Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of 
Alzheimer's disease amyloid-beta peptides. Nature 423:435-439. 
Podlesniy P, Kichev A, Pedraza C, Saurat J, Encinas M, Perez B, Ferrer I, Espinet C (2006) Pro-
NGF from Alzheimer's disease and normal human brain displays distinctive abilities to 
induce processing and nuclear translocation of intracellular domain of p75NTR and 
apoptosis. Am J Pathol 169:119-131. 
Price RD, Milne SA, Sharkey J, Matsuoka N (2007) Advances in small molecules promoting 
neurotrophic function. Pharmacol Ther 115:292-306. 
Rafii MS, Aisen PS (2015) Advances in Alzheimer's disease drug development. BMC Med 
13:62. 
Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, 
Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, Bartus RT 
(2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's 
disease. Alzheimers Dement 10:571-581. 
Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and 




Riley KP, Snowdon DA, Markesbery WR (2002) Alzheimer's neurofibrillary pathology and the 
spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51:567-577. 
Robakis NK (2010) Are Abeta and its derivatives causative agents or innocent bystanders in 
AD? Neurodegener Dis 7:32-37. 
Rodriguez JJ, Verkhratsky A (2011) Neurogenesis in Alzheimer's disease. J Anat 219:78-89. 
SantaCruz KS, Sonnen JA, Pezhouh MK, Desrosiers MF, Nelson PT, & Tyaz, S. L. (2011). 
Alzheimer Disease Pathology in Subjects Without Dementia in Two Studies of Aging: 
The Nun Study and the Adult Changes in Thought Study. Journal of Neuropathology and 
Experimental Neurology, 70(10), 832–840.  
Saragovi HU, Gehring K (2000) Development of pharmacological agents for targeting 
neurotrophins and their receptors. Trends Pharmacol Sci 21:93-98. 
Scheff S (2003) Reactive synaptogenesis in aging and Alzheimer's disease: lessons learned in the 
Cotman laboratory. Neurochem Res 28:1625-1630. 
Scheff SW, Price DA (2003) Synaptic pathology in Alzheimer's disease: a review of 
ultrastructural studies. Neurobiol Aging 24:1029-1046. 
Scheff SW, Price DA (2006) Alzheimer's disease-related alterations in synaptic density: 
neocortex and hippocampus. J Alzheimers Dis 9:101-115. 
Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ (2007) Synaptic alterations in CA1 
in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501-1508. 
Schindowski K, Belarbi K, Buee L (2008) Neurotrophic factors in Alzheimer's disease: role of 
axonal transport. Genes Brain Behav 7 Suppl 1:43-56. 
Schmued LC, Albertson C, Slikker W, Jr. (1997) Fluoro-Jade: a novel fluorochrome for the 
sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 
751:37-46. 
Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, 
Mecocci P, Pani L, Winblad B, Kivipelto M (2014) Clinical trials and late-stage drug 
development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 
275:251-283. 
Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791. 
Sereno L, Coma M, Rodriguez M, Sanchez-Ferrer P, Sanchez MB, Gich I, Agullo JM, Perez M, 
Avila J, Guardia-Laguarta C, Clarimon J, Lleo A, Gomez-Isla T (2009) A novel GSK-
3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. 
Neurobiol Dis 35:359-367. 
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011a) Neuropathological alterations in 
Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189. 
Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, Hyman BT 
(2011b) Reactive glia not only associates with plaques but also parallels tangles in 
Alzheimer's disease. Am J Pathol 179:1373-1384. 
Shankar GM, Walsh DM (2009) Alzheimer's disease: synaptic dysfunction and Abeta. Mol 
Neurodegener 4:48. 
Shioi J, Georgakopoulos A, Mehta P, Kouchi Z, Litterst CM, Baki L, Robakis NK (2007) FAD 
mutants unable to increase neurotoxic Abeta 42 suggest that mutation effects on 
neurodegeneration may be independent of effects on Abeta. J Neurochem 101:674-681. 
Siegel GJ, Chauhan NB (2000) Neurotrophic factors in Alzheimer's and Parkinson's disease 




Silver MH, Newell K, Brady C, Hedley-White ET, Perls TT (2002) Distinguishing between 
neurodegenerative disease and disease-free aging: correlating neuropsychological 
evaluations and neuropathological studies in centenarians. Psychosom Med 64:493-501. 
Simmons DA, Knowles JK, Belichenko NP, Banerjee G, Finkle C, Massa SM, Longo FM (2014) 
A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in 
Alzheimer's disease mouse models with mid- to late-stage disease progression. PloS one 
9:e102136. 
Small DH (2008) Network dysfunction in Alzheimer's disease: does synaptic scaling drive 
disease progression? Trends Mol Med 14:103-108. 
Song JH, Yu JT, Tan L (2015) Brain-Derived Neurotrophic Factor in Alzheimer's Disease: Risk, 
Mechanisms, and Therapy. Mol Neurobiol 52:1477-1493. 
Sperling R (2007) Functional MRI studies of associative encoding in normal aging, mild 
cognitive impairment, and Alzheimer's disease. Ann N Y Acad Sci 1097:146-155. 
Sperling R, Mormino E, Johnson K (2014) The evolution of preclinical Alzheimer's disease: 
implications for prevention trials. Neuron 84:608-622. 
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., 
Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, 
Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward 
defining the preclinical stages of Alzheimer's disease: recommendations from the 
National Institute on Aging-Alzheimer's Association workgroups on diagnostic 
guidelines for Alzheimer's disease. Alzheimers Dement 7:280-292. 
Stellwagen D, Malenka RC (2006) Synaptic scaling mediated by glial TNF-alpha. Nature 
440:1054-1059. 
Stopa EG, Gonzalez AM, Chorsky R, Corona RJ, Alvarez J, Bird ED, Baird A (1990) Basic 
fibroblast growth factor in Alzheimer's disease. Biochem Biophys Res Commun 171:690-
696. 
Stover KR, Campbell MA, Van Winssen CM, Brown RE (2015) Analysis of motor function in 6-
month-old male and female 3xTg-AD mice. Behav Brain Res 281:16-23. 
Straten G, Saur R, Laske C, Gasser T, Annas P, Basun H, Leyhe T (2011) Influence of lithium 
treatment on GDNF serum and CSF concentrations in patients with early Alzheimer's 
disease. Curr Alzheimer Res 8:853-859. 
Supekar K, Menon V, Rubin D, Musen M, Greicius MD (2008) Network analysis of intrinsic 
functional brain connectivity in Alzheimer's disease. PLoS Comput Biol 4:e1000100. 
Talcott KE, Ratnam K, Sundquist SM, Lucero AS, Lujan BJ, Tao W, Porco TC, Roorda A, 
Duncan JL (2011) Longitudinal study of cone photoreceptors during retinal degeneration 
and in response to ciliary neurotrophic factor treatment. Invest Opthamol Vis Sci 
52:2219-2226. 
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, 
Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Menard J, Zetterberg 
H, Wisniewski T, de Leon MJ (2015) Clearance systems in the brain-implications for 
Alzheimer disease. Nat Rev Neurol 11:457-470. 
Tarawneh R, Holtzman DM (2012) The clinical problem of symptomatic Alzheimer disease and 
mild cognitive impairment. Cold Spring Harbor perspectives in medicine 2:a006148. 




Terry RD, Masliah E, Hansen LA (1994) Structural basis of the cognitive alterations in 
Alzheimer's disease. In: Alzheimer's disease (Terry, R. D. et al., eds), pp 179-196 New 
York: Raven Press. 
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R 
(1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the 
major correlate of cognitive impairment. Ann Neurol 30:572-580. 
Terry RD, Peck A, DeTeresa R, Schechter R, Horoupian DS (1981) Some morphometric aspects 
of the brain in senile dementia of the Alzheimer type. Ann Neurol 10:184-192. 
Thoenen H, Sendtner M (2002) Neurotrophins: from enthusiastic expectations through sobering 
experiences to rational therapeutic approaches. Nat Neurosci 5 Suppl:1046-1050. 
Tiraboschi P, Sabbagh MN, Hansen LA, Salmon DP, Merdes A, Gamst A, Masliah E, Alford M, 
Thal LJ, Corey-Bloom J (2004) Alzheimer disease without neocortical neurofibrillary 
tangles: "a second look". Neurology 62:1141-1147. 
Tomlinson BE (1982) Plaques, tangles and Alzheimer's disease. Psychol Med 12:449-459. 
Tomlinson BE, Blessed G, Roth M (1970) Observations on the brains of demented old people. J 
Neurol Sci 11:205-242. 
Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, Patel P, Blesch A, Vahlsing HL, 
Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner 
J (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer 
disease. Nat Med 11:551-555. 
Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD (2002) From acquisition to consolidation: 
on the role of brain-derived neurotrophic factor signaling in hippocampal-dependent 
learning. Learn Mem 9:224-237. 
Uylings HB, de Brabander JM (2002) Neuronal changes in normal human aging and Alzheimer's 
disease. Brain Cogn 49:268-276. 
van Duinen SG, Castano EM, Prelli F, Bots GT, Luyendijk W, Frangione B (1987) Hereditary 
cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer 
disease. Proceedings of the National Academy of Sciences of the United States of 
America 84:5991-5994. Proc Natl Acad Sci USA 
van Praag H, Kempermann G, Gage FH (1999) Running increases cell proliferation and 
neurogenesis in the adult mouse dentate gyrus. Nat Neurosci 2:266-270. 
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, 
Moro RN, Shang N, Goldberg SV, Sterling TR, International Maternal P, Adolescents 
ACTG, Tuberculosis Trials C (2015) Treatment for preventing tuberculosis in children 
and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a 
combination of rifapentine and isoniazid. JAMA Pediatr 169:247-255. 
Waite LM (2015) Treatment for Alzheimer's disease: has anything changed? Aust Prescr 38:60-
63. 
Walker ES, Martinez M, Brunkan AL, Goate A (2005) Presenilin 2 familial Alzheimer's disease 
mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J 
Neurochem 92:294-301. 
Winkler J, Ramirez GA, Kuhn HG, Peterson DA, Day-Lollini PA, Stewart GR, Tuszynski MH, 
Gage FH, Thal LJ (1997) Reversible Schwann cell hyperplasia and sprouting of sensory 





Winters BD, Forwood SE, Cowell RA, Saksida LM, Bussey TJ (2004) Double dissociation 
between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object 
recognition and spatial memory: heterogeneity of function within the temporal lobe. J 
Neurosci 24:5901-5908. 
Wolfe MS (2012) The role of tau in neurodegenerative diseases and its potential as a therapeutic 
target. Scientifica (Cairo) 2012:796024. 
Yagita Y, Kitagawa K, Ohtsuki T, Takasawa K, Miyata T, Okano H, Hori M, Matsumoto M 
(2001) Neurogenesis by progenitor cells in the ischemic adult rat hippocampus. Stroke 
32:1890-1896. 
Yang P, Arnold SA, Habas A, Hetman M, Hagg T (2008) Ciliary neurotrophic factor mediates 
dopamine D2 receptor-induced CNS neurogenesis in adult mice. J Neurosci 28:2231-
2241. 
Zeger S, Liang K-L (1986) Longitudinal data analysis for discrete and continuous outcomes. 
Biometrics 42:121-130. 
Zhang C (2012) Natural compounds that modulate BACE1-processing of amyloid-beta precursor 
protein in Alzheimer's disease. Discov Med 14:189-197. 
Zhang Z, Liu X, Schroeder JP, Chan CB, Song M, Yu SP, Weinshenker D, Ye K (2014) 7,8-
dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of 
Alzheimer's disease. Neuropsychopharmacol 39:638-650. 
Zhao M, Li D, Shimazu K, Zhou YX, Lu B, Deng CX (2007) Fibroblast growth factor receptor-1 
is required for long-term potentiation, memory consolidation, and neurogenesis. Biolog 
Psychiatry 62:381-390. 
Zuccato C, Cattaneo E (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. 
Nat Rev Neurol 5:311-322. 
 
